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ABSTRACT 
 
Chronic pain is responsible for great physical, mental and economic loss. While there are 
diverse methods available for managing pain, such as NSAID, opioids and local 
anesthetics, common issues associated such as addiction and tolerance highlights the 
unmet demand for a novel analgesic aimed at a novel target.  
 
Numerous reports on individuals suffering from loss of function mutations in SCN9A 
marker, which leads to complete inability to feel pain, yet otherwise normal physiology, has 
led to the recognition of voltage gated sodium channel 1.7 (NaV1.7) as a prime pain target. 
Other reports of gain of function mutations that lead to conditions such as paroxysmal 
extreme pain disorder and primary erythromelalgia confirms the validity of this target. 
However the presence of nine closely related subtypes of voltage gated sodium channels, 
NaV1.1-NaV1.9 introduces complications as any cross inhibition may lead to detrimental 
results. For example inhibition of NaV1.5 subtype could result in cardiac arrhythmia to 
complete cardiac arrest and death. Therefor it is of utmost importance that any 
pharmaceutical agent used to inhibit NaV1.7 is highly specific for NaV1.7 and display no 
cross reactivity on other voltage gated channels.  
 
Spiders are one of the most successful terrestrial predators; their venoms have evolved 
over many millions of years to selectively and potently inhibit nervous system targets in 
order to rapidly paralyze their prey. Spider-venom peptidomes have been identified as one 
of the largest known libraries of compounds with very high potency and specificity towards 
nervous system targets.  
 
Spider toxins listed in the Arachnoserver database have been classified into 12 families of 
sodium channel toxins (NaSpTx), denoted NaSpTx Families 1–12, based on the level of 
sequence conservation and intercystine spacing. NaSpTx family 2 is the largest toxin 
family; it comprises 34 peptides of theraphosid origin.  
 
This thesis primarily aims at discovering novel inhibitors of NaV1.7. However the intriguing 
fact that people suffering form congenital indifference to pain also suffers form anosmia, 
has lead to efforts of understanding the role of NaV1.7 in olfaction. This study has been 
	   iii 
completed with the finding that NaV1.7 is located along axons of olfactory neurones. These 
findings have been published and research article is attached as chapter 4.    
 
During the initial discovery phase of this project, an assay guided fractionation method 
was used to identify NaV1.7 inhibitors form six spider venoms. This resulted in nine fully 
sequenced peptides where four of these belonged to NaSpTx family 2. This included the 
well-known β/ω-TRTX-Tp1a (Protoxin1). Three novel peptides discovered were named β-
TRTX-Pe1a, µ-TRTX-Pe1b, and U-TRTX-Pa1a.  
 
A complete alanine scan of β/ω-TRTX-Tp1a on NaV1.7 was conducted using a Xenopus 
laevis oocyte based tethered toxin method. Residues that were important for NaV1.7 
binding were mapped onto the three-dimensional structure of β/ω-TRTX-Tp1a. Three 
novel toxin peptides β-TRTX-Pe1a, β/µ-TRTX-Pe1b, and U-TRTX-Pa1a were 
recombinantly expressed using an Escherichia coli (E. coli) based system. Channel 
modulating activities of these toxins were assessed using a Xenopus laevis oocyte based 
two-electrode voltage clamp system (TEVC). µ-TRTX-Pe1b demonstrated a high degree 
of selectivity for NaV1.7. It is about 20 times more selective over NaV1.2, which is 
abundant in the central nervous system, and appears to mildly potentate NaV1.5, which is 
the cardiac subtype. This is despite the complete set of active residues uncovered in β/ω-
TRTX-Tp1a alanine scan being fully conserved in β/µ-TRTX-Pe1b. β-TRTX-Pe1a and U1-
TRTX-Pa1a have shown very weak NaV1.7 inhibition, hence not investigated in great 
detail.  
 
The introduction of the mutation S35 to the sequence of β/µ-TRTX-Pe1b has resulted in 
the β/µ-TRTX-Pe1b-S35, which has shown increased NaV1.7 activity that is almost 
comparable to β/ω-TRTX-Tp1a.  Structure activity relations (SAR) of β/ω-TRTX-Tp1a and 
β/µ-TRTX-Pe1b-S35 are currently under investigation. It is highly promising that better 
understanding of residues responsible for the high potency of β/ω-TRTX-Tp1a and higher 
NaV selectivity of β/µ-TRTX-Pe1b-S35 would lead to engineering a superior NaV1.7 
inhibiting analgesic agent.   
 
This thesis has widened our understanding of NaSpTx family 2 peptides, and residues, 
which may be important in achieving NaV1.7 selectivity by inhibitor peptides.  
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CHAPTER 1 
 
Introduction 
 
1.1 Chronic pain. 
Pain is a noxious stimulus that indicates current or possible future tissue damage1. Pain is 
emotionally detrimental but crucial for survival. Certain noxious stimuli such as injury, 
temperature extremes, chemicals, and mechanical trauma can be detected by specialized 
receptors known as primary sensory neurons or nociceptors (Fig. 1)2,3. These stimuli are 
transmitted to the central nervous system, via the spinal cord, as an action potential 
through high-threshold unmyelinated C fibres and thinly myelinated Aδ fibres. Afferent 
neurons synapse in the spinal cord, and the data is transmitted to both the brain for 
processing (via second and third order sensory neurons) and to motor nerves (via 
interneurons) for immediate action to avoid possible further damage4. The brain is 
responsible for interpretation of the initial signal from nociceptors as ‘pain’.  
 
 
 
Figure 1: (A) The nociceptive pathway3. Noxious external stimuli detected at the terminus of a 
nociceptor are converted to an action potential and transmitted to the spinal cord via afferent nerve 
bundles5. Within the grey matter of the dorsal horn of the spinal cord, the dorsal root ganglion 
(DRG) neuron synapses with an interneuron that transmits the stimulus to the brain, where the 
nerve impulse is perceived as ‘pain’. The interneuron also synapses with an efferent neuron for 
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immediate involuntary responses4. (B) Molecular components at the synapse between the central 
terminations of nociceptors and interneurons/second-order sensory neurons in the spinal cord. (C) 
Molecular components in the naked terminals of nociceptors. Transient receptor potential (TRP) 
channels in the nociceptors detect intense stimuli generated by thermal, mechanical and chemical 
sources6. Numerous ion channels including the voltage-gated sodium (NaV) channel NaV1.7 are 
located along the axon of the DRG neuron, which are important for the amplification and 
propagation of action potentials.  
 
 
1.2 Categories of pain  
Pain is broadly categorized into three classes. Nociceptive pain arises due to noxious 
stimuli from the external environment5. Inflammatory pain is caused by proinflammatory 
mediators, which are released at sites of infection or tissue damage7. Neuropathic pain, 
which is also known as dysfunctional pain, is indicative of dysfunction or damage to the 
nervous system2. Pain can be further divided, based on its duration, into acute or chronic 
pain.  
 
Acute pain is temporary, and often ceases to exist once the cause is eliminated. Acute 
pain can usually be successfully managed with non-steroidal anti-inflammatory drugs 
(NSAIDs), opioids, local anaesthetics and anticonvulsants. Chronic pain is defined as pain 
that extends beyond the period of healing following the initial trauma. Mechanisms 
common to chronic pain include detection of inflammatory mediators by nociceptors, 
peripheral sensitization and central sensitization2,8,9. Some of these pain states, most 
particularly neuropathic pain, do not respond well to current analgesics10. 
 
1.3 Chronic pain and current management strategies 
Management of chronic pain presents a major challenge. Current estimates show that 15–
20% of the world population suffers from chronic pain, and this increases to 50% for adults 
over 65 years of age11,12. This number is predicted to increase over the next few decades 
as the proportion of seniors increases due to rising life expectancy. Currently used 
painkillers are categorized into three classes based on their strength and uses. Non-opioid 
analgesics such as aspirin, paracetamol and NSAIDs are used at the beginning of the 
treatment. Where the pain persists or increases, weak opioids such as codeine and 
tramadol are used. If this stage also fails, strong opioids such as oxycodone, morphine or 
fentanyl are prescribed in combination with an antidepressant, anticonvulsant or a non-
opioid drug13. Unfortunately the long-term use of strong opioids can lead to tolerance, 
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physical dependence, and addiction14.  Development of opioid tolerance reduces neuronal 
activity in the central nervous system through inhibition of voltage gated calcium (CaV) 
channels and inhibition of adenylyl cyclase15. Moreover, the abovementioned drug 
combinations have failed to provide adequate relief for patients suffering from a number of 
conditions including facial neuralgia, AIDS, multiple sclerosis, nerve injury after accidents 
or surgery, and certain neuropathies. Thus, there is much interest in identifying novel pain 
targets and analgesics with new modes of action. 
 
1.4 What are the likely pain targets and where to find them? 
Ion channels and receptors present on peripheral nociceptors and synaptic junctions in the 
central nervous system (CNS) represent attractive targets for the development of novel 
analgesics. These include NaV1.7, NaV1.8, CaV2.2, CaV3.2, the GABAB receptor, and acid-
sensing ion channels (ASICs) of the peripheral nervous system (PNS), and NaV1.8 and 
CaV3.2 in the CNS16-20. Noting that ongoing peripheral input is important for the 
maintenance of chronic pain, nociceptors have been identified as a very important target 
for the development of novel analgesics21. Reduction of hyperexcitability in peripheral 
nociceptors has been achieved by blocking voltage-gated and ligand-gated ion channels. 
Significant success has been achieved with inhibition of NaV and CaV channels and 
increased expression of NaV1.7 was inhibited with cyclooxygenase inhibitors to relieve 
inflammatory pain22. In a different study it was shown that antisense-mediated knockdown 
of NaV1.8 attenuates complete Freund’s adjuvant (CFA)-induced hyperalgesia23-25. 
Systemic administration of lidocaine, a NaV channel blocker, has yielded significant and 
long lasting pain relief for patients suffering from chronic pain due to postherpetic 
neuralgia, painful diabetic neuropathy, and idiopathic trigeminal neuralgia24. Lacosamide 
(Schwarz Pharma) and ralfinamide (Newron Pharma) have both been shown to inhibit 
tetrodotoxin (TTX)-resistant (R) and TTX-sensitive (S) NaV channels26. Even though 
lacosamide showed efficacy in Phase 3 clinical trials, there have been high rates of 
adverse events and dropout in trials with patients suffering from diabetic neuropathic pain. 
Ralfinamide has shown good tolerability in a mixed population of neuropathic pain patients 
in Phase 2 clinical trials26-28. NaV channels on nociceptors appear to be a prominent target 
for the development of novel analgesic drugs. 
 
 	  
	   4	  
1.5 Voltage gated sodium channels (NaV) 
1.5.1 General function of NaV channels 
NaV channels are transmembrane proteins that cause the rapid depolarization required to 
initiate an action potential in excitable cells29. The single pore forming α-subunit is made 
up of four domains denoted I–IV, where each domain consists of six transmembrane (TM) 
segments (S1–S6) joined via intracellular and extracellular loops (Fig. 2)30-32. TM 
segments S1–S4 of every domain form a voltage sensor domain (Fig. 2B, orange), while 
the S5–S6 segments and the intervening loop come together in a cyclic arrangement to 
form the ion selectivity filter and the channel pore. The S4 segment of each voltage sensor 
contains a positively charged residue in every third position (Arg or Lys), and hence it 
functions as the primary sensor of changes in membrane potential30. This segment is 
responsible for the initiation of voltage dependent activation (i.e., the transition form the 
closed to open state) by responding to membrane depolarization and causing the channel 
to undergo a conformational change that allows selective influx of Na+ ions through the 
pore32. The extracellular linker between S5 and S6 of each domain re-enters the 
membrane to form the ion selectivity filter of the external face of the pore. The intracellular 
linker between domain III and domain IV, carrying residues IFMT (isoleucine, 
phenylalanine, methionine, threonine), is believed to fold into the ion conducting pore, and 
lead to the fast inactivation (i.e., the transition form the open to inactivated state) of the 
channel30,32. NaV channels produce rapidly depolarizing currents in excitable cells33 and 
the typical current profile is demonstrated below (Fig. 2C).     
 
1.5.2 NaV structure 
No three dimensional structure is currently available for any vertebrate NaV channel. 
However, the crystal structure of a bacterial NaV channel (NaVAb) from Arcobacter butzleri 
was solved in 2011 at 2.7 Å resolution; the channel appears to be in pre-open confirmation 
with all four voltage sensor domains in the activated state and the ion-conducting pore 
module closed34. The primary difference between bacterial (NaChBac) and vertebrate NaV 
channels is that the bacterial channels are homotetramers, much like voltage-gated 
potassium (Kv) channels (Fig. 2A). Due to this difference, bacterial NaV channels lack the 
fast inactivation gates found in vertebrate channels. This leads to the assumption that 
bacterial channels employ an inactivation mechanism similar to that of slow inactivation of 
vertebrate NaV channels35. Later work revealed two structures of NaChBacs in the 
inactivated state, which has provided important insights into channel gating mechanisms34. 
Structures of two more NaChBacs became available in 2012. The first was that of NaVRh, 
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a NaChBac from the marine bacterium Rickettsiales sp., solved at 3.05 Å resolution in the 
inactivated state36. A few months later, a 4 Å resolution structure was published of a 
NaChBac from the marine bacterium Magnetococcus sp. (strain MC-1); this structure is 
thought to represent the open channel conformation37.  
 
 
Figure 2: Generic structure of mammalian NaV channels. (A) Eukaryotic NaV channels contain 
four homologous but non-identical domains (I–IV), each consisting of six TM segments (S1–S6). 
The S1-S4 segments within each domain forms a voltage sensor domain (VSD), while the S5–S6 
segments and the re-entrant loop of the four domains come together to form the ion pore and 
selectivity filter. The intracellular loop between domains III and IV forms the inactivation loop30. (B) 
3D structure of the NaV channel from Arcobacter butzleri obtained in a closed-pore and activated 
VSD conformation at 2.7 Å resolution. The central pore is shown in green while the four VSDs are 
shown in orange. (C) Classic NaV channel current profile. When the membrane is polarized to –
90 mV, the channel is inactive. Upon depolarization (shift of membrane potential to +30 mV), the 
channel becomes activated. Sodium ions enter the cell through the NaV channel pore. Within a few 
ms the inactivation loop enters the pore and the channel inactivates. When the membrane is 
repolarized to –50 mV, the channel partially recovers from inactivation, yet no current flows38. 
Further repolarization to -90 mV would return the channel to its inactive (closed) state.  (A), was 
adapted from a pervious review which has been incorporated as part of the introduction32.  
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1.6 NaV channel subtypes 
Vertebrates contain nine different NaV channel α-subunits, denoted NaV1.1– NaV1.9, that 
share 50% identity within their TM and extracellular domains29. All these subtypes, with the 
exception of NaV1.9, have been functionally expressed. They are often characterized by 
their sensitivity to TTX. NaV1.5, NaV1.8 and NaV1.9 are TTX resistant, whereas all other 
subtypes are TTX sensitive29,33. NaV1.1, NaV1.2, NaV1.3 and NaV1.7 are the most closely 
related channels based on the evolutionary distance measured using sequence 
alignments. The genes encoding these channels are all located within the chromosomal 
region 2q23-24. 
 
NaV1.5, NaV1.8 and NaV1.9 are also closely related. They share 64% sequence identity 
and display some level of TTX resistance29. NaV1.4 is primarily expressed in skeletal 
muscle, while NaV1.6 is highly abundant in nodes of Ranvier within both the CNS and 
PNS. These two channels are not closely related to either of the major two groups29.  
 
In mammals, the α-subunit is also associated with one or two smaller auxiliary subunits 
(NaVβ1–NaVβ4) of approximately 33–36 kDa that are required for normal kinetics and 
voltage-dependence of gating but are not required for ion flux, ionic selectivity, and 
pharmacological modulation33.  
 
1.7 NaV channel localization and channelopathies  
NaV1.1 is expressed primarily in soma and apical dendrites of purkinje cells of the 
cerebellum39. Inherited loss-of-function point mutations and deletions of this channel cause 
febrile seizures and severe myoclonic epilepsy during infancy40,41. NaV1.2 is primarily 
found in unmyelinated and premyelinated axons of the CNS42. Various NaV1.2 mutations 
are known to be associated with familial autism, neonatal epilepsy, late onset episodic 
ataxia, myoclonus, and multiple sclerosis43,44. NaV1.1 and NaV1.2 are not restricted to the 
CNS, and there are reports of NaV1.1 and NaV1.2 in sensory neurons of the dorsal root 
ganglia45. NaV1.3 is found in both the CNS and PNS, but is mostly expressed during 
embryonic and early prenatal life. However, NaV1.3 expression is up-regulated following 
nerve injury29. NaV1.4 is expressed in skeletal muscle and loss-of-function mutations are 
known to cause hyperkalemia periodic paralysis, muscle weakness and paralysis46. 
NaV1.5 is found predominantly in cardiac myocytes47, however some evidence shows its 
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presence in denervated skeletal muscles48 and certain brain neurons49. Intriguingly, 
NaV1.5 has also been found to be involved in regulation of endosome acidification in 
primary human monocyte derived macrophages50, hence it plays a significant role in 
defense against mycobacterial infections51. NaV1.5 mutations can lead to long QT 
syndrome, Brugada syndrome and atrial fibrillation52. NaV1.5 shows partial TTX-
resistance, with an IC50 of 1.17 µM53. NaV1.6 is widespread throughout both the CNS and 
PNS. It has been found in soma and dendrites of cerebellum, cerebral cortex and 
hippocampus output neurons54. It is also found in nodes of Ranvier in the CNS and 
sensory and motor neurons in PNS55. Mutations in NaV1.6, such as in domain II S4-S5, 
can cause cerebellar ataxia56. NaV1.7 is only found in the PNS. Loss-of-function mutations 
lead to congenital indifference to pain (CIP) with anosmia17. NaV1.8 is primarily expressed 
in the PNS, and it shows promise as a target for analgesic drugs57. NaV1.8 is a TTX-R 
channel (IC50 of 60 mM for TTX)29. Substitution of Ser356 with an aromatic residue 
removed the TTX resistance of NaV1.858. NaV1.9 is responsible for the persistent sodium 
current in small diameter DRG neurons59. It has been identified as a potential analgesic 
target due to its preferential expression in c-type DRG neurons29. NaV1.9 is TTX-R with an 
IC50 of 40 mM. Table 1 summarizes information about the gene, localization, and 
channelopathies associated with each of the mammalian NaV channel subtypes.  
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Table 1: Function and distribution of voltage gated sodium channels29. 
Subunit Gene 
name 
Function Localization Diseases caused by 
mutations 
NaV1.1 SCN1A Fast kinetics, TTX-
S (Kd ~ 5 µM) 
Soma and apical 
dendrites CNS 
and PNS 
Epilepsy 
NaV1.2 SCN2A Fast kinetics, TTX-
S 
Unmyelinated 
axons of CNS 
and PNS 
Epilepsy 
NaV1.3 SCN3A Fast kinetics, TTX-
S 
CNS and PNS in 
embryonic tissue 
Increased expression following 
nerve injury 
NaV1.4 SCN4A Fast kinetics, TTX-
S 
Skeletal muscles Myotonia, periodic paralysis  
NaV1.5 SCN5A Fast kinetics, TTX-
R 
(Kd ~ 1µM) 
Cardiac muscles Cardiac arrhythmia, long QT, 
Brugada 
NaV1.6 SCN8A Fast kinetics, TTX-
S 
Nodes of Ranvier 
in CNS and PNS 
Cerebral atropathy, cerebellar 
ataxia, mental retardation 
NaV1.7 SCN9A Fast kinetics, TTX-
S 
PNS Altered pain sensitivity, 
anosmia 
NaV1.8 SCN10A Slow kinetics, TTX-
R 
(Kd ~ 30 µM) 
PNS Altered pain sensation, 
paresthesias 
NaV1.9 SCN11A Slow kinetics, TTX-
R 
PNS Familial episodic pain 
NaX SCN7A Activated through 
altered Na+ 
concentration60 
Heart, Uterus Not reported 
 
 
1.8 Congenital indifference to pain 
A case was reported in 1932 of an individual who was insensitive to pain61. This condition 
was later categorized as “congenital indifference to pain” (CIP)62. CIP patients have a 
normal sense of touch, vibration, joint position sense, and temperature perception, 
however they fail to identify noxious stimuli as unpleasant or painful62. In addition to 
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absence of pain perception, CIP patients also display complete or partial loss of smell 
(anosmia)17. CIP is an extremely rare condition with only about 30 reported cases 
worldwide. DNA samples from individuals with CIP were studied using traditional positional 
cloning, and all individuals were found to contain multiple loss-of-function mutations in the 
gene region SCN9A that encodes the pore-forming α-subunit of NaV1.7 (Fig. 2). Thus far, 
there are ~10 characterized SCN9A mutations that cause CIP17,63. In striking contrast to 
CIP, gain-of-function mutations in SCN9A are responsible for two painful inherited 
neuropathies, paroxysmal extreme pain disorder and primary erythromelalgia64-66. In 
addition, it was recently shown that single nucleotide polymorphisms in SCN9A correlate 
with altered pain perception in human populations67. Thus, there is a strong link between 
pain and level of NaV1.7 activity, making it a prominent target in the search for novel 
analgesics.	  	  	  
1.9 Spider venom peptides as NaV-targeted analgesic drugs 
Venoms have been diversified over millions of years of evolution in order to gain an 
advantage in defense, prey capture, or competitor deterrence. Most venoms are a highly 
complex mixture of ligands that affect a variety of pharmacological targets. Venoms include 
both non-peptide and peptide toxins. Non-peptide toxins are usually orally active. Peptide 
toxins however need to be delivered into the soft tissues of the targeted animal using an 
‘envenomation apparatus’68. Mollusks and arachnids depend on their venom to rapidly 
paralyze prey68. These venoms typically contain a large number of peptide neurotoxins that 
target a variety of ion channels, including NaV channels. Indeed, four of the seven 
pharmacological sites on vertebrate NaV channels are defined by the binding of mollusk or 
arachnid toxins.  NaV channel modulation is one of the major pharmacologies of spider 
venoms69,70 and the spider toxins responsible have proved to be valuable tools for 
understanding the structure and function of NaV channels33,71. 
More than 44,500 extant species of spiders have been described72, with an even greater 
number remaining to be characterised73. This makes spiders the largest group of terrestrial 
predators, with the possible exception of predatory beetles. One of the major contributors 
to the evolutionary success of spiders is their ability to produce complex venom for 
predation and predator deterrence74. Spider venoms are complex chemical cocktails but 
the major components are small, disulfide-rich peptides. Since a single venom can contain 
as many as 1000 peptides, it has been conservatively estimated that >10 million bioactive 
peptides are likely to be present in the venoms of spiders75 with only 0.01% of this 
diversity having been characterised. The spider-venom peptides that have been described 
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to date are listed in Arachnoserver, a manually curated database that provides detailed 
information about proteinaceous toxins from spiders76,77. 
 
Voltage gated sodium (NaV) channels play a key role in the rising phase of the action 
potential in excitable cells29. In contrast with vertebrates, insects express only a single NaV 
channels subtype33 and consequently they are extremely sensitive to NaV channel 
modulators, as underlined by the fact that several of the most successful classes of 
chemical insecticides are NaV channel modulators (e.g., pyrethroids, indoxacarb, 
dihydropyrazoles, N-alkylamides, and DTT)78-80. One third of the 186 ion channel 
modulators listed in Arachnoserver target NaV channels (Fig. 3), which is perhaps not 
surprising as these toxins allow spiders to rapidly incapacitate their prey. NaV channel 
toxins are found in a taxonomically diverse range of spiders, which suggests that this 
pharmacology was recruited at a very early stage in venom gland evolution. Moreover the 
ubiquity of NaV channel toxins in spider venoms suggests that these peptides might be 
useful insecticides for the control of arthropod pests81,82.  
 
 
 
Figure 3: Ion channel modulators form spider venoms. Molecular targets of the 186 ion 
channel toxins listed in Arachnoserver (www.arachnoserver.org; accessed February 12, 2012)77. 
The majority of toxins target voltage-gated ion channels (CaV, NaV, KV), followed by calcium-
activated potassium (KCa) channels, mechanosensitive ion channels (MSC), transient receptor 
potential (TRP) channels, and acid-sensing ion channels (ASICs). Note that some toxins target 
more than one type of channel, and therefore the cumulative number of toxins in the histogram is 
>186.    
 
In addition to prey capture, spiders also use their venom to deter predators, which can 
include vertebrates. Moreover, even though the vast majority of spiders prey primarily on 
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invertebrates, there is no evolutionary selection pressure to prevent spider toxins acting on 
vertebrate ion channels. It is therefore not surprising that many spider-venom peptides 
have been found to modulate the activity of vertebrate NaV channels33,70,83. 
 
 
 
Figure 4: Molecular architecture and pharmacology of NaV channels. Coloured regions 
represent neurotoxin receptor sites. The grey circles represent the outer (EEDD) and inner (DEKA) 
rings of amino acid residues that form the ion-selectivity filter and constitute the proposed 
neurotoxin receptor site 1 for the water-soluble guanidinium toxins TTX and saxitoxin. Some m-
conotoxin binding sites overlap with those of TTX and are omitted for clarity. Nevertheless, we 
refer to sites 1a and 1b to distinguish between the different molecular determinants for µ-conotoxin 
and TTX/saxitoxin binding. In the case of receptor sites 3 and 4, only epitopes where mutagenesis 
of key residues leads to more than a five-fold decrease in toxin binding affinity are highlighted. 
Note that TM segment 6 in domain I includes binding epitopes for both site 2 and site 5 toxins. The 
known binding sites for 8 of the 12 families of spider-venom NaV toxins (NaSpTxs) are indicated. 
“F” denotes toxin family (e.g., F2 indicates NaSpTx family 2). While the δ-amaurobitoxins in family 
10 have been shown to bind to neurotoxin receptor site 4, peptides in this family have variable 
pharmacology and some may bind at other sites.  
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Spider venom peptides typically comprise 31–50 amino acid residues and 3–4 disulfide 
bonds77. Three of the disulfide bonds form an inhibitor cystine knot (ICK) motif (Fig. 5)77,83, 
in which one of the disulfides penetrates a loop formed by the other two disulfides and the 
intervening sections of the polypeptide backbone. The ICK motif is responsible for the 
extreme thermal, chemical and enzymatic stability observed for such toxins82,84.  
 
 
 
Figure 5: The inhibitory cystine knot (ICK) motif. A. A three dimensional representation of the 
motif. B. A schematic representation of the ICK motif, that consisted with two conserved 
antiparallel β-sheets and a third β-sheet that may or may not exist in every ICK motif85. 
 
A larger number of spider venom components are also active on vertebrate VGSCs. Many 
toxins show VGSC subtype selectivity, while some other toxins like δ-HXTX-Ar1a are non-
specific and lethal. Subtype selectivity of toxins have number of implications, including the 
design of VGSC inhibitors as analgesics, treatment of arrhythmia, treatment of various 
pain disorders and ion channelopathies. 
 
1.10 Mechanisms of toxin activity 
Venom peptides modulate channel activity by two main mechanisms: they either physically 
occlude the channel pore or they bind to an allosteric site that induces a conformational 
change in the channel that alters the equilibrium between the open, closed and inactivated 
states86. All known NaV channel toxins from spider venoms are allosteric modulators, also 
known as “gating modifiers”. However they modulate channel activity in quite different 
ways. For example the lethal toxin form the Sydney funnel-web spider Atrax robustus (δ-
HXTX-Ar1a) inhibits inactivation of both insect and vertebrate NaV channels 87,88. Some 
other toxins shift the activation voltage to the left or to the right of a current-voltage 
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distribution. When the activation voltage shifts to the left (to more negative potentials), 
increasing the probability of the channel opening closer to the resting potential. When a 
toxin shifts the activation voltage to the right, the channel opens at more positive voltages, 
and the opening event become less and less likely. Some toxins bind and hold the S3-S4 
paddle motif in open state of the channel89.  
 
1.11 NaSpTx family 2 
We have conducted a full survey to classify all available spider-venom peptides that target 
NaV channels form Arachnoserver, based on sequence homology and disulfide bond 
configurations. When this survey was completed there were 12 distinct families of spider-
venom peptides identified (Fig 6 and Fig 7). This thesis primarily uses the rational 
nomenclature recently developed for spider-venom peptides90 in order to facilitate 
identification of orthologs and paralogs, but for convenience we also provide original 
names of toxins where appropriate. The term NaScTx is employed for scorpion toxins that 
target NaV channels91, and here we introduce the term NaSpTx for spider toxins that target 
this channel.    
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Figure 6: NaSpTx families 1–4, 7 and 10. The consensus sequence is shown above each 
alignment, with the disulfide bond connectivity indicated in blue. Red asterisks denote C-terminal 
amidation. Strictly conserved residues are highlighted in bold colour while semi-conserved 
residues are highlighted in a lighter colour. Toxin names are based on the rational nomenclature 
devised for spider-venom peptides, as used in ArachnoServer and UniProt90. The structure of a 
representative member from each NaSpTx family is shown adjacent to each alignment: family 1, µ-
TRTX-Hh2a (PDB ID: 1MB6); family 2, κ-TRTX-Gr1a (PDB ID: 1D1H); family 3, κ-TRTX-Gr2a 
(PDB ID: 1LUP); family 4, δ-HXTX-Hv1a (PDB ID: 1VTX); family 7, κ-TRTX-Gr3a (PDB ID: 1S6X); 
family 10, δ-AMATX-Pl1b (PDB ID: 1V91). β strands are depicted in cyan, helices are red, and 
disulfide bridges are yellow. All spider photos were taken by Bastian Rast. 
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Figure 7: NaSpTx families 5, 6, 8, 9, 11 and 12. The consensus sequence is shown above each 
alignment, with the disulfide bond connectivity indicated in blue. Dotted lines represent predicted 
disulfide bond connectivities that have not been experimentally validated. Red asterisks denote C 
terminal amidation. Strictly conserved residues are highlighted in bold colour while semi-conserved 
residues are highlighted in a lighter colour. Toxin names are based on the rational nomenclature 
devised for spider-venom peptides90, as used in ArachnoServer and UniProt. The structure of a 
representative member of F5 is shown adjacent to the alignment (β-HXTX Mg1a; PDB ID: 2GX1). 
Disulfide bridges are coloured yellow. No structures are available for any member of the other 
NaSpTx Families depicted in this figure. Spider photos are by Bastian Rast (M. gigas and P. reidyi) 
and Aloys Staudt (H. melloteei). 
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Table 2 summarizes some of the features of each NaSpTx family, including an indication 
of their subtype preferences. Notably, peptides that potently block NaV1.5 tend to be lethal 
in rodents, consistent with the critical role of this subtype in cardiac function. This 
highlights the need to pinpoint the residues on these peptides that mediate their selectivity 
and potency in order to be able to rationally engineer improved versions that preferentially 
bind NaV1.7. This will be the major challenge in progressing these peptides to the clinic. 
On a positive note, however, peptides have already been isolated from Families 1–3 that 
potently block NaV1.7 (IC50 ≤ 51 nM) and that have at least some selectivity over other NaV 
subtypes.  
 
Table 2: Subtype selectivity and other selected properties of the 12 families of NaSpTx. 
NaSpT
x 
family 
NaV channel subtype 
TTX-S TTX-R Lethal 
Other ion 
channel 
targets 
High 
resolutio
n 
structure1
6 
1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 
1 407a 0.6b 42b 288b 722b - 26c - 1.1d - Yes CaV/KV Yes 
2 - - - - 447e - 51f 27f 85g - No CaV/KV/TRPV1 Yes 
3 41h 230i 103h 330i 79h 26h 0.3h 146h 30.2k 27.6k Yes KV/CaV Yes 
4 - - - - - - - - - - Yes - Yes 
5 - 1200l - - - - - - - - Yes - Yes 
6 - - - - - - - - - - Yes - No 
7 - - - - 32m 130m 130m - - - - KV Yes 
8 - 0.08n - - - - - - - - Yes - No 
9 - - - 155o - - - - - - - KV No 
10 - - - - - - - - - - N0 - Yes 
11 - - - - - - - - - - No - No 
12 - - - - - - - - - - No - No 
For each NaSpTx family, the IC50 value (in nM) is given for the peptide that most potently 
modulates the activity of each NaV subtype. Columns labeled “TTX-S” and “TTX-R” indicate 
potency of peptides on TTX-S and TTX-R NaV channels, usually tested in rat dorsal root ganglion 
neurons. The column labeled “Lethal” refers to the toxicity of peptides in rodents. aβ-TRTX-
Cm1b92, bβ-TRTX-Ps1a 92, cµ-TRTX-Hh2a93, dµ-TRTX-Hhn2b94, eβ-TRTX-Cm2a92, fβ/ω -TRTX-
Tp1a95, gµ-TRTX-Cj1a96, hβ/ω-TRTX-Tp2a95, iβ-TRTX-Gr1a97, jβ-TRTX-Gr1b97, kκ-TRTX-Cj2a98, lβ -
HXTX-Mg1a99, mδ-TRTX-Cj1a100, nµ-CNTX-Pn1a101, oµ-TMTX-Hme1b102, p“high-resolution 
structures” are defined as NMR-derived solution structures with a backbone RMSD <0.5 Å. 
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Family 2 is the largest family of NaSpTxs with 34 members, all originating from 
theraphosid venoms. Of these, 18 peptides were isolated from the Chinese tarantula 
Chilobrachys jingzhao. Family 2 peptides range in size from 33 to 41 residues and they 
each contain three disulfide bonds that form an ICK motif. Currently, there is experimental 
proof of NaV channel activity for only four of the 34 peptides in this family. However, they 
are very interesting from a therapeutic perspective as one member of this family, β/ω-
TRTX-Tp1a (ProTx1), is one of the most potent blockers of human NaV1.7 reported to 
date, with an IC50 of 51 nM95,103. 
 
κ-TRTX-Cj1a (Jingzhaotoxin-11) is a weak modulator of NaV currents in cardiac myocytes 
(i.e., mainly TTX-R NaV1.5), causing a significant reduction in peak NaV current amplitude 
and a slowing of NaV current inactivation (IC50 = 1280 nM)104. It also inhibits KV2.1 with 
moderate potency (IC50 = 740 nM), with even weaker block of KV4.1 and KV4.2 and no 
effect on KV1.1, KV1.2, KV1.3, KV1.4 and KV3.1104. A peptide with identical sequence has 
been isolated from the venom of the related theraphosid spider Plesiophrictus 
guangxiensis. It has been proposed that κ-TRTX-Cj1a binds to the extracellular S3–S4 
linker region of channel domain IV (i.e., neurotoxin receptor site 3; see Fig. 4)104, which is 
a common target of gating modifier toxins such as κ-TRTX-Gr1a (Hanatoxin-1) in the same 
family105.  
 
β-TRTX-Cm2a (Ceratotoxin-3) has moderate affinity towards NaV1.5 (IC50 = 447 nM), and 
at a concentration of 2 mM it weakly blocks NaV1.8 (45% reduction in current) but has no 
activity against NaV1.1–1.492. In striking contrast with κ-TRTX-Cj1a and β-TRTX-Cm2a, µ-
TRTX-Cj1a (Jingzhaotoxin-34) is a potent blocker of TTX-S NaV channels in rat dorsal root 
ganglion (DRG) neurons (IC50 = 85 nM) but it has no effect on TTX-R NaV currents106. 
Thus, residues that are conserved in κ-TRTX-Cj1a and β-TRTX-Cm2a, but which are 
absent from µ-TRTX-Cj1a, should provide some insight into residues that are important for 
interaction of this family of peptides with NaV1.5.  
 
Six toxins from family 2 have confirmed activity on voltage-gated calcium (CaV) channels, 
with 12 toxins active against KV channels. Nevertheless, the high level of sequence 
identity within this family and the potency of the known family 2 NaV modulators described 
above indicate that a thorough functional analysis of all toxins in this family could reveal 
many more toxins acting on NaV channels. However, from a therapeutic perspective, the 
promiscuous activity of several family members on multiple types of voltage-gated 
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channels indicates that it will be critical to carefully determine the selectivity of any family 2 
peptides that are being considered as therapeutic leads96. 
 
 
1.12. Research aims 
The long term goal of this research is to develop potent and selective blockers of hNaV1.7 
that can be used as leads for the development novel analgesics for treatment of chronic pain, 
and to understand the impact that such drugs might have on olfaction. The specific aims of 
my PhD thesis project were as follows: 
Aim 1: Examine the localization of NaV1.7 in the rat olfactory system.   
Aim 2: Characterize novel hNaV1.7 inhibitors from NaSpTx family 2. 
Aim 3: Determine the pharmacophore of the most promising peptide and optimise its affinity 
and selectivity for hNaV1.7. 
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CHAPTER 2 
 
STRUCTURE-ACTIVITY RELATIONSHIPS OF ProTx1: ACHIEVING BETTER 
SPECIFICITY FOR NaV1.7 
 
 
2.1 Introduction 
Spiders are one of the most successful terrestrial predators. Their venoms have evolved 
over many millions of years to selectively and potently inhibit nervous system targets in 
order to rapidly paralyze their prey107. The spider-venom peptidome has been identified as 
one of the largest known libraries of compounds with high potency and specificity towards 
nervous-system targets.  
 
The majority of components in spider venoms are small, disulfide-rich peptide toxins that 
typically comprise 31–50 amino acid residues and 3–4 disulfide bonds107. In many cases, 
three of these disulfide bonds form an inhibitor cystine knot (ICK) motif in which one of the 
disulfide bonds penetrates a loop formed by the other two disulfides and the intervening 
sections of the polypeptide backbone85,107. The ICK motif is responsible for the extreme 
thermal, chemical and enzymatic stability observed for such toxins85,107.  
 
Spider toxins listed in the Arachnoserver database76,77 have been classified into 12 
families of sodium channel toxins (NaSpTx), denoted NaSpTx Families 1–12, based on 
the level of sequence conservation and intercystine spacing32. NaSpTx family 2 is the 
largest toxin family; it comprises 34 peptides of theraphosid origin, most of which are 33–
41 residues in length and contain three disulfide bonds that form an ICK motif. 
Experimental data for NaV channel activity is only available for four of these toxins, 
however this group includes β/ω-TRTX-Tp1a, one of the most potent NaV1.7 inhibitors 
reported to date95.  
 
β/ω-TRTX-Tp1a, commonly known as ProTx1, was initially isolated from the Peruvian 
green-velvet tarantula Thrixopelma pruriens. Native ProTx1 inhibits NaV1.7 and NaV1.8 
expressed in Xenopus laevis oocytes with an IC50 of 51 nM and 27 nM, respectively95. 
Furthermore, 730 nM ProTx1 causes 73–83% inhibition of NaV1.2 and NaV1.5. ProTx1 
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also inhibits the human voltage gated calcium (CaV) channel subtype 3.1 (hCaV3.1) (IC50 = 
200 nM), while having essentially no effect on hCaV3.2 (IC50 >31 µM)108. 
 
The high potency of ProTx1 on NaV1.7 has evoked interest in this molecule as the starting 
point for development of a NaV1.7-directed analgesic. However, its lack of specificity over 
other neuronal ion channels, such as NaV1.6 and CaV3.1108, has frustrated these efforts.  
 
In this study we obtained IC50 values for ProTx1 inhibition of NaV1.2, NaV1.5 and NaV1.6. 
We also determined the pharmacophore on ProTx1 that mediates its interaction with 
NaV1.7 and mapped the key functional residues onto the three-dimensional structure of 
the toxin that we determined using NMR spectroscopy. Furthermore we used a 
KV2.1/NaV1.7 chimeric channel to identify ProTx1 binding sites on NaV1.7. Finally, we used 
all of this information to rationally design several ProTx1 mutants in an attempt to obtain 
improved specificity for NaV1.7. 
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2.2 Materials and methods 
2.2.1 TEVC for tethered-toxin-based ProTx1 alanine scan 
The gene construct for hNaV1.7 (a kind gift from Dr Frank Bosmans, John Hopkins 
University, Baltimore, USA) was linearized with NotI restriction enzyme and cRNA was 
produced by in vitro transcription reaction with T7 RNA polymerase (mMessenger 
mMachine kit, Ambione, USA). The tethered-toxin (t-toxin) gene constructs for the 28 
ProTx1 mutants and the wild-type toxin (a kind gift from A/Prof Michael Nitabach, Yale 
University, New Haven, USA) was also linearized with Not1 restriction enzyme and cRNA 
was produced by in vitro transcription reaction with SP6 RNA polymerase (mMessenger 
mMachine kit, Ambion, USA). Concentrations of both cRNA stocks were determined using 
a NanoDrop 2000 (Thermo Scientific, USA). cRNA stocks with concentrations of 0.8–1.0 
µg/µl were used for injections mixed at 1:1 ratio. Each oocyte was injected with about 55 
nL of mixed cRNA. 
 
Currents within the range of 200–2000 nA were considered to be a positive response, 
whereas currents below 100 nA were considered to indicate insufficient sodium channels 
on the surface or inhibition of channels by t-ProTx1. Each mutant was tested in at least 
two different batches of oocytes, each containing 8–12 oocytes. 
 
2.2.2 Oocyte surface protein assay 
Surface protein assays were performed 2 days after cRNA injection. For surface labelling, 
oocytes were blocked for 1 h in ND96 with 3% bovine serum albumin (BSA) at RT on 
shaker, then treated with 1 µg/ml rat monoclonal anti-Myc antibody (1:500, Cell Signaling), 
in 3% BSA for 1 h at RT, washed 3 x 5 min at RT in ND96, and incubated with horseradish 
peroxidase (HRP)-coupled secondary antibody (1:2000, Pierce), in 3% BSA for 1 h at RT. 
Cells were extensively washed (3 x 5 min in ND96 with 0.1% Tween 20) and transferred to 
ND96 solution without BSA. Individual oocytes were placed in 65 µl 1-Step Ultra TMB-
ELISA solution (Thermo Scientific, USA) in a 96-well culture plate, incubated at RT for 15 
min, and the reaction stopped by adding 25 µl of 2 M H2SO4. Chemiluminescence was 
quantitated using a Bio-Rad Model 680Microplate Reader (Bio-Rad, USA). 
 
2.2.3 Electrophysiological assay of toxin activity 
Oocytes were surgically removed from Xenopus laevis frogs and treated with 30 mg of 
collagenase (Sigma type1) in 20 mL of calcium-free ND96 (96 mM NaCl, 2 mM KCl, 2 mM 
MgCl2, 5 mM HEPES, pH 7.4) for 60–90 min. Oocytes were washed with calcium-free 
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ND96, three times or until brown, cloudy medium was completely removed. Healthy-
looking oocytes with clearly defined animal and vegetal poles, with each pole of uniform 
color and elastic membrane, were selected and allowed to rest about 1 h in modified ND96 
medium (96 mM NaCl, 2 mM KCl, 1 mM CaCl2, 2 mM MgCl2, 5 mM HEPES, 5 mM pyruvic 
acid, 50 µg/mL gentamicin, 5% horse serum, pH 7.4). Selected oocytes were injected with 
41 nL of about 200–800 ng/µL cRNA synthesized using a mMessage mMachine cRNA 
transcription kit (Life Technologies), and purified using an RNeasy Mini Kit (Qiagen). 
Oocytes were incubated at 17°C, media was changed every 24 h, and recordings were 
conducted using TEVC electrophysiology (Axoclamp 900A amplifier, Molecular Devices, 
Sunnyvale, CA, USA) 2–5 days after theRNA injection. Two standard glass 
microelectrodes with 0.5–2 MΩ resistance when filled with 3 M KCl solution were used for 
recordings. Capillary glass for oocyte injections and electrodes was purchased from SDR 
Clinical Technology (Sydney, Australia).  
 
Data acquisition and analysis was performed using pCLAMP software, version 10 
(Molecular Devices). All recordings were conducted at room temperature in ND96 
containing 0.1% fatty acid-free BSA (Sigma). A data set was acquired to determine the 
current-voltage relationship (I-V curve) for the channel in the absence of any channel 
modulators. Oocytes were clamped at –90 mV, and data was sampled at 20,000 Hz. 
Inward NaV currents were invoked by applying 50 ms depolarizing steps from –70 mV to 
+45 mV with 5 mV increments, while holding the oocyte at –90 mV. Then the toxin was 
added, and the current was allowed to equilibrate. A test pulse to –10 mV every 10 s was 
used to detect the equilibration status before acquiring a full I-V curve. 
 
2.2.4 Generation of NaV1.7/Kv1.1 chimeras 
Chimeras were generated using sequential polymerase chain reactions (PCRs) with 
KV2.1Δ7109,110 and hNaV1.7111 as template. The KV2.1Δ7 construct contains seven point 
mutations in the outer vestibule, rendering the channel sensitive to agitoxin-2, a pore-
blocking toxin from scorpion venom112. The DNA sequence of all constructs and mutants 
was confirmed by automated DNA sequencing and cRNA was synthesized using T7 
polymerase (mMessage mMachine kit, Ambion) after linearizing the DNA with appropriate 
restriction enzymes. 
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2.2.5 TEVC recordings using NaV1.7/Kv1.1 chimeras 
Channel constructs were expressed in Xenopus oocytes and studied following 1–2 days 
incubation after cRNA injection (incubated at 17°C in 96 mM NaCl, 2 mM KCl, 5 mM 
HEPES, 1 mM MgCl2 and 1.8 mM CaCl2, 50 µg/ml gentamycin, pH 7.6) using TEVC 
recording techniques (OC-725C, Warner Instruments) with a 150 µl recording chamber. 
Data were filtered at 2 kHz and digitized at 20 kHz using pClamp software (Molecular 
Devices). Microelectrode resistances were 0.3–1 MΩ when filled with 3 M KCl. For KV 
channel experiments, the external recording solution contained 50 mM KCl, 50mM NaCl, 5 
mM HEPES, 1 mM MgCl2 and 0.3 mM CaCl2, pH 7.6. All experiments were performed at 
room temperature (~22 °C). Leak and background conductance, identified by blocking the 
channel with agitoxin-2, were subtracted for all KV currents. All chemicals were obtained 
from Sigma-Aldrich. 
 
Voltage–activation relationships were obtained by measuring tail currents for KV channels. 
Occupancy of closed or resting channels by toxins was examined using negative holding 
voltages where open probability was very low, and the fraction of unbound channels was 
estimated using depolarizations that are too weak to open toxin-bound channels110,113-115. 
After addition of toxin to the recording chamber, equilibration between the toxin and the 
channel was monitored using weak depolarizations elicited at 5–10 s intervals. For all 
channels, voltage–activation relationships were recorded in the absence and presence of 
toxin. Off-line data analysis was performed using Clampfit (Axon), Origin 7.5 (Originlab) 
and Microsoft Solver (Microsoft Excel) to calculate apparent Kd values. 
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2.3 Results  
2.3.1 ProTx1 activity on NaV channels 
ProTx1 is a potent inhibitor of many NaV channel subtypes. In order to obtain better NaV 
subtype selectivity data, we used two-electrode voltage clamp (TEVC) electrophysiology to 
examine the effect of the toxin on human NaV1.2, NaV1.5, NaV1.6, and NaV1.7 expressed 
in Xenopus laevis oocytes. We found that chemically-synthesised ProTx1 inhibited NaV1.7 
with an IC50 of 76 nM (Fig. 8), which is close to the reported value of 51 nM95, thus 
validating the activity of the synthetic toxin. ProTx1 inhibited NaV1.2 and NaV1.6 with IC50 
values of 98 nM and 17 nM, respectively (Fig. 8). NaV1.6 is present in nodes of Ranvier on 
myelinated nerves within both the CNS and PNS54 and therefore inhibition of this channel 
could have detrimental consequences, thus reducing the toxin's desirability as a drug lead. 
ProTx1 was also found to inhibit NaV1.5, the dominant NaV channel in cardiac muscle, with 
an IC50 ~ 340 nM. Although this is about 4.5-fold higher than its IC50 for inhibition of 
NaV1.7, inhibition of NaV1.5 might be a significant off-target liability as inhibition of this 
channel is likely to cause cardiac failure. The ability of ProTx1 to inhibit NaV1.1, NaV1.3, 
and NaV1.9 remains to be determined.  
 
 
 
Figure 8: Concentration-response curves for ProTx1 inhibition of human NaV channels. 
ProTx1 potently inhibited NaV1.2, NaV1.4 and NaV1.7 heterologously expressed in Xenopus 
oocytes, with very similar IC50 values of 98 nM, 57 nM and 76 nM, respectively. ProTx1 inhibited 
NaV1.6 more potently, with IC50 ~17 nM. ProTx1 also inhibited NaV1.5, albeit more weakly, with an 
IC50 of about 340 nM. Error Bars show SEM. Data obtained using TEVC (n = 2). 
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2.3.2 Identifying the ProTx1 pharmacophore for NaV1.7 
Understanding the nature of peptide-target interactions is fundamental to the development 
of a peptide drug lead. Identification of the ProTx1-NaV1.7 interaction surface 
(pharmacophore) is crucial both in terms of describing the toxin activity and enabling 
rational design of mutants with improved potency and/or selectivity. In this study, a 
tethered toxin (t-toxin)-based alanine scanning strategy was used to determine the NaV1.7 
pharmacophore116. Briefly, an expression vector was designed to encode the t-toxin as a 
fusion protein, containing an N-terminal secretory signal, followed by the toxin sequence, 
hydrophilic linker (with c-Myc epitope tag), and C-terminal glycophosphatidylinositol (GPI) 
membrane-anchor targeting sequence (Fig. 9). This construct enables the t-toxins to be 
secreted but they remain attached to the plasma membrane of the secreting cell via the 
GPI anchor. The long hydrophilic linker is expected to allow sufficient freedom of motion so 
that the tethering process does not affect toxin activity. In contrast to traditional peptide-
based alanine scanning mutagenesis process, this technique is much faster and cheaper. 
The peptide-based alanine-scanning process requires every mutant peptide to be 
chemically synthesised, or produced recombinantly, and folded into the correct 
conformation, which can be very expensive and time consuming. In the t-toxin approach, 
the cRNA is transcribed from a plasmid vector, and injected into the oocyte, which uses its 
own protein expression and folding machinery to produce the final folded toxin. 
 
When tethered ProTx1 (t-ProTx1) was co-expressed in Xenopus oocytes with NaV1.7 
channels (using equal quantities of cRNA), complete inhibition of channel current was 
observed (Fig. 10A). In cases where partial currents were observed, the activation voltage 
was right-shifted in current-voltage (I–V) traces. This shift was identical to that observed 
for partial inhibition of NaV1.7 currents by untethered ProTx1. Furthermore, Nitabach and 
colleagues established that both soluble and tethered ProTx1 are capable of binding to 
NaV1.2 channel and stabilizing the NaV activation gate116. This was demonstrated using 
TEVC by applying a large prepulse (from –100 mV to +100 mV) to oocytes expressing 
NaV1.2 and t-ProTx1, and NaV1.2 with soluble ProTx1 added, where currents were fully 
inhibited by the toxin. The prepulse was applied for varying lengths of time (0 to 1000 ms), 
and the maximum current amplitude was observed after a subsequent –100 mV to –10 mV 
test pulse. The magnitude of the current recovered was directly proportional to the 
duration of the prepulse, and oocytes treated with both soluble and tethered toxin 
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exhibited identical current recovery. This indicates that the tethering process has minimal 
or no effect on ProTx1 activity.  
 
 
Figure 9: The tethered toxin approach. (A) The fusion construct contains an N-terminal 
secretory signal sequence, followed by the toxin sequence, a hydrophilic linker with a c-Myc 
epitope tag (for antibody-based detection of the t-toxin on cell surface), and a C-terminal GPI 
membrane-anchor targeting-sequence. (B) Schematic diagram of the tethered toxin expressed on 
the oocyte surface, and interacting with the channel. The GPI anchor is shown in orange, the linker 
containing a c-Myc epitope tag is yellow, and the toxin is shown binding to the pore of the channel. 
Panel A taken from Gui and colleges (2014) publication116. 
 
Expression vectors encoding a panel of 28 ProTx1 mutants were received as a kind gift 
from Prof. Michael Nitabach (Yale University, USA); this panel included mutations of all 
non-Ala and non-Cys residues to alanine. Xenopus oocytes were co-injected with cRNA 
synthesised from each of the mutant expression vectors plus NaV1.7 RNA. Oocytes were 
incubated at 17°C, and currents were recorded 48 h later. The maximum current amplitude 
(activated by pulses from –90 to –10 mV) was recorded for every oocyte. Oocytes injected 
with only NaV1.7 RNA served as the negative control, and oocytes injected with cRNA 
encoding wild-type (WT) ProTx1 served as the positive control. Each mutant was tested in 
at least two batches of oocytes, and the maximum current amplitude for each oocyte was 
recorded (Fig. 10A). In order to confirm that tethered toxins were expressed, an ELISA 
assay was conducted that recognized the c-Myc epitope in the tethered-toxin linker region 
(See Materials and Methods for details). This assay was conducted with the same oocytes 
used in the TEVC recordings for consistency. Mean surface signal measured as the 
absorbance at 450 nm was normalized to that of WT oocytes (Fig. 10B). Oocytes with no 
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injections were used as the negative control, and subtracted from all surface protein 
values prior to normalization.  
NaV1.7 currents were still observed when NaV1.7 was co-expressed with the tethered 
ProTx1 mutants L6A, L19A, W27A, V29A, W30A, and D31A, whereas NaV1.7 currents 
were completely absent when NaV1.7 was co-expressed with WT t-ProTx1 (Fig. 10A). The 
recovery of channel current was not due to lack of surface expression of these mutant t-
toxins (Fig. 10B). L19 is deeply buried in the toxin with little surface exposure (see below) 
and hence we speculate that recovery of channel current for this t-toxin mutant is due to 
misfolding of the toxin. Thus, we conclude that the NaV1.7 pharmacophore comprises 
residues L6, W27A, V29, W30, and D31. Based on the t-toxin alanine scan, residue L6, 
W30 and D31 appear to be the most critical residues for block of NaV1.7. 
 
 
 
Figures 10: Alanine scanning mutagenesis of ProTx1. (A) Mean of maximum current 
amplitudes for each mutant in comparison to the NaV1.7 current when a similar quantity of NaV1.7 
RNA alone was injected. (B) Levels of surface expression of each mutant, normalized to the 
expression of WT t-ProTx1 expression (dotted line). Oocytes with no RNA injected ("Uninjected") 
were used as a negative control.  
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2.3.3 Structure of ProTx1: comparison of NaV1.7 and NaV1.2 pharmacophores 
This structure of the chemically synthesised ProTx1 was determined using 2D 
homonuclear NMR spectroscopy in collaboration with Dr Mehdi Mobli (Centre for 
Advanced Imaging, UQ) and Prof. Norelle Daly (James Cook University). The toxin forms 
a canonical ICK motif in with the C1–C4 and C2–C5 disulfide bonds and the intervening 
sections of polypeptide backbone form a 20-residue loop that is pierced by the C3–C6 
disulfide bond. 
 
The ProTx1 pharmacophores for NaV1.2 and NaV1.7 were mapped onto the 3D structure 
of ProTx1 (Fig. 11). The availability of the NaV1.2 pharmacophore facilitated efforts to 
identify residues that might be important for selectivity for NaV1.7 over NaV1.2. 
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Figure 11: Structure of ProTx1 highlighting pharmacophores for NaV1.7 and NaV1.2. The 
residues critical for ProTx1 inhibition of NaV1.7 (left panel) are shown in yellow (L6, L19, W27, V29, 
W30) and red (D31). Note that these residues form a largely hydrophobic cluster on one face of 
the toxin. L19 is mostly buried. Of the 11 residues in the ProTx1 pharmacophore for NaV1.2, five 
are shared with the pharmacophore for NaV1.7. Two basic residues in the NaV1.2 pharmacophore, 
R3 and R23, are exposed on the outer surface of the molecule, facing the opposite direction to the 
hydrophobic patch. This might be an indication of extra interactions that ProTx1 makes with 
NaV1.2, but not with NaV1.7.  
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2.3.4 ProTx1 interacts primarily with the domain II and domain IV paddle motifs of hNaV1.7 
The helix-turn-helix motif, which is also the paddle motif of the voltage sensor domain, is 
know to be the integral component in KV channels, that moves near the protein-lipid 
interface to drive the activation of the channel by opening the pore117-121. Further, it is also 
known that certain tarantula toxins, including ProTx1, exert their inhibitory effect on KV, 
and NaV channels by interacting with VSD paddle motif, thereby modulating the channel 
function110,113,120,122-127. It has been previously established that ProTx1 binds to NaV1.2 
VSDs of different domains, with varying affinity114. Bosmans and colleagues (2008) have 
used a chimeric channel technique, where VSD paddle motifs of NaV1.2 were transplanted 
on the KV2.1 channel, which is structurally very similar to a single domain of a NaV 
channel. This resulted in four chimeric channels of rNaV1.2a/KV2.1 for each VSD paddle 
motif. This experiment was conducted to observe the change in toxin affinity for the 
chimeric channel, hence to determine individual VSD-ProTx1 affinities in an isolated 
system114. In this experiment it is of most importance that the toxin in question does not 
have high affinity toward the KV2.1 channel, which would complicate the binding process 
and would make it impossible to come to a conclusion of toxin interaction with the chimeric 
channel.  
 
As mentioned before Bosmans and colleagues uncovered that ProTx1 binds to VSD of 
domains II and IV, exhibiting minimal affinity towards KV2.1 channel. To understand 
whether ProTx1 inhibits NaV1.7 opening by interacting with one or more VSDs, effect of 
ProTx1 on KV2.1 and the four hNaV1.7/KV2.1 paddle chimeras were examined. It was 
found that 100 nM of the toxin only slightly influenced wild-type KV2.1 (apparent Kd = 2408 
± 189 nM) whereas the domain II and domain IV chimeras are strongly inhibited with an 
apparent Kd of 114 ± 12 nM and 199 ± 48 nM, respectively. In addition, the NaV1.7/KV2.1 
domain I paddle chimera is also sensitive to ProTx1, albeit at higher concentrations 
(apparent Kd = 612 ± 98 nM) whereas the domain III chimera is not inhibited at 100 nM 
(apparent Kd = 10452 ± 836 nM).  
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Figure 12: 4 Identification of hNaV1.7 voltage sensing domains that interact with ProTx1. (A) 
KV2.1 potassium current elicited by a depolarization to 0 lmV clamped back to –60mV from a 
holding potential of –90 mV before (black) and in the presence of 100 nM ProTx1 (grey). (B) 
Apparent affinity of ProTx1 for KV2.1. Concentration dependence for toxin inhibition measured at 
negative voltages is shown. The apparent equilibrium dissociation constant (Kd) for toxin 
interaction with KV2.1 was calculated assuming four independent toxin-binding sites per channel, 
with single occupancy being sufficient to inhibit opening in response to weak depolarizations. (C) 
Potassium currents elicited by depolarizations near the foot of the voltage–activation curve for 
hNaV1.7/KV2.1 chimeric constructs. Currents are shown before (black) and in the presence of 
100 nM ProTx1. Scale bars are 50 ms (abscissa) and 0.3 µA (ordinate axis). 
 
2.3.5 Design and characterization of ProTx1 mutants 
In order to increase ProTx1's utility as an analgesic lead, it is essential to increase its 
selectivity towards NaV1.7 in order to reduce potential off-target effects. Three ProTx1 
mutants were designed to investigate the effect of these mutations on NaV1.7 selectivity. 
These designs were based on the NaV1.7 and NaV1.2 pharmacophores mapped onto the 
structure of ProTx1 (Fig. 11), as well as a sequence alignment of ProTx1 with two novel 
ProTx1 orthologs (Fig. 13). The three ProTx1 mutants were K17E, ProTx1-NH2 (amidated 
C-terminus), and ProTx1-G32A-NH2 (G32A mutation with amidated C-terminus). The 
K17E mutant was designed before the 3D structure of ProTx1 became available. A 
sequence alignment of ProTx1 and its orthologs, and the NaV1.7 affinity of each toxin, 
were analysed (Fig. 13). Notably, the entire ProTx1 pharmacophore for NaV1.7 is 
conserved in β-TRTX-Pe1b, but this toxin lacks the potency of ProTx1 for NaV1.7. This 
suggests that additional residues might be involved in the toxin-channel interaction. µ-
TRTX-Pe1a also has high homology to ProTx1, but lower potency against NaV1.7. These 
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toxins appear to contain a high density of acidic residues near C15 and C16. In particular, 
we wondered whether the charge reversal at position 17 (K17 in ProTx1 and E17 in β-
TRTX-Pe1b) might contribute to the loss of potency seen in β-TRTX-Pe1b. In the absence 
of the ProTx1 structure to identify the topological disposition of this residue in the folded 
toxin, it was decided to make the K17E mutant synthetically.  
 
 
Figure 13: Sequence alignment of ProTx1, µ-TRTX-Pe1a and β-TRTX-Pe1b. The five NaV1.7 
residues comprising the ProTx1 pharmacophore are shown in orange (hydrophobic residues) and 
red (acidic residues). The IC50 values for block of NaV1.7 by each toxin are indicated. All five 
pharmacophore residues are conserved in β-TRTX-Pe1b, yet the potency toward NaV1.7 is about 
two-fold less. Four out of five active residues are conserved in µ-TRTX-Pe1a, and it shows about 
130-fold loss of activity in comparison to ProTx1.  
 
The K17E mutant was produced by solid-phase peptide synthesis and tested using TEVC 
electrophysiology. The charge reversal mutation lead to reduced activity against all NaV 
channel subtypes that were tested (Fig. 15). Activity against NaV1.6 was reduced about 
11-fold, while activity against NaV1.7 was 6.7-fold lower. NaV1.2 and NaV1.5 were least 
affected with about a 3-fold loss of activity (Table 3). 
 
Amidated ProTx1 and amidated ProTx1-G32A mutants were designed after the ProTx1 
structure became available. Many toxins within NaSpTx family 2 are amidated (Fig. 14, red 
asterisks). We therefore wondered whether C-terminal amidation might affect ProTx1 
activity. As mentioned previously, F34 is an important part of the NaV1.2 pharmacophore, 
and G32 appears to be critical for the positioning of this residue in the last turn prior to the 
C-terminus of the toxin. Thus, we decided to mutate G32 to an alanine, with the 
expectation that the ProTx1-G32A-NH2 mutant would have compromised affinity for 
NaV1.2, but maintain affinity for NaV1.7.  
 
When tested using TEVC electrophysiology, the ProTx1-G32A-NH2 showed reduced 
activity towards all NaV channels tested. Activity against NaV1.6 was 32-fold lower (IC50 
increase from 20 nM to 636 nM). Activity against NaV1.5, NaV1.2 and NaV1.7 was reduced 
12-fold, 8-fold, and 5.4-fold, respectively.  
 
ProTx-1    ECRYWLGGCS AGQTCCKHLV CSRRHGWCVW DGTFS   76 nM
β-TRTX-Pe1b   GECRYWLGGCS KTGDCCEHLS CSPKWHWCVW DGTF   152 nM
µ-TRTX-Pe1a   GECKYLWGTCS KDEDCCAHLG CNRKHDWCGW DYTF   >10 µM
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The ProTx1-NH2 mutant had 14-fold increased activity towards NaV1.2 with an IC50 of ~7 
nM for inhibition of this channel. C-terminal amidation led to a 3-fold loss of activity against 
NaV1.5 (IC50 ~ 800 nM), and a 2-fold loss of activity against NaV1.6. In contrast, C-terminal 
amidation had no affect on ProTx1 activity against NaV1.7 (IC50 ~ 77 nM). 
 
 
 
Figure 14: Sequence alignment of NaSpTx Family 2 peptides. This is the largest NaSpTx 
family, and it contains the well-known ProTx1 (β/ω-TRTX-Tp1a) and the close ortholog SGTX1 (κ-
TRTX-Scg1a). Peptides that are C-terminally amidated are marked with a red asterisk.  
 
typically resistant to extremes of pH, organic solvents,
high temperatures, and proteases (Saez et al., 2010). Of the
10 families of NaSpTxs whose disulfide connectivity has
been determined or which can be confidently predicted
based on homology (see Figs. 3 and 4), nine contain an ICK
motif.
One member of Family 1 (m/u-TRTX-Hh1a; huwentoxin-
1) was found to be analgesic in a rat model of formalin-
induced pain when administered intrathecally (Chen
et al., 2005), although in another study the same peptide
was reported to be lethal to mice when delivered via the
intraperitoneal or intracisternal route (Liang et al., 1993).
Fig. 3. NaSpTx families 1–4, 7 and 10. The consensus sequence is shown above each alignment, with the disulfide bond connectivity indicated in blue. Red
asterisks denote C-terminal amidation. Strictly conserved residues are highlighted in bold colour while semi-conserved residues are highlighted in a lighter
colour. Toxin names are based on the rational nomenclature devised for spider-venom peptides (King et al., 2008b), as used in ArachnoServer and UniProt (King
et al., 2008b). The structure of a representative member from each NaSpTx family is shown adjacent to each alignment: Family 1, m-TRTX-Hh2a (PDB ID: 1MB6);
Family 2, k-TRTX-Gr1a (PDB ID: 1D1H); Family 3, k-TRTX-Gr2a (PDB ID: 1LUP); Family 4, d-HXTX-Hv1a (PDB ID: 1VTX); Family 7, k-TRTX-Gr3a (PDB ID: 1S6X);
Family 10, d-AMATX-Pl1b (PDB ID: 1V91). b strands are depicted in cyan, helices are red, and disulfide bridges are yellow. All spider photos were taken by Bastian
Rast.
J.K. Klint et al. / Toxicon 60 (2012) 478–491 481
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Figure 15: Effect of ProTx1 mutants on activity against NaV1.2, NaV1.5, NaV1.6, and NaV1.7. A 
K17E mutation reduced the potency of ProTx1 for NaV1.2 and NaV1.5 by approximately 3-fold. 
Potency for NaV1.7 was reduced about 7-fold, while potency against NaV1.6 was reduced ~10-fold. 
The ProTx1-G32A-NH2 mutant exhibited even greater changes in activity. Activity against NaV1.2 
was least affected, with a 8-fold reduction in IC50, while potency against NaV1.6 and NaV1.7 was 
reduced ~30-fold. C-terminal amidation of ProTx1 significantly improved potency against NaV1.2.  
 
 
Table 3: NaV channel activity of ProTx1 mutants. IC50 values for inhibition of various NaV 
channel subtypes by wild-type (WT) ProTx1 and mutants thereof. In columns 3–5, the fold increase 
in IC50 for each mutant compared to that for WT ProTx1 is shown in parentheses.  
Channel WT-ProTx1 K17E G32A-NH2 ProTx1-NH2 
NaV1.2 98 nM 304 nM (3.1x) 770 nM (8x) 7 nM  
NaV1.5 237 nM 800 nM (3.3x) 3000 nM (12.6x) 800 nM (3.3x) 
NaV1.6 20 nM 220 nM (11x) 636 nM (32x) 43 nM (2x) 
NaV1.7 67 nM 450 nM  (6.7x) 362 nM (5.4x) 77 nM  
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2.4 Discussion  
The experiments described in this chapter provide data on the potency of ProTx1 and 
various mutants thereof against NaV1.2, NaV1.4, NaV1.5 and NaV1.6, data that is very 
important for developing a selectivity profile for ProTx1. The NaV1.7 pharmacophore of 
ProTx1 was identified and compared to the NaV1.2 pharmacophore identified by Nitabach 
and colleagues116. The NaV1.7 pharmacophore is primarily composed of hydrophobic 
residues (L6, W27, V29 and W30) plus one charged residue (D31). Additional 
mutatagensis data indicated that G32 has a significant role in the ProTx1 interaction with 
NaV1.7. Although K17E mutation showed significant changes to the toxin activity, the 
alanine scan did not reveal this effect (Fig. 10). One explanation could be that K17 is not a 
critical residue in the ProTx1-NaV1.7 interaction, however the introduction of E, which is a 
charge reversal mutation introduces rather unfavourable interactions. Thereby displaying 
substantially changed potency on various NaV. In contrast, the ProTx1 pharmacophore for 
interaction with NaV1.2  is much larger and consists of 11 residues, with five residues (L19, 
W27, V29, W30 and D31) being shared with the NaV1.7 pharmacophore.  
 
The most remarkable feature of this structural comparison was the set of four hydrophobic 
residues W5, L6, W27 and W30. Together, these residues comprise a very distinguishable 
hydrophobic protrusion on one side of the molecule. Looking at this patch of 
hydrophobicity, one might expect all of them to form part of a binding surface. Intriguingly, 
the mutational studies described above revealed that a W5A mutation has no effect on the 
ability of ProTx1 to inhibit NaV1.7, while an L6A mutation has very little effect on the ability 
of ProTx1 to inhibit NaV1.2. However, if one examines the original data from the NaV1.2 
tethered-toxin alanine scan, it appears that the L6A mutation was just below the cut-off for 
selection as a pharmacophore residue (Supplementary Figure 1). Thus, the NaV1.2-
ProTx1 interaction appears to be mediated by all four hydrophobic residues, W5, L6, W27 
and W30, while the NaV1.7-ProTx1 interaction does not require W5.  
 
The NaV1.7 pharmacophore lacks the ring of charged residues  (R3, R23) and polar 
uncharged residue (S22) (Fig. 11B). These are away from the hydrophobic patch, facing 
the opposite side of the molecule, around the widest region of the folded peptide.  This 
motif of a hydrophobic patch surrounded by a ring of charged/polar residues has been 
observed before in other NaSpTx Family 2 toxins such as ω-TRTX-Gr1a (GrTx), κ-TRTX-
Gr1a (Hanatoxin-1) and κ-TRTX-Scg1a (SGTx)128-130. 
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A full alanine scan mutagenesis study was conducted to determine the pharmacophore on 
κ-TRTX-Scg1a that mediates its interaction with KV2.1; the minimal active surface consists 
of 11 residues130. Four of these (Y4, L5, F6 and W30) form a hydrophobic patch, while 
other polar residues form a ring-like assembly concentrically arranged around this 
hydrophobic patch. Most importantly, alanine mutations of basic residues R3 and R23 led 
to a dramatic loss of activity, indicating that these residues may be directly interacting with 
the voltage sensor domain of KV2.1130.  
 
Previous studies revealed that an L19A mutant of κ-TRTX-Scg1a failed to fold properly130. 
L19 is fully conserved across the NaSpTx family 2 (Fig. 14), and it is completely buried 
within the ProTx1 structure. An L19A mutation abrogated the ability of t-ProTx1 to inhibit 
both NaV1.2 and NaV1.7. While ELISA assays indicated that this t-toxin mutant is 
expressed on the cell surface of oocytes, these assays do not address whether the L19A 
mutant is properly folded. It therefore seems likely that L19 has an important structural role 
in ProTx1. Thus, we conclude that an L19A mutation is likely to perturb ProTx1 folding but 
is unlikely to be part of the ProTx1 pharmacophore for NaV1.2 or NaV1.7. 
 
As discussed previously (Section 2.3.4) ProTx1 binds to voltage sensor domains (VSDs) 
on channel domains II and IV (DII and DIV). Scanning mutagenesis of the rat NaV1.2 α-
subunit (rNaV1.2) VSDs revealed several important residues on the DII VSD for the 
interaction with ProTx1 (Fig. 16). The mutations L840A, A841V, E844A, E844K, G845A, 
S847A, S851A, and L854A on DII all changed the apparent affinity of ProTx1 for 
rNaV1.2114. This sequence of this region in the DII-VSD is identical in rat and human 
NaV1.2, and the same region of human NaV1.7 differs from rNaV1.2/hNaV1.2 by only four 
residues, not inclusive of the residues listed above. The mutations F1610A, E1613A, 
L1614A and Y1619A in the DIV-VSD of rNaV1.2 also significantly reduced apparent affinity 
for ProTx1. Again, the sequence of this region is identical in rNaV1.2 and hNaV1.2 and only 
two residues are different in hNaV1.7. In NaV1.7, E1613 is conservatively substituted for 
Asp, while a Lys to Thr substitution at position 1618 is not significant for ProTx1 binding. 
Thus, while it may be assumed that the ProTx1 binding surface on NaV1.7 is similar to that 
of NaV1.2, the precise NaV1.7 VSD residues that bind to ProTx1 remain to be determined.  
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Figure 16: ProTx1 binding residues of rNaV1.2. Alignment of the S3-S4 segments of the DII and 
DIV VSDs of hNaV1.2 and hNaV1.7. Transmembrane residues are marked in black, and the 
extracellular loops of DII and DIV are marked in red and purple respectively. The rNaV1.2 residues 
that are involved in ProTx1 binding are marked with blue boxes. Two sequences of NaV1.2 and 
NaV1.7 are mostly identical; differences are marked with an asterisk. All ProTx1 binding residues in 
the DII-VSD of rNaV1.2 DII are conserved in NaV1.7. Three of the four ProTx1 binding residues in 
the DIV-VSD of rNaV1.2 are conserved with NaV1.7.  E1613 is substituted by an Asp residue in the 
NaV1.7 DIV-VSD.      
 
In a previous study aimed at understanding the role of the κ-TRTX-Scg1a pharmacophore 
residues in lipid partitioning, it was found that alanine point mutations of eight residues 
(Y4, L5, F6, K17, H18, K26, G32, F34) each lost the capacity to partition significantly into 
lipid membrane130,131. Therefore it was argued that these residues have a role in lipid 
partitioning prior to binding the channel. However, the authors ruled out the possibility that 
the toxin exerts its inhibitory effect purely by disrupting lipid packing around the VSD and 
pore region. This was demonstrated by construction of the D-enantiomer of κ-TRTX-
Scg1a, which showed very similar lipid partitioning capacity, yet no inhibition of KV2.1. On 
the other hand, removing polar head groups of membrane lipids by converting 
sphingomyelin to ceramide, diminished the stability of the toxin-channel complex131,132. In 
conclusion, it was demonstrated that toxins such as κ-TRTX-Scg1a can partition into 
membranes under physiologically relevant conditions, and interact with the S3-S4 
transmembrane helices of the VSD to inhibit KV2.1132. Thus, many toxins of the NaSpTx 
Family 2 likely have two sets of overlapping functional residues that are important for their 
channel inhibitory function, where one set is important for lipid partitioning, and the second 
set makes direct protein-protein interactions with the channel. 
 
Two of the ProTx1 mutants constructed here, K17E and G32A, showed different selectivity 
and potency towards NaV1.2, NaV1.5, NaV1.6 and NaV1.7 relative to wild-type ProTx1. The 
K17E charge reversal mutation did not improve ProTx1 specificity towards NaV1.7. 
However, the ProTx1-G32A mutant had slightly improved selectivity for NaV1.7 over other 
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NaV channels. The side chain of glycine comprises a single hydrogen atom, and hence it 
can never contribute to energetically important protein-protein interactions. Therefore, we 
speculate that G32 plays an important role in the ProTx1-NaV channel interaction by 
helping to position C-terminal residues that are important for direct interactions with NaV 
channels.   
 
The S3-S4 extracellular loops in the DII-VSD of NaV1.7 and NaV1.6 are identical, yet the 
G32A mutation caused a greater loss of activity against NaV1.6 than NaV1.7. Similarly, 
though less profound, the K17E mutation also showed a difference in loss of activity 
between NaV1.6 and NaV1.7. These observations suggest that there are additional regions 
on the extracellular surface of NaV channels that are required for the interaction with 
ProTx1. 
 
ProTx1 binds to NaV1.6, NaV1.7 and NaV1.8 with similarly high affinity (IC50 range of 20–90 
nM).  However the S3-S4 loop in the DII-VSD region of NaV1.8 is substantially different to 
that of NaV1.2, NaV1.6 and NaV1.7. Therefore it seems that the promiscuous activity of 
ProTx1 on NaV might arise from a region with higher conservation, such as the S3/S4 
transmembrane segments of the VSD, or perhaps ProTx1 simply interacts with different 
VSDs on the different channels.  
 
NaSpTx Family 2 toxins, including ProTx1, may use a set of residues to partition into the 
membrane and interact with highly conserved transmembrane helices S3 and S4, while 
the ring of charged residues, which are exposed to the solvent, make interactions with the 
extracellular loop.   
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Figure 17: Sequence alignment of the S1–S2 and S3–S4 segments of domains I, II and IV 
from each of the nine human NaV channel subtypes. 
 
ProTx1, a member of NaSpTx family 2 (Fig. 14), is a potent NaV1.7 inhibitor with 
promiscuous activity on a number of other neuronal targets including TRPV1, CaV 
channels and other NaV channels. This makes it a challenging molecule to develop into an 
analgesic drug lead. We identified the ProTx1 pharmacophore responsible for interaction 
with ProTx1, and identified the ProTx1 binding domain on NaV1.7 using a panel of 
KV2.1/NaV1.7 chimeric channels. We also designed and tested three ProTx1 mutants in 
the hope of achieving increased selectivity for NaV1.7. One of these ProTx1 mutants, 
G32A-NH2, had increased selectivity for NaV1.7, although this was achieved by slightly 
compromising toxin potency. The ProTx1 G32A-NH2 mutant therefore provides a solid 
foundation for development of ProTx1 as an analgesic drug lead.  
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Supplementary figures/ Appendix 
 
 
Supplementary Figure 1: Membrane tethering has no effect on ProTx1 inhibition of NaV 
channels. (A) I–V traces for human NaV1.7 expressed in Xenopus oocytes with no toxin (blue), 
addition of soluble ProTx1 (orange), or co-expressed with t-ProTx1 (green). ProTx1 shifts the 
activation voltage to more positive potentials. (B) A large voltage prepulse (–100 mV to +100 mV) 
applied to NaV1.2-expressing oocytes before the test pulse (–100 mV to –10 mV) for a varying 
duration of time (0–1000 ms). (C) and (D) show recovery of NaV1.2 currents with increasing 
duration of the prepulse, in the presence of tethered ProTx1. (E) and (F) show the increasing 
NaV1.2 recovery with longer prepulse, in the presence of the soluble ProTx1. This indicates that 
tethering does not alter the mode of action of ProTx1 (NaV1.2 data from Prof. Michael Nitabach, 
Yale University).  
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Supplementary Figure 2: Alanine-scanning mutagenesis of t-ProTx1. cRNAs of WT and 
alanine mutant t-ProTxI were transcribed in vitro and co-injected into Xenopus oocytes with 
hNaV1.2. 2-4 days after injection, voltage- or mustard oil-induced currents were recorded by two-
electrode voltage clamp. Currents were normalized to oocytes in which the channel of interest is 
co-expressed with a control t-toxin: ACTX=δ-ACTX-Hv1a, an inhibitor of Na+ channel inactivation; 
PLTX=PLTX-II, an inhibitor of N-type Ca2+ channel133. Asterisks indicate alanine mutants with 
significantly larger currents compared to oocytes co-expressing the channel of interest with wild-
type t-ProTxI (p<0.05, one-way ANOVA with Bonferroni's paired-comparison versus control). 
 
 
 
 
Supplementary Figure 3: Immunoassay of alanine mutant surface expression. cRNAs of WT 
and mutant t-ProTxI were transcribed in vitro and injected into Xenopus oocytes. After 2-3 days 
incubation, surface expression of WT and mutant t-ProTx1 were measured by immunodetection of 
the linker domain epitope tag in living unpermeabilized oocytes and normalized to the surface 
signal of WT t-ProTx-I. 
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CHAPTER 3 
 
DISCOVERY AND CHARACTERIZATION OF A NOVEL NaV1.7 INHIBITOR, β/µ-TRTX-
Pe1b 
 
 
3.1 Introduction 
 
Chapter 2 revealed how alanine-scanning mutagenesis was successfully employed to 
uncover structure-activity relationships of protoxin-1. However, an alternative approach to 
understanding structure-activity relationships, which was employed in the work described 
in this Chapter, is to investigate the consequences of natural sequence variations found in 
homologous spider toxins.  
 
Spider venoms are highly complex cocktails of peptides, proteins, small organic 
molecules, and salts75,85,134. Traditional proteomics-based estimates revealed that one 
venom could contain up to 1000 unique peptides75, whereas newer data suggests that this 
number can be as high as 3000135. Due to the incredible speciosity of the spiders (~45,000 
extant species have been characterised;72), as a group they provide a vast number of 
peptides with varying levels of homology to each other. This natural sequence variation 
can be utilized as a tool to discover sequence variations that alter potency and specificity 
for selected pharmacological targets. 
 
The discovery of novel bioactive peptides is a complicated process. Traditionally, this has 
been done via chromatographic fractionation of venoms92,95, but profiling of venom-gland 
transcriptomes is now being used more commonly135,136. In either case, there is usually a 
heavy emphasis on the dominant component in the venom or transcriptome, and this 
component is often screened against a series of ion channels and receptors to identify its 
natural target. This method can overlook compounds present in minor quantities. In many 
cases, a combined proteomic and trascriptomic approach is taken to identify full 
sequences of novel peptides, subject to availability of time and resources135,137. However 
the traditional discovery process remains an extremely time consuming process.  
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In contrast, assay-guided fractionation presents researchers the opportunity to rapidly 
screen a range of compounds against one or more selected targets, and follow up only on 
compounds with activity against these targets. Assay-guided fractionation consists of three 
major stages138. In the first stage, a panel of venoms is screened against the target of 
interest to identify venoms with desired activity. The screening assay can be high 
throughput (HTP) or low throughput. These methods are further discussed in next 
paragraph. In the second stage, venoms with desired activity ("hit" venoms) are 
chromatographically fractionated using reverse-phase high performance liquid 
chromatography (RP-HPLC) and then individual fractions are screened in the target assay. 
The purity of these fractions can be assessed using mass spectroscopic techniques such 
as matrix-assisted laser desorption (MALDI). In many cases, an additional orthogonal 
chromatographic fractionation of the "hit" RP-HPLC fractions will be required to isolate the 
pure bioactive compound. In the third stage, the purified bioactive peptide is sequenced 
using a combination of Edman degradation and MS/MS sequencing and, if it is available, 
reference to a venom-gland transcriptome. 
 
As mentioned above, the venom screens can be conducted using high- or low-throughput 
methods. Many high-throughput techniques such as the fluorescent imaging plate reader 
(FLIPR) and automated patch clamp systems have been developed over the last decade, 
and many compound libraries have been screened very efficiently using these methods139. 
Although high-throughput techniques provide fast and cost-effective discovery of lead 
molecules, there is always the risk of false positives and false negatives. In contrast, low 
throughput techniques typically allow better accuracy, but the number of samples that can 
be tested in a given time is restricted. Therefore, the most appropriate screening technique 
needs to be selected based on the size and quality of the compound library tested and the 
time permissible for the initial screening process. 
 
The advantage of assay-guided fractionation is not limited to the discovery of novel 
peptides. It can also be utilized as a tool to probe the inherent SAR potential of peptides. 
When a large number of spider venoms are fractionated and assessed on a single target, 
it is normal to find a number of homologous peptides amongst the hits. This is particularly 
true for screens against NaV and CaV channels, which are the dominant pharmacology of 
spider-venom peptides32,33. Minor sequence variations between homologous peptides can 
lead to drastic differences in potency and target subtype selectivity. For example, the two 
spider-venom peptides β-TRTX-Cm1a and β-TRTX-Cm1b only differ by a single amino 
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acid residue (D32 in β-TRTX-Cm1a compared to Y32 in β-TRTX-Cm1b)92. Nevertheless 
they show substantial difference in activity towards NaV1.3, with β-TRTX-Cm1b having 
IC50 of 88 ± 25 nM and β-TRTX-Cm1a showed no observable effect up to a concentration 
of 2 µM. Therefore the availability of homologous toxins provides a great resource for 
understanding the target activity and selectivity of venom peptides. 
 
The primary aim of this chapter is to demonstrate the power of assay-guided fractionation 
in the search for novel toxins and analogues of known toxins. Secondly, this chapter will 
demonstrate how a homology-model-based mutagenesis approach can be employed to 
enhance the preferred selectivity profile of a NaV channel toxin in order to obtain a potent 
and selective NaV1.7 inhibitor as an analgesic drug lead. 
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3.2 Materials and methods 
 
3.2.1 Fractionation and purification of spider venoms 
3.2.1.1 RP-HPLC 
Crude venom (1 mg) from each spider was fractionated using an analytical C18 RP-HPLC 
column (Vydac). Buffer A was 0.05% trifluoroacetic acid (TFA) in water and buffer B was 
0.05% TFA in 90% acetonitrile. Fractionation was performed using the gradient of 5% 
solvent B for 5 min, 5-20% solvent B for 5 min, 20-40% solvent B for 40 min, 40-80% 
solvent B for 4 min, wash at 80% solvent B for 2 min, 80-5% solvent B for 4, and a final 
5% solvent B wash for 10 min at a flow rate of 1 ml/min. The total program length was 70 
min. 
 
3.2.1.2 Ion exchange HPLC 
“NaV1.7-active” RP-HPLC fractions selected on the basis of FLIPR assays were further 
fractionated using ion exchange HPLC. A polysulfoethyl ion exchange column was used 
with buffer A (20 mM KH2PO4, 20% acetonitrile, pH 2.7) and buffer B (20 mM KH2PO4, 
20% acetonitrile, 1 M KCl). Fractionation was performed using a salt gradient of 0% 
solvent B for 3 min, 0-45% solvent B for 45 min, 45-100% in 1 min, at 100% for 2 min, 
100-0% in 1 min, and at 0% solvent B for 3 min at a flow rate of 1 ml/min The total 
fractionation time was 55 min.  
 
3.2.1.3 Desalting by reverse phase HPLC 
Ion exchange fractions were desalted using RP-HPLC on a Monolithic C18 column 
(Phenomenex). Buffer A was 0.1% formic acid in water and buffer B was 0.1% formic acid 
in 90% acetonitrile. Desalting was performed using a gradient of 5–60% solvent B over 8 
min at a flow rate of 1 ml/min.  
 
3.2.2 FLIPR assays 
FLIPR assays were performed by Dr Irina Vetter (Institute for Molecular Bioscience, The 
University of Queensland). Human neuroblastoma cells, SH-SY5Y (Max Planck Institute 
for Experimental Medicine, Goettingen, Germany) were incubated in the presence of 5% 
CO2 with 15% of fetal bovine serum and 2 mM L-glutamine at 37°C. SH-SY5Y cells were 
routinely passaged ever 3-5 days at a 1:5 dilution with 0.25% trypsin and EDTA (Gibco). 
Cells were plated on an uncoated black-walled 96-well imaging plate (Corning, Lowell, MA, 
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USA) approximately 150,000 cells per well density, 48 h prior to the FLIPR assay. At the 
beginning of the assay cells were treated with Fluo-4 AM (5 µM) in physiological salt 
solution (PSS; composition NaCl 140 mM, glucose 11.5 mM, KCl 5.9 mM, MgCl2 1.4 mM, 
NaH2PO4 1.2 mM, NaHCO3 5 mM, CaCl2 1.8 mM, HEPES 10 mM) with 0.3% BSA and 
incubated at 37°C for 30 min. At the end of 3 min, cells were treated with PSS and 
incubated another 10 min to ensure complete de-esterification of the fluorophore. Cells 
were washed twice with PSS. The 96 well-plate was transferred into the FLIPRTETRA 
(Molecular Devices, Sunnyvale, CA) fluorescent plate reader. Calcium responses were 
measured using a cooled CCD camera. The excitation and emission wavelengths of Flou-
4 AM are between 470–495 nm and 515–575 nm respectively. Ten baseline fluorescence 
readings were taken prior to the addition of the spider venom, or venom fraction. Then, 
fluorescent readings were taken for 300 s and NaV1.7 potentiator, veratridine, was added. 
Fluorescent readings were continued for another 300 s to observe the effect of the toxin or 
venom component in NaV1.7 activity.  
 
3.2.3 Reduction of disulfide bonds and alkylation of cysteine residues 
Purified peptides were lyophilized and centrifuged at 13,000 rpm for 2–3 min in a 1.5 mL 
microcentrifuge tube. 50 µL of reduction/alkylation mixture (88% acetonitrile, 10% 
iodoethanol, 2% triethylphosphine) was placed on to the lid of the tube. The tube was 
closed carefully and the tube was then placed in a 37°C incubator for 45 min, after which 
the reduction/alkylation mixture was discarded along with the lid of the tube. The solid 
peptide at the bottom of the tube was dissolved in 50 µL of water and transferred into a 
fresh tube for further analysis. The extent of reduction and alkylation was assessed using 
mass spectrometry.  
 
3.2.4 Mass spectrometry (MALDI-TOF and MADLI-ISD)  
Peptides masses were determined using MALDI time-of-flight (MALDI-TOF) mass 
spectrometry on a Model 4700 proteomics analyzer (Applied Biosystems). 1 µL of the 
sample was mixed with a 0.5 µL of α-cyano-4-hydroxycinnamic acid (CHCA) matrix (5 
mg/ml in 50% acetonitrile) in a MALDI plate spot and dried at room temperature. Results 
were analyzed with Data Explorer® software (Applied Biosystems).  
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3.2.5 Recombinant expression of µ-TRTX-Pe1b  
3.2.5.1 Transformation 
Transformation of E. coli cells with pLic-MBP expression vector was carried out as follows. 
Competent DH5α cells frozen at –80°C were thawed on ice for about 5 min, then 5 µL of 
plasmid was dissolved in nuclease-free water. Cells were left on ice for 45 min then heat-
shocked at 42°C for 45 s. Cells were then placed on ice for another 5 min. 1 mL of Luria-
Bertani (LB) medium was then added into the tube prior to incubation at 37°C for 1 h. The 
cell culture was then centrifuged at 8000 rpm for 5 min and ~900 µL of supernatant was 
removed. The pellet was resuspended in the remaining 100 µL of medium, plated on 
LB/agar + ampicillin (100 µg/ml), and incubated overnight at 37°C. Plasmids were 
extracted using a QIAprep Spin Miniprep Kit (Qiagen, Australia), and used to transform 
into E. coli strain BL21 (Invitrogen).  
 
3.2.5.2 Recombinant expression, purification and cleavage of the fusion protein 
Production of recombinant venom peptides was performed using a modified version of a 
published protocol 140. Briefly transformed BL21(λDE3) cells were grown in 2 L of Luria-
Bertani (LB) medium to OD600 of 0.8, induced with 250 µM β-D-1-thiogalactopyranoside 
(IPTG) (Invitrogen), incubated for 24 h at 16°C, and harvested by centrifugation at 4000 
rpm for 15 min at 4°C. The cell pellet was resuspended in 40 mM Tris, 400 mM NaCl, pH 8 
(TN buffer), then cells were lysed by continuous flow cell disruption (TS Series Benchtop 
System, Constant Systems Ltd, Northants, UK) at a constant pressure of 25 kPa. The 
soluble fraction was separated by centrifuging the cell lysate at 15,000 rpm for 30 min at 
4°C. The His6-MBP-toxin fusion protein was purified by passing the soluble fraction 
through an affinity chromatography column containing charged Ni-NTA super flow resin 
(Pierce, USA). The resin was then washed with 15 mM imidazole in TN buffer in order to 
remove proteins that were bound nonspecifically. The fusion protein was then eluted with 
500 mM imidazole in TN buffer. The fusion protein sample was concentrated by centrifugal 
filtration (Amicon® Ultra, Millipore). Following concentration, the fusion protein was 
cleaved by incubation at 30°C for 3 h on a shaker with His6-tagged TEV protease (0.02 
mg/mL) in the presence of reduced (GSH) and oxidized (GGSG) glutathione (0.2 mM 
GSH/0.04 mM GSSG) (Sigma). The TEV protease was produced in-house according to a 
published protocol 141. 
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3.2.5.3 Purification using a solid phase extraction column  
Sufficient HPLC solvent B (90% acetonitrile, 0.05% TFA) was added to the cleavage 
mixture to make a final concentration of 5% solvent B, then the mixture was centrifuged at 
5500 rpm and filtered through a 0.45-µm syringe filter to remove MBP precipitates. The 
toxin was purified away from MBP and uncleaved fusion protein using a syringe solid 
phase extraction column (C18-LP; Alltech) conditioned with methanol and equilibrated with 
5% solvent B. The column was washed with 5% solvent B, and toxin eluted with 50% 
solvent B. Any remaining components were eluted with 100% solvent B and methanol. 
Each fraction was lyophilized overnight. The 50% elution was resuspended in HPLC 
solvent A (water with 0.05% TFA), filtered with a 0.45 µm syringe filter and analysed using 
RP-HPLC. Toxins were further purified to obtain a single isoform on an analytical grade 
C18 Vydac column (4.6 × 250 mm, 5 µm) using a Shimadzu HPLC system (Shimadzu, 
Kyoto, Japan). 
 
3.2.5.4 Purification of the cleaved peptide with C4 semi-preparative column 
When a semi-preparative C4 column (Phenomenex Jupiter, 250 x10 mm, 10 µm) became 
available, the cleavage mixture could be purified in one step without use of SPE column 
purification described before. The cleavage mixture was acidified with 0.5% TFA and 5% 
solvent B was added to equilibrate the mixture to RP-HPLC baseline conditions. The 
cleavage mixture was centrifuged at 5500 rpm for 15 min to remove precipitated MBP, 
then the clear supernatant was filtered through a 0.45 µm filter before injection into the 
HPLC system. 
 
3.2.6 Two-electrode voltage clamp electrophysiology 
3.2.6.1 Electrophysiological assay of toxin activity 
Oocytes were surgically removed form Xenopus laevis frogs and treated with 30 mg of 
collagenase (Sigma type1) in 20 mL of calcium-free ND96 solution (96 mM NaCl, 2 mM 
KCl, 2 mM MgCl2, 5 mM HEPES, pH 7.4) for 1–1.5 h. Oocytes were washed three times 
with calcium-free ND96, or until the brown cloudy medium was completely removed. 
Healthy-looking oocytes were selected and allowed to rest about 1 h in modified ND96 
medium (96 mM NaCl, 2 mM KCl, 1 mM CaCl2, 2 mM MgCl2, 5 mM HEPES, 5 mM pyruvic 
acid, 50 µg/ml gentamicin, 5% horse serum, pH 7.4). Selected oocytes were injected with 
41 nL of about 200–800 ng/µL cRNA synthesized using a mMessage mMachine cRNA 
transcription kit (Life Technologies) and purified using an RNeasy Mini Kit (Qiagen). 
Oocytes were incubated at 17°C, media was changed every 24 h, and recordings were 
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conducted using two-electrode voltage-clamp (TEVC) electrophysiology (Axoclamp 900A 
amplifier, Molecular Devices, Sunnyvale, CA, USA) 2–4 days after the RNA injection. Two 
standard glass microelectrodes with 0.5–2 MΩ resistance when filled with 3 M KCl solution 
were used for recordings. Capillary glass for oocyte injections and electrodes was 
purchased from SDR Clinical Technology (Sydney, Australia). Data acquisition, and 
analysis was performed using pCLAMP software version 10 (molecular Devices). All 
recordings were conducted at room temperature in ND96 containing 0.1% fatty acid-free 
BSA (Sigma). Oocytes were clamped at –90 mV, and data were sampled at 20,000 Hz. 
Inward NaV currents were invoked by applying 50 ms depolarizing steps form –80 mV to 
+45 mV with 10-mV increments, while holding the oocyte at –90 mV. A test pulse to –10 
mV every 10 s was used to detect the presence of NaV channels and reach equilibrium 
upon toxin additions. 
 
3.2.6.2 Analysis of Electrophysiological data 
All electrophysiological data were analysed using the software CLAMPEX®, Microsoft 
Excel (2011), and Prism 6. Voltage-current relationship curves (V-I curves) were plotted for 
each control trace and test traces with toxin. For each toxin experiment, the maximum 
current amplitude at a pre-selected voltage (e.g., -20 mV) was normalized to that of the 
current without the toxin added (0.2% BSA containing ND96 buffer only). This value was 
used as the fraction of the current remaining after the addition of a toxin dilution (I/Imax) for 
construction of dose-response curves. The maximum current amplitudes for NaV1.2 and 
NaV1.7 experiments were measured at –20 mV, while –30 mV was used for analyzing 
NaV1.5 and NaV1.6. 
 
3.2.7 Construction of the β-TRTX-Pe1b homology model  
A homology model of β-TRTX-Pe1b was constructed based on the 3D structure of β/ω-
TRTX-Tp1a (Chapter 2, Sections 2.3.3). A sequence alignment was made using 
CLUSTALW. MODELLER software was used to build the homology model, which was 
based on sequence and structure alignments of the peptides.  
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3.3 Results 
 
3.3.1 Fractionation and purification of crude venoms to identify active peptides  
The workflow for this part of the project is shown schematically in Fig. 18A. In the initial 
stage, a unique in-house panel of more than 200 tarantula venoms was tested using a 
high-throughput FLIPR-based assay (Fig. 18B) to isolate venoms that inhibited human 
NaV1.7. The hit rate was an astonishing 36%, making spider venoms likely to be the best 
natural source for discovering novel modulators of this channel. Crude venoms were 
prioritized for follow-up based on the amount of material available for deconvolution of the 
venom to isolate pure active compounds.  
 
 
Figure 18: Assay guided fractionation and discovery of analgesic drug leads. (A). Workflow 
for isolating and characterizing NaV1.7 blockers from crude spider venoms. The isolation of active 
peptides from crude venoms involves HPLC separation techniques (reverse-phase and ion-
exchange) and FLIPR-based assays. Sequencing involves Edman degradation and tandem MS. A 
recombinant expression system is then required in order to produce sufficient peptide for 
determination of the peptide’s structure, pharmacophore, and subtype selectivity. (B). FLIPR-
based assay for isolating modulators of NaV1.7. Human neuroblastoma cells (SH-SY5Y) are 
incubated with venom, venom fractions, or purified peptide for ~5 min while baseline fluorescent 
readings are taken. Then veratridine, a NaV1.7 activator, is added. If NaV1.7 channels are not 
inhibited, Na+ enters the cell leading to membrane depolarization, which activates endogenous CaV 
channels. This causes Ca2+ ions to enter the cell and bind to a calcium-sensitive dye (Fluo-4), 
leading to increase in fluorescence. If the added venom, venom fraction, or purified peptide inhibits 
NaV1.7, no Na+ enters the cell, and there is no change in fluorescence. In contrast, if the venom, 
venom fraction, or purified peptide contains an activator of NaV1.7, an increase in fluorescence will 
be seen prior to addition of veratridine. 
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Six spider venoms were chosen for follow-up based on the initial FLIPR screen (Fig. 19). 
Three of the spiders were of Central and South American origin (Sericopelma sp., 
Pamphobeteus antinous and Euanthlus pulcherimaklaasi), while the other three were of 
Asian origin (Ornithoctoninae sp., Phormingochilus everetti and Monocentropus balfouri). 
Four of the venoms cased a complete block of veratridine-induced fluorescence (Fig. 19A–
D), and therefore might contain blockers of hNaV1.7, whereas two venoms induced a 
fluorescence response prior to the addition of veratridine (Fig. 19E,F), and therefore might 
contain activators of hNaV1.7. 
 
 
 
Figure 19: FLIPR-based screen of crude spider venoms. (A). Spiders from which venom was 
sourced for isolation of NaV1.7 modulators: (a) Monocentropus balfouri (#473); (b) Sericopelma sp. 
(#531); (c) Phormingochilus everetti (#730); (d) Pamphobeteus antinous (#785); (e) Euathlus 
pulcherrimaklaasi (#662); (f) Ornithoctoneae sp. (#748). (B). FLIPR-based screen of crude 
spider venoms. The fluorescence response was abrogated when venoms from spiders 473, 531, 
662, 730, 748, and 785 were added prior to addition of veratridine, indicating that these venoms 
most likely contain blockers of the human NaV1.7 channel. Venoms 531 and 748 shows initial 
bursts of fluorescence prior to the addition of veratridine, indicating that these venoms may contain 
activators of NaV1.7 as well as inhibitors.  
 
 
Small portions (about 1mg) of the six selected crude venoms were fractionated using RP-
HPLC (Fig. 20), then individual fractions were examined for activity in the FLIPR assay. All 
venoms produced ~50 different fractions from the first RP-HPLC fractionation, and all six 
venoms yielded RP-HPLC fractions that blocked hNaV1.7. Overall, 12 RP-HPLC fractions 
were obtained that contained putative modulators of the hNaV1.7 (Fig. 21). 
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Figure 20: Fractionation of crude spider venoms using RP-HPLC. Chromatograms showing 
fractionation of crude venom from (A) Monocentropus balfouri (#473); (B) Sericopelma sp. (#531); 
(C) Phormingochilus everetti (#730); (D) Pamphobeteus antinous (#785); (E) Euathlus 
pulcherrimaklaasi. (#662); (F) Ornithoctoneae sp. (#748). In each case, peaks corresponding to 
fractions that were active in the FLIPR-based NaV1.7 assay are coloured.  
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Figure 21: FLIPR-based assay profiles for the 12 selected spider-venom fractions. Activation 
of endogenous hNaV1.7 channels in SH-SY5Y human neuroblastoma cells with veratridine leads to 
a fluorescence response as shown in the control well labelled CTRL-H2O. In contrast, the 
veratridine-induced fluorescence response was inhibited when cells were pre-incubated with 
selected venom fractions. This inhibition of the fluorescence signal is similar to that obtained with 
tetrodotoxin (TTX), a potent inhibitor of NaV1.7 and various other NaV channel subtypes. The two 
fractions of venom #531 displays increased levels of fluorescence prior to the addition of 
veratridine, indicating the presence of NaV1.7 agonists. 
 
 
The five RP-HPLC fractions that caused NaV1.7 inhibition were impure as judged by MS, 
and consequently they were further fractionated using an orthogonal cation-exchange 
chromatography (CEX) step in an attempt to obtain pure active peptides. For example, 
faction 785-20 produced one symmetrical peak in CEX (Fig. 22A), while fraction 785-24 in 
CEX produced two fractions 785-24-1 and 785-24-2 (Fig. 22B). All three CEX fractions 
from venom #785 were found to inhibit hNaV1.7 in the FLIPR assay.  
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Figure 22: Purification of active peptides from venom 785. (A) Chromatogram from CEX 
separation of RP-HPLC fraction 785-20.The peak labeled in yellow was lyophilized and desalted. 
The monoisotopic mass (MIM) of the fraction was determined by MALDI-TOF MS to be 
4388.40 Da. (B) Chromatogram resulting from CEX separation of RP-HPLC fraction 785-24 which 
yielded two major fractions 785-24-1 (blue) and 785-24-2 (green). Both fractions were desalted 
using RPHPLC. MALDI-TOF analysis yielded MIMs of 3937.8 Da and 4037.8 Da for peptides 785-
24-1 and 785-24-2, respectively.  
 
Overall, 14 RP-HPLC fractions were obtained containing putative modulators of the human 
NaV1.7 channel. After omitting four fractions that eluted early on rpHPLC and which 
therefore might be polyamines or other non-peptidic venom components, and one toxin 
due to purification difficulties, nine purified toxin peptides were sent to Australian Proteome 
Analysis Facility (APAF) for Edman sequencing; the sequences of the nine peptides are 
shown in Table 4. 
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Table 4: NaV1.7 inhibitor peptides isolated from crude venom  
Sequence 
name/numbe
r 
Sequence 
Mono- 
Isotopic 
Mass (Da) 
NaSpTx 
Family 
Tp1a(662-33) ECRYWLGGCSAGQTCCKHLVCSRRHGWCVWDGTFS 3985.20 Family 2 
Pe1b(730-44) GECRYWLGGCSKTGDCCEHLSCSPKWHWCVWDGTF 3974.70 Family 2 
Pe1a(730-30) ECKYLWGTCSKDEDCCAHLGCNRKHDWCGWDYTF-NH2 4066.29 Family 2 
Pa1a(785-20) ACREMYGGCEKDEDCCKHLGCKPTLNYCAWDGTFV-NH2 3937.60 Family 2 
662-29 YCQKWMWTCDSERKCCEGMVCRLWCKKKLW 3825.23 Family 3 
748-11 ACLGFGKSCNPSNDQCCKSSSLACSTKHKWCKYEL 3819.87 Family 1 
785-24 DDCLGWFRGCDPKNDKCCEGYKCSRRDQWCK--- 4037.00 Family 1 
662-19 DCLKFGWKCNPRNDKCCSGLKCGSNHNWCKLH 3800.25 Family 1 
785-20-13-2 FECVISCDIKKEGKPCKPKGGKKCSGGWRCK?K 4388.40 
ω-TRTX-
Asp1d* 
*This peptide shows no homology with any of the established NaSpTx families, however it is 90% 
identical to ω-TRTX-Asp1d, a CaV channel inhibitor. The second last residue could not be 
determined by Edman degradation. Due to the low activity of this peptide on NaV1.7, no further 
attempts were made to determine the complete sequence of peptide 785-20-13-2. 
 
Four of the nine NaV1.7-active peptides were isolated from crude venom of the spiders 
Euanthlus pulcherimaklaasi (U1-TRTX-Ep1a), Pormingochillus everetti (U1-TRTX-Pe1a 
and U1-TRTX-Pe1b), and Pampobetious antinous (U1-TRTX-Pa1a) (see Table 4). U1-
TRTX-Ep1a is 100% identical to the known NaV1.7 inhibitor β/ω-TRTX-Tp1a (ProTx1), 
which potently blocks the human channel with an IC50 of 51 nM95. This provided an 
excellent validation of the FLIPR-based NaV1.7 assay. The other three peptides are close 
homologs of β/ω-TRTX-Tp1a; all four peptides belong to the NaSpTx Family 2 (Fig. 23), 
which is the largest family of spider toxins with predicted NaV inhibitory function32. 
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Figure 23: Sequence alignment of toxins in NaSpTx Family 2 32. Toxin names are based on the 
rational nomenclature devised for spider-venom peptides90. Light green names indicate peptides 
discovered in this study. Toxins marked in dark green have been well studied95. NaSpTx Family 2 
divides into four major groups based on the primary activity of the toxin. The largest group of toxins 
contains KV channel blockers; while NaV channel blockers make the second largest group inclusive 
of the two novel toxins Pe1a and Pe1b. NaV1.7-active surface residues (marked in purple) of 
ProTx1 have been identified previously (Chapter 2, Section 2.3.2). This active site shares some 
similarities with the KV2.1 active site of SGTx (κ-TRTX-Scg1a)130, especially L6 and W30.  
 
 
3.3.2 Recombinant expression of toxins 
Once the peptide sequences were determined, they were used to construct E. coli 
expression vectors to produce the peptides recombinantly. Recombinant expression 
enables large quantities of each peptide to be obtained for structure-function 
characterization and it enables isotopic labeling of the peptides for structure determination 
using multidimensional heteronuclear NMR140,142. A synthetic gene encoding the peptide of 
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interest, with codons optimised for E. coli expression, was cloned into a variant of the pLic-
MBP expression vector143. The fusion protein encoded by the plasmid contains a MalE 
signal sequence (MalEss), that directs the fusion protein to the E. coli periplasm where the 
cellular machinery for disulfide bond formation is located144, a His6 tag for affinity 
purification, a maltose binding protein (MBP) fusion tag to aid solubility145, a tobacco etch 
virus (TEV) protease recognition site, and the spider-venom peptide (Fig. 24).  
 
 
Figure 24: Design of the recombinant expression system. (A). Schematic representation of the 
coding region of the pLic-MBP expression vector. This IPTG-inducible plasmid contains genetic 
components encoding the MalESS-His6-MBP-toxin fusion protein with a TEV protease recognition 
site between the MBP and toxin coding regions. Other major components include the T7 promoter 
at the beginning of the construct, Lac operator, ribosomal binding site (RBS), KpnI and SspI 
restriction sites using for cloning in the toxin gene, and the T7 terminator (B). The cellular 
processes involved in expression of toxins in the periplasm of E. coli. The fusion peptide is 
expressed within the cytoplasm, then the MalE signal sequence directs the fusion peptide to the 
periplasm. The signal sequence is cleaved off once the peptide reaches the periplasm via the 
SecYEG translocase system. The Dsb machinery in the periplasm allows formation and shuffling 
of disulfide bonds in order to achieve the native fold of the peptide. 
 
 
Three novel toxins, β-TRTX-Pe1a (hereafter Pe1a), β/µ-TRTX-Pe1b (hereafter Pe1b) and 
U1-TRTX-Pa1a (hereafter Pa1a), were successfully produced by expression in the 
periplasm of E. coli BL21 cells (Figs 25–27). Following TEV protease cleavage the 
peptides contained an additional non-native N-terminal glycine residue, a vestige of the 
TEV protease recognition site, making the recombinant peptides 35 residues long140. The 
recombinant Pe1b folded into a single isoform. 
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When the recombinant Pe1b was tested on human NaV1.7 heterologously expressed in 
Xenopus oocytes using TEVC electrophysiology, 100 nM of peptide was found to inhibit 
nearly 50% of the current, therefore confirming the correct folding of the toxin. Pe1a 
produced eight isoforms, however only fraction 7 co-eluted with the native toxin (Fig. 26C). 
Fraction 7 showed weak NaV1.7 inhibition, with 10 µM toxin inhibiting 25% of the total 
current (Fig. 26D), while the other isoforms showed no activity on NaV1.7. 
 
 
Figure 25: Recombinant production of Pe1b. (A). SDS-PAGE gel showing outcome of various 
purification steps. Lanes are as follows: L, protein size marker; ISF, insoluble fraction following cell 
disruption; SF, soluble fraction containing the fusion protein; FT, flow through from the Ni-NTA 
column; W, wash of Ni-NTA column; Elu, first eluate from wash of Ni-NTA column with 500 mM 
imidazole; Elu3, third eluate from wash of Ni-NTA column with 500 mM imidazole; CFT, flow 
through during protein concentration; CF, concentrated fraction of His6-MBP-toxin fusion protein; 
and Tev, His6-MBP after TEV cleavage. (B). HPLC chromatogram resulting from final purification 
of Pe1b using a C18 analytical column. Black line indicates the absorbance at 214 nm, while the 
red line shows the absorbance at 280 nm. The dotted line shows the solvent B gradient used for 
the RP-HPLC purification. Inset is the MALDI-TOF trace obtained for recombinant Pe1b showing 
expected monoisotopic mass of 4035.65 Da.  
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Figure 26: Recombinant production of Pe1a, a NaV1.7-active peptide from the spider 
Pormingochillus everetti. (A). SDS-PAGE gel showing outcome of various purification steps. 
Lanes are as follows: ISF, insoluble fraction following cell disruption; SF, soluble fraction 
containing the fusion protein; FT, flow through from the Ni-NTA column; W, wash of Ni-NTA 
column; Elu, first eluate from wash of Ni-NTA column with 500 mM imidazole; Elu3, third eluate 
from wash of Ni-NTA column with 500 mM imidazole; CFT, flow through during protein 
concentration; CF, concentrated fraction of His6-MBP-toxin fusion protein; Tev, His6-MBP after 
TEV cleavage, and L, protein size marker.  (B). HPLC chromatogram resulting from final 
purification of Pe1a using a C18 semi prep column. The left ordinate axis shows the absorbance in 
arbitrary units (AU), and the right ordinate axis shows the % solvent B (90% acetonitrile and 0.05% 
TFA). Black line indicates the absorbance at 214 nm, while the red line shows the absorbance at 
280 nm. The dotted line shows the solvent B gradient used for the RP-HPLC purification. Pe1a 
elutes as many isoforms between 42–48% solvent B. (C). HPLC-based purification of various Pe1a 
isoforms, denoted fractions 1 to 8. Pe1a-F7 has a similar retention time to native Pe1a (orange 
line). (D). 10 µM recombinant Pe1a inhibits about 25% of the total NaV1.7 current with a small 
leftward shift of the I-V curve. The ascissa shows voltage steps (mV) ranging form -80 mV to +45 
mV, while the ordinate axis shows the maximum current amplitude (nA) at each voltage step.   
 
 
 
 
Retention  Time  (min)
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Figure 27: Recombinant expression of Pa1a, a 
NaV1.7-active peptide from the spider 
Pampobetious antinous (A). SDS-PAGE gel 
showing the outcome of various purification steps. 
Lanes are as follows: ISF, insoluble fraction 
following cell disruption; L, protein size marker; 
SF, soluble fraction containing the fusion protein; 
FT, flow through from the Ni-NTA column; W, 
wash of Ni-NTA column; Elu, first eluate from 
wash of Ni-NTA column with 500 mM imidazole; 
Elu3, third eluate from wash of Ni-NTA column 
with 500 mM imidazole; CFT, flow through during 
protein concentration; CF, concentrated fraction of 
His6-MBP-toxin fusion protein; and Tev, His6-MBP after TEV cleavage. (B). HPLC chromatogram 
resulting from final purification of Pa1a using a C18 analytical column. The left ordinate axis shows 
the absorbance (AU), while the right ordinate axis shows the % solvent B. Black and red lines 
indicates the absorbance at 214 nm and 280 nm, respectively. The dotted line shows the solvent B 
gradient used for the RP-HPLC purification. Pa1a elutes around 35% solvent B. 
 
 
3.3.3 Pe1a and Pa1a activities on NaV channels  
When tested on human NaV1.7 heterologously expressed in Xenopus oocytes, Pe1a only 
inhibited about 25% of the total NaV current at 10 µM concentration (Fig. 26D), 
demonstrating that the peptide is a weak inhibitor of hNaV1.7. However it should be noted 
that native Pe1a is amidated (Table 4), and the recombinant peptide is not. Lack of a C-
terminal amidation may have affected the NaV1.7 activity of the peptide. Pe1a showed no 
effect on NaV1.2 currents (data not shown).  
 
Pa1a did not display any activity hNaV1.7 expressed in Xenopus oocytes. As for Pe1a, 
native Pa1a is amidated at the C-terminus. Lack of amidation may be responsible for the 
difference in NaV1.7 activity between the native and recombinant peptides. Pa1a showed 
very high sequence identity (69–71%) with many KV channel modulators in NaSpTx family 
2 (see Fig. 23, Pa1a sequence marked in light green), and therefore it would be interesting 
in the future to examine the activity of Pa1a against a range of KV channels.  
 
	   61	  
3.3.4 Pe1b activities on NaV currents 
Pe1b was tested for its activity against hNaV1.2, hNaV1.5, hNaV1.6 and hNaV1.7 
heterologously expressed in Xenopus oocytes (Fig. 28). Cells were held at –80 mV and 
current traces were evoked by 50-ms depolarizing steps to –10 mV every 10 s. Once the 
maximum current stabilized (typically ~1 min), a current versus voltage step (IV) trace was 
acquired. Pe1b was found to be a weak inhibitor of NaV1.2 (IC50 ~ 2.8 µM; Fig.29) with no 
shift in activation voltage. Pe1b inhibited NaV1.7 most potently (IC50 ~152 nM; Fig. 29), 
while demonstrating less potency towards NaV1.6 (IC50 ~696 nM; Fig.29). Based on data 
currently available, Pe1b is a very weak inhibitor of NaV1.5. At 1 nM-10 µM concentrations, 
the toxin showed only a weak concentration-dependent inhibition of NaV1.5. At a 
concentration of 10 µM, Pe1b inhibited about 40% of the NaV1.5 current (Fig. 28).  
 
 
 
Figure 28: Current-voltage (IV) relationships for Pe1b inhibition of hNaV1.2, hNaV1.5, hNaV1.6 
and hNaV1.7. The voltage (mV) is shown on the abscissa and the current (µA) is shown on the 
ordinate axis. The channel current in the absence of toxin is shown in black, while current after the 
addition of Pe1b is shown in color. All traces except NaV1.5 show the effect of 1 µM Pe1b. NaV1.5 
trace shows the effect of 10 µMPe1b on channel current. Pe1b weakly inhibited NaV1.2, with no 
shift in activation voltage. Pe1b partially inhibited NaV1.5 at 10 µM with no shift in channel 
activation voltage. Pe1b inhibited NaV1.6 and NaV1.7 with about a 10 mV shift of the activation 
voltage in the positive direction. The current-voltage step protocol used is shown at the far right of 
the figure. 
 
 
3.3.5 Construction of Pe1b mutants 
Pe1b and ProTx1 are 70% identical, yet they display significant differences in activity 
against NaV channels. We therefore wondered whether it might be possible to determine 
which residues are responsible for the differences in NaV channel selectivity of these two 
peptides. Although recombinant production of Pe1b adds a glycine at the N-terminus of 
the peptide, the amino acid residue numbers for native Pe1b are used in this chapter as 
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this allows direct comparison with ProTx1 and other NaSpTx family 2 peptide sequences 
without causing confusion. 
 
Amino acid residues that are markedly different between ProTx1 and Pe1b were at the 
primary focus of this investigation. Five main regions of difference were identified (Fig. 29 
B, C), which can be summarized as follows: (i) the four residues K11, T12, G13, and D14 
within the second loop of Pe1b were significantly different to that of ProTx1. However 
when these residues were mapped onto the structure of ProTx1 (Fig. 29C, residues 
marked in cyan), this loop is located far form the NaV1.7 active site of the toxin (residues 
marked in orange). Therefor these residues were expected to have minimal effect on toxin 
activity against NaV1.7; (ii) the basic K17 in ProTx1 is substituted with an acidic Glu 
residue in Pe1b, leading to a charge reversal; (iii) residue V20 in ProTx1 is substituted with 
a Ser residue in Pe1b; (iv) four residues, P23, K24, W25 and H26, within loop 4 of Pe1b 
are different to that of ProTx1; and (v) ProTx1 contain a Ser at the C-terminus, which is not 
present in Pe1b. Based on these differences, I decided to produce four Pe1b mutants to 
investigate the effect of above-mentioned substitutions (Fig. 29D). These mutant peptides 
were named Pe1b-E17K, Pe1b-L2, Pe1b-S20V and Pe1b-S35, in contrast to wild-type 
Pe1b (Pe1b-wt). 
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Figure 29: Pe1b activity on NaV channels and design of Pe1b mutants. (A). Concentration-
response curves for modulation of hNaV1.2 (orange), hNaV1.5 (green), hNaV1.6 (light blue) and 
hNaV1.7 (deep blue) by Pe1b. Pe1b inhibited NaV1.7 with an IC5o of ~152 nM, which is about 22-
fold lower (i.e., more potent) that its activity on hNaV1.2 (IC50 ~ 2.8 µM) and about 5.5-fold more 
potent that its activity on hNaV1.6 (IC50 ~ 696 nM). Pe1b shows only very weak activity against 
hNaV1.5, with 10 µM toxin inhibiting ~40% of the current. (B). Sequence alignment of ProTx1 
(green) and Pe1b (orange). These toxins have a similar cystine framework, and many identical 
non-Cys residues. The four major regions of sequence variation within proximity of the ProTx1-
NaV1.7 pharmacophore are marked with grey boxes. (C). The structure of ProTx1. Residues 
marked in orange indicate the NaV1.7-binding pharmacophore of ProTx1. Residues marked in 
yellow are not conserved in Pe1b, however located in close proximity to the NaV1.7 binding 
pharmacophore residues. Hence might provide some clues to the difference in NaV activities of two 
peptides. Residues marked in cyan, are also not conserved with Pe1b, however these are far from 
the active site. Therefore effects of mutations in these residues were not examined further. The 
loop 4 (as indicated on Fig. 29C) residues R23, R24, H25, and G26 are poorly conserved in Pe1b. 
(D). Sequences of Pe1b mutants designed by substituting the corresponding residue of ProTx1 
(indicated in green). Mutants were only designed for residues that are close to the hypothesized 
NaV1.7 pharmacophore (highlighted in yellow in panel C), The mutant Pe1b-S35 contains an 
additional non-native C-terminal serine residue. 
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3.3.6 Recombinant expression and activity of Pe1b mutants 
All four Pe1b mutants were successfully produced via recombinant expression (Fig. 30). 
All mutants yielded a single isoform upon final RP-HPLC purification, and they were of 
very high purity as judged by MALDI-TOF MS. The activity of each of the Pe1b mutants 
was assessed against hNaV1.2, hNaV1.5 and hNaV1.7 expressed in Xenopus oocytes. 
 
 
Figure 30: Recombinant expression of Pe1b-E17K, Pe1b-S20V, Pe1b-L2 and Pe1b-S35. Left 
panels are SDS-PAGE gels showing the outcome of various steps in the purification of each 
mutant peptide. Right panels are RP-HPLC chromatograms resulting from purification of each 
Pe1b mutant using a C4 semi-preparative column. The peaks corresponding to the desired Pe1b 
mutants are marked with as asterisk. Pe1b-E17K, Pe1b-L2, and Pe1b-S20 eluted at ~45% solvent 
B, whereas Pe1b-S35 elutes at ~40% solvent B. Black and red traces correspond to absorbance at 
214 nm and 280 nm, respectively. The dotted line indicates the gradient of solvent B gradient that 
was used.  
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ProTx1 is a potent inhibitor of NaV1.7 (IC50 ~50 nM) but it lacks the Nav channel selectivity 
required for it to be a useful analgesic lead. In contrast, Pe1b shows better NaV channel 
selectivity, but it lacks potency against NaV1.7 (IC50 ~152 nM). We therefore constructed 
four Pe1b mutant peptides in order to investigate the effect of each mutation on the 
potency and selectivity of the toxin. The activity of each mutant peptide against NaV1.2, 
NaV1.5 and NaV1.7 is shown in Fig. 31 and the results are summarized in Table 5.  
 
 
Figure 31: Activity of Pe1b mutants. The black dotted line in each panel shows the activity of 
Pe1b-wt, while the coloured unbroken line (orange for NaV1.2, green for NaV1.5 and blue for 
NaV1.7) shows the activity of each Pe1b mutant peptide. (The number of repeats for each 
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concentration point ranges from 1 to 3). IC50 values calculated from each of the concentration-
response curves are indicated on the figures. Data were collected via TEVC electrophysiological 
analysis of hNaV1.2, hNaV1.2, and hNaV1.2 currents in Xenopus oocytes. 
 
 
Table 5: IC50 values for inhibition of NaV1.2, NaV1.5 and NaV1.7 by wild-type and mutant Pe1b 
peptides. The table also shows the fold-increase in activity for each mutant compared to the wild-
type toxin (Pe1b-wt). 
 IC50 and the fold increase in activity in comparison to Pe1b-wt 
NaV1.2  NaV1.5  NaV1.7  
Pe1b-wt 2.8 µM > 10 µM 152 nM 
Pe1b-E17K >1 µM 724 nM (13.7x) 50 nM (3x) 
Pe1b-L2 200 nM (14x) 1.2 µM (8.3x) 123 nM 
Pe1b-S20V 660 nM (4.2x) ~ 10 µM 107 nM (1.4x) 
Pe1b-S35 525 nM (5.3x) > 10 µM 80 nM (2x) 
 
The Pe1b-E17K mutant (IC50 50 nM) proved to be about 3-fold more potent against NaV1.7 
than native Pe1b (IC50 152 nM). Critically, however, potency against NaV1.2 was not 
greatly changed due to this mutation (IC50 >1 µM). Unfortunately, potency against NaV1.5 
(IC50 ~ 725 nM), was improved about 14-fold compared to the Pe1b-wt. Nevertheless, 
Pe1b-17K still has a 15-fold preference for NaV1.7 over NaV1.5. 
 
The Pe1b-L2 mutant showed a small increase in potency against NaV1.7 (IC50 ~ 123 nM) 
compared to native Pe1b, whereas activity against NaV1.2 was improved dramatically (i.e., 
the IC50 decreased 14-fold from 2.8 µM to 200 nM). Activity against NaV1.5 was also 
markedly improved, with Pe1b-L2 exhibiting an IC50 of 1.2 µM against this channel 
compared to >10 µM for the native toxin. 
 
Pe1b-S20V activity against NaV1.7 (IC50 143 nM) was similar to Pe1b-wt (IC50 152 nM). 
Pe1b-S20V potency against NaV1.2 (IC50 660 nM) was about 4.2-fold better than wild-type 
Pe1b (IC50 2.8 µM). Potency against NaV1.5 was very poor as for the native toxin. At a 
concentration of 10 µM, Pe1b-S20V only inhibited ~50% of the NaV1.5 current. 
 
Pe1b-S35 had increased potency against hNaV1.7 in comparison to Pe1b-wt. The 
laboratory's standard operating protocol for oocyte recordings uses 0.2% BSA in ND96 
buffer to treat the recording oocyte before any peptide is added. Inhibition of hNaV1.7 by 
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Pe1B-S35 was comparable to that obtained with Pe1b-wt when recordings were 
performed in this manner (i.e., IC50 ~ 150 nM). However, when the protocol was modified 
to use ND96 buffer containing no BSA, Pe1b-S35 had markedly improved activity against 
NaV1.7, with an IC50 of 80 nM. This observation was made by accident, and the effect of 
various BSA concentrations on peptide activity has not been tested for any other peptide 
described in this thesis.  
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3.4 Discussion  
Assay-guided fractionation is an efficient technique to rapidly identify peptides that 
modulate the activity of a specific channel. The FLIPR assay described herein has proved 
to be a useful tool for screening spider venoms for NaV1.7 inhibitors. Once the individual 
peptide component responsible for the activity has been identified and sequenced, it is 
essential to produce the peptide in quantities sufficient for full characterization (i.e., 
determination of biological activity, three-dimensional structure and structure-activity 
relationships). An Escherichia coli-based periplasmic expression system was successfully 
employed here to produce several spider-venom peptides with activity against hNaV1.7. 
The major advantage of this technique is the protein folding machinery available in E. coli 
periplasm. All NaSpTx family 2 toxins are disulfide-rich peptides, and therefore it is crucial 
that the correct disulfide-bond isoform is produced146. 
 
ProTx1 and Pe1b share 70% sequence identity. The 3D structure of ProTx1 is available 
(Chapter 2, Section 2.3.3), and the Pe1b structure was modeled based on this structure. 
Both peptides form a hydrophobic patch at a very similar surface of the toxin scaffold, 
leading to the hypothesis that they share a significant level of similarity in their NaV1.7 
binding site.   
 
An E17K charge reversal mutation in Pe1b had little effect on its activity against NaV1.2. 
While this mutation increased NaV1.7 potency by 3-fold, it unfortunately also increased 
potency against NaV1.5 by almost 14-fold. While Pe1b-E17K still has ~15-fold selectivity 
for NaV1.7 over NaV1.5, we conclude that its improved potency against NaV1.7 has been 
obtained with too much sacrifice of the selectivity over NaV1.5. Therefore Pe1b-E17K is 
not a useful analgesic drug lead. 
 
The Pe1b-L2 mutation caused a drastic 16-fold gain of activity against hNaV1.2 in 
comparison to a 2-fold increase in activity against NaV1.7. It appears that the set of 
residues (RRGH) that substituted into loop 2 in place of the PKWH sequence in Pe1b-wt 
contains one or more residues that are important for hNaV1.2 binding. The Pe1b-L2 
mutation also caused an 8-fold gain of activity against NaV1.5, making this peptide 
undesirable as an analgesic drug lead.   
 
An S20V mutation did not cause a significant change in Pe1b activity against NaV1.7, and 
therefore S20 cannot be an important part of the toxin's NaV1.7 pharmacophore. This is 
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consistent with the pharmacophore that mediates the interaction of ProTx1 with NaV1.7 
(see Chapter 2, Section 2.3.2. Although S20 in Pe12b-wt and V20 in ProTx1 are not 
related to the NaV1.7 activity of either peptide, V20 appears to be one source of the higher 
potency of ProTx1 against NaV1.2 since introduction of a S20V mutation increased Pe1b 
potency against NaV1.2 by 4.2-fold (Table 5). 
 
The increased NaV1.7 activity of the Pe1b-S35 mutant is a good indication that the C-
terminus of Pe1b is involved in its interaction with NaV1.7. Although this mutation 
compromised the NaV1.7/NaV1.2 selectivity of the peptide, it is possible that additional, 
complementary mutations might serve to increase its NaV1.7/NaV1.2 selectivity. Clues to 
such mutations are available from the ProTx1 pharmacophore mapped using alanine-
scanning mutagenesis (Chapter 2, Section 2.3.2 and Supplementary Figure 2)116. 
Residues that are not shared between the NaV1.7 and NaV1.2 pharmacophores of ProTx1, 
such as R3, W5, and F34, might be the most interesting to examine. Alanine mutations of 
R3, W5 and F34 should provide an indication of whether alterations of these residues can 
lead to altered NaV1.7/NaV1.2 selectivity. 
 
Furthermore, the effect of BSA in the recording buffer observed with Pe1b-S35 needs to 
be further investigated. The low potency of the peptide in the presence of BSA may have 
been due to the peptide binding to BSA and reducing the effective concentration of toxin 
available for binding with the channel. In future, peptide activity against NaV1.7 should be 
compared in ND96 buffer with and without BSA.  
 
In conclusion, the four Pe1b mutations studied here have deepened our understanding of 
the surface of Pe1b that mediates its interaction with NaV1.7 and other therapeutically 
important NaV subtypes. Moreover, the Pe1b-E17K and Pe1b-S35 analogs have provided 
a foundation for developing Pe1b into an analgesic lead molecule for therapeutic inhibition 
of NaV1.7.  
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CHAPTER 4 
 
LOCALIZATION OF NaV1.7 IN THE NORMAL AND INJURED 
RODENT OLFACTORY SYSTEM INDICATES A CRITICAL ROLE 
IN OLFACTION, PHEROMONE SENSING AND IMMUNE 
FUNCTION (Incorporated research paper)  
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Introduction
Voltage-gated sodium (Na
v
) channels are transmembrane pro-
teins that provide a current pathway for the rapid depolariza-
tion of excitable cells. The pore-forming α subunits are classified 
into nine subtypes denoted Na
v
1.1 to Na
v
1.9.1,2 In recent years, 
the tetrodotoxin (TTX)-sensitive sodium channel Na
v
1.7 has 
emerged as a well-validated analgesic target based on several 
remarkable human genetic studies. Gain-of-function mutations 
in the SNC9A gene encoding the α subunit of Na
v
1.7 cause pain-
ful inherited neuropathies, including primary erythromelalgia3 
and paroxysmal extreme pain disorder,4 whereas truncation and 
loss-of-function mutations in SCN9A result in a congenital insen-
sitivity to all forms of pain or CIP.5,6 Moreover, single nucleotide 
polymorphisms in SCN9A correlate with an individual’s level of 
pain perception.7 Thus, there is much interest in developing sub-
type-selective blockers of Na
v
1.7 as analgesics for the treatment of 
various types of pain.8-13
To date, 13 distinct mutations in SCN9A have been mapped 
in people with CIP.5,6 These individuals have a normal sense of 
Loss-of-function mutations in the pore-forming α subunit of the voltage-gated sodium channel 1.7 (Nav1.7) cause 
congenital indifference to pain and anosmia. We used immunohistochemical techniques to study Nav1.7 localization in 
the rat olfactory system in order to better understand its role in olfaction. We confirm that Nav1.7 is expressed on olfactory 
sensory axons and report its presence on vomeronasal axons, indicating an important role for Nav1.7 in transmission 
of pheromonal cues. Following neuroepithelial injury, Nav1.7 was transiently expressed by cells of monocytic lineage. 
These findings support an emerging role for Nav1.7 in immune function. This sodium channel may provide an important 
pharmacological target for treatment of inflammatory injury and inflammatory pain syndromes.
Localization of Nav1.7 in the normal and injured 
rodent olfactory system indicates a critical role 
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touch, vibration, joint position sense and temperature perception 
but fail to identify noxious stimuli as unpleasant or painful. In 
addition to their inability to detect pain, people with CIP have a 
complete loss of smell (anosmia).14,15 Similarly, mice containing 
an olfactory-specific knockout of Na
v
1.7 exhibit an absence of 
odor-guided behaviors.15 Thus, it is clear that Na
v
1.7 plays a criti-
cal role in the detection of both nociceptive and olfactory cues.16
The primary olfactory pathway in mammals comprises the 
olfactory epithelium (OE), cranial nerve I and the main olfac-
tory bulb (OB). The vomeronasal organ and accessory olfactory 
bulb (AOB) provide a second level of olfactory detection in cer-
tain vertebrates, including rodents. While there is debate as to 
whether or not the vomeronasal organ detects all pheromone-like 
cues in mammals, and whether its sensory capacity is restricted to 
pheromonal sensing, the vomeronasal system is generally agreed 
to be essential for detecting and processing social, behavioral and 
reproductive cues.17,18
Primary sensory neurons in the OE detect external olfactory 
stimuli at their dendritic terminals, which causes transmission of 
action potentials along their axons. These axons converge into 
© 2012 Landes Bioscience.
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raised against a unique epitope, was first examined and con-
firmed in vitro via staining of stably transfected mammalian cell 
lines expressing different Na
v
 channel subtypes. The antibody 
was found to recognize Na
v
1.7 but not related Na
v
 channel sub-
types including Na
v
1.4, Na
v
1.5 and Na
v
1.6 (see Fig. S1).
Na
v
1.7 localizes to axons of primary olfactory sensory neu-
rons and central termination zones. We explored the role of 
Na
v
1.7 in olfaction by studying its expression pattern along the 
primary olfactory neuraxis. In the nasal neuroepithelium, we 
observed prominent (++) staining for Na
v
1.7 in the fila olfac-
toria of the lamina propria (LP) (Fig. 1A and B). We did not 
detect staining for Na
v
1.7 on the cell bodies and dendrites of 
primary olfactory sensory neurons in the rat, consistent with 
recent observations in mice.15,23 These findings indicate a par-
ticularly high abundance of Na
v
1.7 along the trajectory of the 
olfactory nerve, which was confirmed by co-localization of 
olfactory marker protein (OMP) and Na
v
1.7 staining (Fig. 1C), 
the former being a marker for olfactory sensory neurons and 
their projections.
Coronal sections (taken at ~1.5 mm intervals) through the 
rostro-caudal axis of the rat OB were next examined for Na
v
1.7 
staining (Fig. 2). The olfactory nerve layer (ONL) within ros-
tral sections of the OB, demonstrated by regions ‘a’, ‘b’, ‘c’ and 
‘d’ (Fig. 2B), was darkly stained (++, Fig. 2A). The observed 
intensity was similar to that seen in axonal bundles in the lamina 
propria. The glomerular layer (GL), which is located internal 
to the ONL and comprises the termination zone of the axons 
from olfactory sensory neurons, was more lightly stained (+; Fig. 
2A). At lower magnification, Na
v
1.7 staining within glomeruli 
appeared most intense close to the ONL, gradually losing some 
intensity as axons spread throughout the glomerulus. However, 
axonal bundles (fila olfactoria) within the lamina propria under-
neath the OE. They then pass through the cribriform plate into 
the nerve layer of the OB, where each axon ultimately synapses 
with the dendrites of mitral cells (2nd order neuron) in defined 
OB glomeruli, the functional units of olfactory coding.19,20 An 
axonal bundle projecting out of the OE is generally composed 
of about 2,000–3,000 olfactory sensory neuron axons wrapped 
within a tightly connected channel of olfactory ensheathing cells 
(OECs).21 Because of their exposed location, olfactory sensory 
neurons are constantly replenished from an endogenous stem cell 
compartment. Therefore, the primary olfactory pathway contin-
uously repairs itself (reviewed in ref. 22).
The precise role of Na
v
1.7 in olfaction has been unclear, with 
no descriptions of the presence of this channel in the mammalian 
olfactory system until very recently.15,23 We therefore decided to 
examine the anatomical localization of Na
v
1.7 in the rat olfactory 
system to gain more insight into its role in olfaction. Our results 
support the view that Na
v
1.7 plays an essential role in relaying 
action potentials initiated by the detection of olfactory cues, 
including pheromones, between the nasal olfactory neuroepithe-
lium and the main OB, as well as between the vomeronasal organ 
and the AOB. We also show that within this same system Na
v
1.7 
is expressed on infiltrating inflammatory cells and thus may play 
important roles in monocyte actions at sites of tissue injury.
Results
We examined the localization of Na
v
1.7 in rat olfactory tissue via 
standard immunohistochemical and immunofluorescent staining 
procedures (for details, see Materials and Methods). Specificity 
of the commercially available anti-Na
v
1.7 antibody, reportedly 
Figure 1. Localization of Nav1.7 in rat olfactory epithelium. (A) Immunohistochemical staining for Nav1.7 in the rat OE. The approximate location from 
which the photomicrographs were taken is shown in (B) (red boxed area). Note that axonal bundles (nb) are intensely stained (++) for Nav1.7 within 
the lamina propria (LP). Co-localization of Nav1.7 (red) and OMP (green) was revealed through double immunofluorescent staining. Note the overlap 
between the individual staining patterns in the merged image (right). (C) Higher power photomicrograph of an axonal bundle showing localization of 
Nav1.7 (red, left panel), OMP (green, middle panel), and the merged image (right panel). Scale bars: 100 μm (A) and 12 μm (C).
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caudal pole, we observed Na
v
1.7 staining on vomeronasal axons 
in the AOB, consistent with that of ONL (AOB; Fig. 2D and E).
Expression of Na
v
1.7 on inflammatory cell infiltrate in the 
injured mouse olfactory epithelium. Because of the emerging 
role of Na
v
1.7 in immune function,24 we studied expression of 
when viewed at higher optical resolution using confocal micros-
copy, Na
v
1.7 staining appeared relatively uniformly distributed 
throughout the glomeruli (Fig. 2C). We again observed colocal-
ization of Na
v
1.7 and OMP staining, confirming the presence 
of Na
v
1.7 on axons of primary olfactory sensory neurons. At the 
Figure 2. Localization of Nav1.7 in the rat main olfactory bulb and accessory olfactory bulb. (A) Localization of Nav1.7 in four different regions (a–d) of a 
rostral section of the OB, shown schematically in (B). The four parts in each row, from left to right, show DAB staining followed by immunofluorescent 
staining for Nav1.7 and OMP as a marker for axons of olfactory sensory neurons; a merged image of Nav1.7 and OMP staining patterns is shown on 
the right. In each DAB-stained section, the ONL is stained darkly (++) for Nav1.7, whereas the glomerular layer (GL) is stained more lightly (+). Double 
immunofluorescent staining procedures again show co-localization between Nav1.7 and OMP in both the ONL and GL. (C) Higher-power confocal 
photomicrograph (4 μm thick slice) of a single glomerulus, showing co-localization of Nav1.7 and OMP. (D) Schematic representation of a more caudal 
section through the OB, showing the accessory olfactory bulb (AOB, red boxed area). (E) Note that the AOB is lightly (+) but uniformly stained for both 
Nav1.7 and OMP. Scale bars: 200 μm (A and E), 15 μm (C).
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to drug-induced cell death within the olfactory neuroepithelium. 
Horizontal basal cells, the neuroepithelial stem cells, remain 
largely unaffected and regenerate the OE in time (~1–2 mo).26,27 
We examined Na
v
1.7 staining along the primary olfactory path-
way at 2, 5, 10 and 18 d after methimazole injection.
this channel in the olfactory pathway after injury. Methimazole 
drug treatment or Triton-X lesions (data not shown) were used to 
induce turnover of olfactory sensory neurons and explore expres-
sion of Na
v
1.7 on inflammatory cell infiltrate (Fig. 3).25 Treatment 
with methimazole causes robust recruitment of macrophages due 
Figure 3. Degeneration and regeneration of the olfactory epithelium following chemical ablation. (A and B) Representative images showing intact 
olfactory epithelium (OE) and lamina propria (LP). Well-organized axonal bundles (nb) within the LP are stained for NaV1.7. Cell bodies of OMP
+ neu-
rons (~9–10 layers) were also be observed in the stratified OE. (C and D) Two days after methimazole injection, a substantial loss of olfactory sensory 
neurons was evident by the dramatic reduction in OMP+ cell numbers. Remnants of olfactory tissue containing OMP+ neurons had detached from the 
basal cells layers and the LP (C, white two-headed arrow). Cx3cr1
gfp/+ cells of monocytic lineage (L) were visible within detached epithelial remnants, 
some of which appeared to co-express Nav1.7 (D). Additional GFP
+ cells, many with typical macrophage-like morphology, were present in the LP. (E) At 
5 d after injury, no OMP staining was visible within the OE, indicating a near complete ablation of mature (OMP+) olfactory sensory neurons follow-
ing methimazole treatment. Some residual OMP staining was still present in degenerating axon bundles in the LP (white arrowhead). As anticipated, 
a clear reduction in staining intensity for Nav1.7 was observed at 2 and 5 d post-injury compared with non-injured controls (D and F vs. B). Note, 
however, the prominent staining for NaV1.7 on inflammatory cell infiltrate accumulating almost exclusively within the LP at 5 d-post-injury (F). (M) 
Immunohistochemical staining for GFP on adjacent sections revealed that cells of monocytic lineage were present in both the LP and OE. At 10 d after 
injury, the first OMP+ cells began to re-appear in the regenerating OE (G, white arrowhead) and little, if any, Nav1.7 immunoreactivity was observed 
within olfactory nerve bundles (H). By this stage, most of Nav1.7
+ cell infiltrate had disappeared and the few remaining cells were primarily observed in 
close association with blood vessels (black arrow). However, numerous macrophage-like cells were present in OE and LP at this time point (N). By 18 d 
after injury, epithelial regeneration was now clearly evident by a substantial increase in OMP+ cell numbers (I) and the reappearance of Nav1.7 staining 
in olfactory nerve bundles (J). The number and distribution of Cx3cr1
gfp/+ macrophage-like cells had also returned to normal control levels (O).33 Quanti-
tative counts of GFP+ cells within the olfactory neuroepithelium are shown in (K). Note that the appearance of Nav1.7
+ cells in the LP precedes the peak 
of macrophage infiltration into the OE. Scale bars: 50 μm.
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this channel must be present in olfactory tissue and that it must 
play a pivotal role in olfaction. Electrophysiological studies have 
revealed the presence of TTX-sensitive Na+ currents in cultured 
rat olfactory sensory neurons29 and mouse OE tissue slices.15 All 
Na
v
 subtypes except Na
v
1.5, Na
v
1.8 and Na
v
1.9 are TTX-sensitive, 
but those responsible for Na+ currents in olfactory receptor neu-
rons were unclear until very recently. It is now known that Na
v
1.7 
is the predominant Na
v
 channel in ORNs23 and that this chan-
nel is essential for action potential conduction in olfactory nerve 
terminals in OB glomeruli.15
We observed little, if any, Na
v
1.7 expression on the apical den-
drites of both rat and mouse primary olfactory sensory neurons, 
which is in line with other recent observations in mice15,23 and 
suggests that this channel does not play a direct role in odor-
ant detection. Rather, the observed distribution of Na
v
1.7 within 
the rat olfactory system, in combination with the severe olfactory 
deficit in people with CIP that lack Na
v
1.7, indicates that this 
channel plays a fundamental role in amplifying and propagating 
action potentials to the OB following the detection of olfactory 
cues. This function is similar to the role of Na
v
1.7 in nociceptive 
neurons, where it is believed to act as a threshold channel that 
amplifies pain signals transmitted above a certain level.30
Publication of two independent reports detailing the role of 
Na
v
1.7 in olfaction in mice coincided with preparation of this 
paper.15,23 We extended the two previous studies on Na
v
1.7 
expression along the mouse olfactory pathway by showing that 
this channel is also present in the rat AOB. The AOB and the 
vomeronasal organ are responsible for pheromone sensing in 
mammals.17 Pheromonal cues are detected within the vomero-
nasal organ at the base of the nasal cavity and carried via vom-
eronasal receptor neurons to the AOB, where this information is 
processed. An earlier report demonstrated through in situ hybrid-
ization techniques that Na
v
1.3 is also expressed in the mouse 
vomeronasal organ, together with Na
v
1.1 and Na
v
1.2, albeit at 
extremely low levels.31 Subsequent patch-clamp electrophysiol-
ogy studies showed that the voltage-dependent Na+ currents were 
completely inhibited by 2 μM TTX, confirming the presence of 
TTX-sensitive Na
v
 channels in rodent vomeronasal organ neu-
rons.32 The relatively uniform Na
v
1.7 staining we observed in the 
AOB demonstrates that Na
v
1.7 is present in terminations of the 
At 2 d following methimazole treatment, the OE appeared 
severely damaged and disorganized with some regions completely 
detached from the more basement membrane (compare Fig. 3A 
and C). Olfactory sensory neurons were virtually absent from 
the OE at 5 and 10 d after methimazole treatment, as expected, 
although OMP+ remnants of their axons were still detected within 
olfactory nerve fascicles (Fig. 3E and G). Regeneration of the OE 
became evident by a thickening of the cellular layers with time 
and the reappearance of OMP+ olfactory sensory neurons at 18 d 
after methimazole treatment (Fig. 3I). Epithelial thickness aver-
aged ~70% of normal control values at this point in time and the 
intensity of Na
v
1.7 staining returned to normal (++) levels at 18 d.
We noted a high abundance of Na
v
1.7+ inflammatory cells imme-
diately following injury. Specifically, at 2 d following methimazole 
treatment, and even more so after 5 d, Na
v
1.7+ expression was evi-
dent on smaller cells with a globular morphology in the lamina 
propria underneath the OE (Fig. 3D and F). Significantly fewer 
Na
v
1.7+ cells were observed at later time points (i.e., ≥10 d) after 
methimazole treatment, at which stage immunoreactive cells were 
mostly present in close association with blood vessels within the 
lamina propria (Fig. 3H). As the vasculature of the lamina propria 
forms the entry point for circulating leukocytes into the OE, these 
findings suggest that expression of Na
v
1.7 may be downregulated 
as monocyte precursor cells enter, differentiate and transmigrate 
into the neuroepithelium for debris clearance and phagocytosis. 
Such a hypothesis was supported by the fact that numerous mac-
rophage-like cells were present within the lesioned olfactory tissue 
from Cx
3
cr1gfp/+ mice28 at all time points investigated (Fig. 3L–O), 
and that the appearance of Na
v
1.7+ cells in the lamina propria 
preceded the peak of macrophage infiltration into the OE (Fig. 
3K). Subsequent double-staining procedures confirmed Na
v
1.7 
expression on a subset of green fluorescent protein (GFP)+ cells 
of monocytic lineage. GFP+ Na
v
1.7+ cells lacked the cytoplasmic 
protrusions more characteristic of mature macrophages, suggest-
ing they were indeed newly recruited monocytes (Fig. 4).
Discussion
The fact that people with CIP as a result of loss-of-function 
mutations in Na
v
1.7 also suffer from anosmia indicates that 
Figure 4. Expression of Nav1.7 on a subset of cells of the monocytic lineage. (A) Nav1.7 staining can be detected on small round cells at 5 d after exper-
imentally-induced death of olfactory sensory neurons in Cx3cr1
gfp/+ mice (arrowheads). (B) Co-expression of GFP was observed for these cells, indicating 
that they are most likely newly recruited inflammatory monocytes based on their morphology. Note that GFP+ cells with more mature macrophage 
morphology do not stain positively for Nav1.7. A merged image is shown in (C). Scale bar: 50 μm.
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cells. AlexaFluor 488 goat anti-rabbit antibody alone showed no 
nonspecific binding (not shown).
Rat tissue collection and processing. Male, 5 mo-old Sprague-
Dawley rats (n = 5) were deeply anaesthetized via intraperitoneal 
injection with sodium pentobarbital (80–100 mg/kg; Virbac), 
followed by transcardial perfusion with 100 ml of heparinized 
saline (0.9% NaCl) and 300 ml of Zamboni’s fixative. The OE 
and OB were then extracted by dissection followed by overnight 
post-fixation at 4°C. Samples were subsequently decalcified via 
overnight immersion incubation in phosphate-buffered saline 
(PBS) containing 250 mM EDTA (EDTA), followed by cryo-
protection in graded (10 and 30%) sucrose solution. Next, tissue 
samples were snap-frozen in dry ice-cooled isopentane and stored 
at -80°C until further processing. Tissue samples were sectioned 
into 20 μm thick slices on a Leica CM 3050 S cryostat and serial 
sections were collected on Superfrost®-Plus glass slides (Menzel 
Glaser), air-dried and again stored at -80°C until used.
Immunostaining procedures. Slides were air-dried at RT for 
40 min followed by several washes in PBS (3 x 5 min each) for re-
hydration. For peroxidase-based immunohistochemistry, the tis-
sue was first incubated with 500 μL/slide of quenching solution 
(0.6% H
2
O
2
 and 10% methanol in PBS) to block endogenous 
peroxidase activity within the tissue. Slides were then washed 
again in PBS and blocked with 2% bovine serum albumin (BSA) 
and 0.2% Triton-X100 in PBS for 1 h at RT in a humidified 
chamber. Next, slides were incubated overnight at 4°C with pri-
mary rabbit polyclonal anti-Na
v
1.7 antibody (1:200; Millipore, 
AB5390-200UL). The following day, slides were extensively 
washed (3 x 10 min) in PBS to remove unbound antibody fol-
lowed by incubation with biotinylated goat anti-rabbit second-
ary antibody (1:400; Jackson ImmunoResearch Laboratories, 
711-066-152) at RT. Slides were then washed again and incu-
bated with 1:400 peroxidise-conjugated avidin-biotin complex 
(ABC; Vector Laboratories, SP-2002) for 1 h at RT. Slides were 
washed and stained for 3–5 min at RT using 3,3'-diaminobenzi-
dine (DAB) as a chromogen (Sigma Life Science, D4293). The 
reaction was stopped via immersion of slides into ddH
2
O. Slides 
were dehydrated through a graded series of ethanol washes (70–
100%), cleared in xylene, and coverslipped with DePex mount-
ing medium (Merck, 13514).
For double immunofluorescent staining procedures, similar 
procedures were followed, except that incubation with quench-
ing solution was omitted. In brief, tissue sections on slides were 
washed with PBS and blocked with 2% BSA for 1 h. Sections 
were then incubated overnight at 4°C with a mixture of rab-
bit anti-Na
v
1.7 antibody (1:200) and goat anti-OMP antibody 
(1:1,000; Wako, 019-22811). Staining for OMP was used to 
visualize primary olfactory sensory neurons and their projec-
tions in the nasal neuroepithelium. The next day, sections were 
washed (3 x 10 min) and incubated with Cy3-conjugated don-
key anti-rabbit (1:400) (Jackson ImmunoResearch Laboratories, 
711-165-162) and biotin-conjugated donkey anti-goat secondary 
antibodies (1:400; Jackson ImmunoResearch Laboratories, 705-
065-003) for 1.5 h at RT. Following this, sections were washed 
(3 x 10 min) and incubated with Alexa 488 conjugated strep-
tavidin (1:400; Sigma, S11223). Finally sections were washed 
vomeronasal receptor neurons and most likely plays a critical role 
in pheromone detection. Given that Na
V
1.3 is primarily confined 
to neuronal cell bodies, our findings indicate that, similar to the 
main olfactory system,15,23 the TTX-sensitive Na
v
1.7 channel is 
very likely responsible for the propagation of action potentials 
along the vomeronasal axonal pathway.
Lastly, we noted prominent expression of Na
v
1.7 on the early 
inflammatory cell infiltrate present within the lamina propria 
after injury. The OE normally contains both macrophages 
and dendritic cells33 and after injury these populations actively 
increase through recruitment of circulating monocytes.34,35 
Na
v
1.7+ cellular infiltrate was transiently observed during the 
acute phase of macrophage recruitment. The use of Cx
3
cr1gfp/+ 
mice revealed that even though a sharply diminished Na
v
1.7 
immunoreactivity was observed in the sub-acute phase after 
injury (day 5 onwards), there was a continued presence of 
monocyte-derived cells within the tissue, suggesting a down-
regulation of this channel. These observations are consistent 
with a recent report showing downregulation of Na
v
1.7 during 
maturation of dendritic cells.24,36 The role of Na
v
1.7 in immune 
cell function and differentiation remains largely unclear. 
However, emerging evidence suggests a critical role for Na
v
1.7 
in the maturation and migration of a subset of dendritic cells as 
well as the production of pro-inflammatory cytokines.24 These 
findings warrant further investigation into the role of Na
v
1.7 
in other cells of the monocytic lineage, since therapeutics that 
target Na
v
1.7 might be useful immune modulators for the treat-
ment of post-injury inflammation and chronic inflammatory 
pain, in addition to being effective analgesics.
Materials and Methods
Cell culture and immunofluorescence. Chinese hamster ovar-
ian (CHO) cells stably transfected with Na
v
1.4, Na
v
1.6 and 
Na
v
1.7 (Genionics AG) were grown on poly-D-lysine coated 
glass coverslips in F-12 medium (Gibco) supplemented with 
9% fetal bovine serum (Lonza, BW14-502E), 0.9% penicillin/
streptomycin (Gibco, 15070-063), and 100 μg/ml hygromycin B 
(Invitrogen, 10687-010). HEK-293 cells stably transfected with 
Na
v
1.5 (Genionics) were grown in Dulbecco’s modified Eagle 
medium (Gibco, 12491015), 0.9% penicillin/streptomycin and 
100 μg/ml zeocin (Invitrogen, R250-01).
Sub-confluent cells were fixed with 10% paraformaldehyde 
(Sigma, 158127-100G), permeabilized with 10% Triton-X 
(Sigma, T8532-100ML), then nonspecific binding was blocked 
by incubation with 10% goat serum (Invitrogen, PCN500). Cells 
were incubated for 2 h at room temperature (RT) with a rabbit 
anti-Na
v
1.7 antibody (1:2,000; Millipore, AB5390-200UL) and, 
after additional washing steps, for 1 h with an AlexaFluor 488 
goat anti-rabbit antibody (1:1,000; Invitrogen, A11008). Nuclei 
were counterstained with 4',6-diamidino-2-phenylindole (DAPI) 
(1:2,000; Invitrogen, D21490). Coverslips were mounted in 
fluorescent mounting media (DAKO, S3023) and observed with 
fluorescence microscopy. To control nonspecific binding, anti-
Na
v
1.7 antibodies were blocked for 30 min with a 5-fold excess 
of its antigen or incubated together with nontransfected HEK 
© 2012 Landes Bioscience.
Do not distribute.
www.landesbioscience.com Channels 109
Olfactory ablation. Methimazole drug treatment or Triton-X 
lesions were performed as described in references 25 and 37. In 
brief, mice received two consecutive intraperitoneal injections of 
methimazole (Sigma, M8506; 50 mg/kg) on days 0 and 3 fol-
lowed by perfusion and tissue processing as detailed above 2, 5, 
10 or 18 d following the first injection.
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again (3 x 10 min) and coverslipped with ProLong® Gold anti-
fade reagent (Invitrogen, P36935) containing DAPI. Na
v
1.7 
staining specificity was verified via omission of the primary 
antibody and/or incubation with control (pre-immune) rabbit 
serum. Cross-reactivity with other Na
v
 channels was excluded 
in separate in vitro experiments (see Fig. S1). Cx
3
cr1gfp/+mice28,33 
were used to visualize Nav1.7 expression on cells of monocytic 
lineage. For this purpose, immunohistochemical staining for 
Nav1.7 (as described earlier) was examined in relation to native 
GFP fluorescence.
Microscopy and image analysis. DAB-stained tissue sections 
were scanned using an Aperio scanscope XT. The staining pat-
tern and distribution were analyzed using ImageScope software 
(Aperio). Different levels of staining intensity representing the 
relative abundance of Na
v
1.7 were documented as: (1) ‘-’ indi-
cates no staining, defined as not above background levels; (2) ‘+’ 
indicates light staining that is clearly elevated above background 
levels; (3) or ‘++’ for darkly stained regions with the highest 
abundance of Na
v
1.7. Photomicrographs of immunofluorescent 
stainings were taken with an Olympus BX-51 fluorescence micro-
scope and a Zeiss LSM 710 FCS confocal microscope. Greyscale 
images were false colored and channels were merged to visualize 
colocalization using Image J.
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CHAPTER 5 
 
Conclusion and future directions 
Conclusion 
The overall aim of this thesis was to develop potent and selective blockers of hNaV1.7 that 
can be used as leads for the development novel analgesics for treatment of chronic pain, 
and to understand the impact that such drugs might have on olfaction. I used an assay-
guided fractionation approach to identify several NaV1.7 modulators, including the novel 
peptide µ-TRTX-Pe1b and the well-known Nav1.7 modulator ProTx1. A recombinant 
expression system was successfully employed to produce higher quantities of µ-TRTX-
Pe1b necessary for SAR studies. ProTx1 was synthetically produced and the structure 
was determined in collaboration with several groups and individuals, which facilitated the 
SAR work.  
 
The work presented in this thesis has shown that ProTx1 is a promiscuous molecule that is 
not suitable as an analgesic drug lead in its native form. However, the ProTx1-G32A-NH2 
mutant I constructed has significant promise as an analgesic drug lead. The Pe1b-S35 
mutant I engineered has a high level of NaV1.7 inhibitory activity and selectivity over other 
NaV channels. Further mutations of this peptide may provide insights into the NaV1.7 
pharmacophore of Pe1b and facilitate rational engineering of its subtype selectivity. 
 
The localization of NaV1.7 in the rodent olfactory system was determined using a 
combination of immunohistochemical and fluorescent localization methods. NaV1.7 was 
found to be localized on axons of primary olfactory sensory neurons. This indicated that 
NaV1.7 is associated with the amplification and propagation of olfactory signals to the 
olfactory bulb. This finding explains the anosmia and hyposmia observed in patients 
suffering form CIP. However, as an indirect observation it was noted that monocyte-
derived cells of inflammatory infiltrate downregulate NaV1.7 expression following injury. 
Although the exact role of NaV1.7 in these monocyte-derived cells are not clear, there is 
emerging evidence to suggest that NaV1.7 is associated with maturation and migration of 
certain monocyte-derived cells, and production of pro-inflammatory cytokines. This 
observation warrants further investigation; it would be worth investigating, for example, 
whether CIP patients display any abnormal immune responses. 
Future Directions 
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The structure of Pe1b is currently not available. The 3D structure of Pe1b would be of 
immense use in future SAR studies as more mutational data becomes available. In 
addition, testing of Pe1b against the panel of NaV1.7/KV chimeras described in Chapter 2 
will enable identification of the voltage sensor domains (VSDs) that Pe1b interacts with. 
Construction of point mutations in the cognate VSD for Pe1b binding would then enable 
identification of specific NaV1.7 residues that mediate binding of Pe1b. Knowledge of the 
interaction sites on both Pe1b and NaV1.7, as well as having access to the 3D structure of 
Pe1b and a homology model of the cognate VSD, would enable the initiation of docking 
studies to construct a testable model of the Pe1b-NaV1.7 complex. 
 
The activity of Pe1b-S35 has not yet been tested against potential off-target channels such 
as hERG and KV and CaV channels. Future work should include testing of Pe1b against a 
wide range of pharmacologically relevant targets, including other voltage gated ion 
channels. Testing of the analgesic efficacy of Pe1b in rodent models of chronic pain could 
follow if the off-target profile of Pe1b turns out to be good. If not, additional engineering will 
be required to remove off-target activity that might cause undesirable side effects. 
 
This research has also shown that although some peptides belong to the same NaSpTx 
family, and share significant sequence similarity, there exists sufficient variation within 
these sequences to achieve a high level of subtype selectivity. The flip side of this, 
however, is that one has to be very careful when engineering these peptides for improved 
potency to ensure that the introduced modifications do not alter subtype selectivity, which 
is clearly governed by very subtle differences in binding to each VSD. 
 
Although NaV1.7 is a very promising analgesic target, the potential side effects associated 
with therapeutic inhibition of NaV1.7 are not fully understood. For example, it is unclear 
whether patients with chronic pain would suffer from induced anosmia if they took NaV1.7 
inhibitors over a long period of time. Peptide blockers of NaV1.7 that were delivered orally 
or by subcutaneous injection might never reach the olfactory neurons in sufficient quantity 
to affect olfaction, but this issue remains to be examined. Clearly, every effort should be 
made to fully understand the role of NaV1.7 in the human body, which might reveal the 
best routes of administration, or localized treatment methods, that would minimize 
undesirable side effects.  
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APPENDIX 1
rapidly incapacitate their prey. NaV channel toxins are
found in a taxonomically diverse range of spiders, which
suggests that this pharmacology was recruited at a very
early stage in venom gland evolution. Moreover, the ubiq-
uity of NaV channel toxins in spider venoms suggests that
these peptides might be useful insecticides for the control
of arthropod pests (Maggio et al., 2010; Windley et al.,
2012).
In addition to prey capture, spiders also use their
venom to deter predators, which can include vertebrates.
Moreover, even though the vast majority of spiders prey
primarily on invertebrates, there is no evolutionary
selection pressure to prevent spider toxins acting on
vertebrate ion channels. It is therefore not surprising that
many spider-venom peptides have been found to modu-
late the activity of vertebrate NaV channels (Nicholson and
Little, 2005; Escoubas and Bosmans, 2007; King et al.,
2008a).
2. NaV channels
In both vertebrates and invertebrates, functional NaV
channels are composed primarily of a large pore-forming
a subunit (220–260 kDa) whose gating and kinetics are
modified via associationwith one of four smaller b subunits
(33–36 kDa) in the case of vertebrates or the unrelated TipE
accessory subunit (65 kDa) in the case of invertebrates
(King et al., 2008a). The a subunit is composed of four
homologous but non-identical domains (designated I–IV)
connected by intracellular linkers (Fig. 2). Each of
these domains contains six transmembrane (TM) segments
(S1–S6) joined by intracellular or extracellular loops.
Membrane re-entrant loops between TM segments S5 and
S6 dip into the TM region of the protein and form the
narrow ion-selectivity filter at the extracellular end of the
pore (Fig. 2). During action potential generation, the
channel cycles through three states: closed, open, and
inactivated. The S4 segments contain a positively charged
amino acid (Arg or Lys) at every third position; this
segment serves as a ‘voltage sensor’ that initiates voltage-
dependent activation (i.e., the transition from the closed
to open state) by responding to membrane depolarization
and causing the channel to undergo a conformational
change that allows selective influx of Naþ ions through the
pore. Sodium channel inactivation (i.e., the transition from
the open to inactivated state) is mediated by a short
intracellular loop termed the “inactivation gate” that
connects domains III and IV (Fig. 2). In a major break-
through, the three-dimensional structure of a bacterial NaV
channel in the closed state was recently determined
(Payandeh et al., 2011), which should allow molecular
modelling of the interaction between NaV channels and
ligands that modulate their activity.
In vertebrates, the a subunits are classified into nine
different subtypes, denoted NaV1.1 to NaV1.9, and they are
further characterised by their sensitivity to tetrodotoxin
(TTX). NaV1.5, NaV1.8 and NaV1.9 are TTX-resistant, whereas
all other subtypes are TTX-sensitive (Catterall et al., 2005;
King et al., 2008a). A combination of site-directed muta-
genesis, binding studies, and electrophysiological
approaches have been used to identify at least seven
distinct ligand binding sites in or around the pore region of
the NaV channel a subunit, as shown in Fig. 2. The majority
of these sites have been identified using venom molecules
and alkaloids as pharmacological probes (King et al.,
2008a). Venom peptides modulate channel activity by
two main mechanisms: they either physically occlude the
channel pore or they bind to an allosteric site that induces
a conformational change in the channel that alters the
equilibrium between the open, closed, and inactivated
states (Ekberg et al., 2008).
All known NaV channel toxins from spider venoms are
allosteric modulators, also known as “gating modifiers”.
However, they modulate channel activity in quite
different ways. For example, the lethal toxin from the
Sydney funnel-web spider Atrax robustus (d-HXTX-Ar1a)
inhibits the inactivation of both insect and vertebrate NaV
channels (Nicholson et al., 1998; Grolleau et al., 2001),
whereas the m-agatoxins from unrelated American funnel
spiders shift the voltage for channel activation to more
negative potentials, increasing the probability of channel
opening at the resting membrane potential (Adams,
2004).
3. Spider toxins that target NaV channels
The primary aim of this review is to survey the range
of peptide sequences and three-dimensional scaffolds
that have been evolved by spiders for targeting NaV
channels, with an emphasis on those peptides that might
have therapeutic potential. The ‘Browse by Molecular
Targets’ ontology in ArachnoServer (Wood et al., 2009;
Herzig et al., 2011) was used to extract all known spider-
venom peptides with activity on NaV channels (both
vertebrate and invertebrate). Homologues of these
toxins were found by using the BLAST function within
Fig. 1. Ion channel modulators from spider venoms. Molecular targets of
the 186 ion channel toxins listed in ArachnoServer (www.arachnoserver.
org; accessed February 12, 2012) (Herzig et al., 2011). The majority of
toxins target voltage-gated ion channels (CaV, NaV, and KV), followed by
calcium-activated potassium (KCa) channels, mechanosensitive ion chan-
nels (MSC), transient receptor potential (TRP) channels, and acid-sensing
ion channels (ASICs). Note that some toxins target more than one type of
channel, and therefore the cumulative number of toxins in the histogram
is >186.
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ArachnoServer. CLC sequence viewer 6 (CLC bio,
Denmark) was used to align the peptides and generate
families of related peptides based on the level of
sequence identity and intercysteine spacings. This resul-
ted in 12 different families of spider-venom peptides that
target NaV channels, as outlined in Figs. 3 and 4. The
following sections describe the activity data that is
currently available for each family. These sections employ
the rational nomenclature recently developed for spider-
venom peptides (King et al., 2008b) in order to facilitate
identification of orthologs and paralogs, but for conve-
nience we also provide original names of toxins. The term
NaScTx is employed for scorpion toxins that target NaV
channels (Rodriguez de la Vega and Possani, 2005), and
here we introduce the term NaSpTx for spider toxins that
target this channel.
3.1. NaSpTx family 1
All peptides in Family 1 were isolated from the venom
of tarantulas (Theraphosidae), and they consist of 33–35
amino acid residues with three disulfide bridges that
form an inhibitor cystine knot (ICK) motif, defined as an
antiparallel b sheet stabilised by a cystine knot (Pallaghy
et al., 1994). In spider toxins, the b sheet typically
comprises only two b strands although a third N-terminal
strand is sometimes present (King et al., 2002). The
cystine knot itself comprises a ring formed by two disul-
fides and the intervening sections of the peptide back-
bone, with a third disulfide piercing the ring to create
a pseudo-knot (Saez et al., 2010). This “knot” converts ICK
peptides into hyperstable mini-proteins with tremendous
chemical, thermal, and biological stability. ICK toxins are
Fig. 2. Molecular architecture and pharmacology of NaV channels. The pore-forming a subunit of NaV channels is comprised of four homologous domains denoted
I–IV connected by intracellular linkers. Each of these domains contains six transmembrane (TM) helical segments (labelled 1–6) joined by intra- or extracellular
loops. TM segments 5 and 6 from each domain, along with the intervening membrane re-entrant loops (highlighted with a light green box), come together to
form the channel pore and the ion-selectivity filter at the extracellular end of the pore. TM segments 1–4 of each domain form the voltage-sensing units, as
indicated for domain I; the highly positively charged TM segment 4 is primarily responsible for sensing changes in membrane polarization. Sodium channel
inactivation is mediated by a short stretch of hydrophobic residues (the “inactivation gate”; orange balls) in the intracellular linker connecting domains III and IV.
Coloured regions represent neurotoxin receptor sites. The grey circles represent the outer (EEDD) and inner (DEKA) rings of amino acid residues that form the
ion-selectivity filter and constitute the proposed neurotoxin receptor site 1 for the water-soluble guanidinium toxins TTX and saxitoxin. Some m-conotoxin
binding sites overlap with those of TTX and are omitted for clarity. Nevertheless, we refer to sites 1a and 1b to distinguish between the different molecular
determinants for m-conotoxin and TTX/saxitoxin binding. In the case of receptor sites 3 and 4, only epitopes where mutagenesis of key residues leads to more
than a five-fold decrease in toxin binding affinity are highlighted. Note that TM segment 6 in domain I includes binding epitopes for both site 2 and site 5 toxins.
The known binding sites for 8 of the 12 families of spider-venom NaV toxins (NaSpTxs) are indicated. “F” denotes toxin family (e.g., F2 indicates NaSpTx Family 2).
While the d-amaurobitoxins in Family 10 have been shown to bind to neurotoxin receptor site 4, peptides in this family have variable pharmacology and some
may bind at other sites. Adapted from Catterall et al. (2007) and King et al. (2008a).
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typically resistant to extremes of pH, organic solvents,
high temperatures, and proteases (Saez et al., 2010). Of the
10 families of NaSpTxs whose disulfide connectivity has
been determined or which can be confidently predicted
based on homology (see Figs. 3 and 4), nine contain an ICK
motif.
One member of Family 1 (m/u-TRTX-Hh1a; huwentoxin-
1) was found to be analgesic in a rat model of formalin-
induced pain when administered intrathecally (Chen
et al., 2005), although in another study the same peptide
was reported to be lethal to mice when delivered via the
intraperitoneal or intracisternal route (Liang et al., 1993).
Fig. 3. NaSpTx families 1–4, 7 and 10. The consensus sequence is shown above each alignment, with the disulfide bond connectivity indicated in blue. Red
asterisks denote C-terminal amidation. Strictly conserved residues are highlighted in bold colour while semi-conserved residues are highlighted in a lighter
colour. Toxin names are based on the rational nomenclature devised for spider-venom peptides (King et al., 2008b), as used in ArachnoServer and UniProt (King
et al., 2008b). The structure of a representative member from each NaSpTx family is shown adjacent to each alignment: Family 1, m-TRTX-Hh2a (PDB ID: 1MB6);
Family 2, k-TRTX-Gr1a (PDB ID: 1D1H); Family 3, k-TRTX-Gr2a (PDB ID: 1LUP); Family 4, d-HXTX-Hv1a (PDB ID: 1VTX); Family 7, k-TRTX-Gr3a (PDB ID: 1S6X);
Family 10, d-AMATX-Pl1b (PDB ID: 1V91). b strands are depicted in cyan, helices are red, and disulfide bridges are yellow. All spider photos were taken by Bastian
Rast.
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Fig. 4. NaSpTx families 5, 6, 8, 9, 11 and 12. The consensus sequence is shown above each alignment, with the disulfide bond connectivity indicated in blue.
Dotted lines represent predicted disulfide bond connectivities that have not been experimentally validated. Red asterisks denote C-terminal amidation. Strictly
conserved residues are highlighted in bold colour while semi-conserved residues are highlighted in a lighter colour. Toxin names are based on the rational
nomenclature devised for spider-venom peptides (King et al., 2008b), as used in ArachnoServer and UniProt. The structure of a representative member of Family 5
is shown adjacent to the alignment (b-HXTX-Mg1a; PDB ID: 2GX1). Disulfide bridges are coloured yellow. No structures are available for any member of the other
NaSpTx families depicted in this figure. Spider photos are by Bastian Rast (M. gigas and P. reidyi) and Aloys Staudt (H. melloteei).
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Intraperitoneal administration of m-TRTX-Hhn1b (hai-
nantoxin-IV) is also lethal to micewith an LD50 of 0.2mg/kg
(Liu et al., 2003), as is intracerebroventricular (i.c.v.)
administration of b-TRTX-Ps1a (phrixotoxin-3), b-TRTX-
Cm1a (ceratotoxin-1), and b-TRTX-Cm1b (ceratotoxin-1)
(Bosmans et al., 2006).
Despite the high level of residue conservation
throughout this family, the selectivity of the peptides for
the various NaV channel subtypes varies dramatically. For
example, b-TRTX-Ps1a potently blocks NaV1.5 with an IC50
of 72 nM (Bosmans et al., 2006) whereas m-TRTX-Hh2a
(huwentoxin-4), which is 62% identical to b-TRTX-Ps1a,
does not have any effect on NaV1.5 at concentrations up to
10 mM (Xiao et al., 2008). Based on homology with other
toxins, peptides in Family 1 are presumed to function as
gating modifiers (Bosmans et al., 2006). Consistent with
this hypothesis, analysis of the binding of m-TRTX-Hh2a to
mutants of NaV1.4 revealed that the peptide interacts with
the S3–S4 linker of channel domain II (i.e., neurotoxin
receptor site 4; see Fig. 2), with the blocking effect achieved
by trapping the domain II voltage sensor in the closed
configuration (Xiao et al., 2008). In contrast, m-TRTX-Hhn1b
was shown to have no effect on the activation or inactiva-
tion kinetics of TTX-S NaV currents in rat dorsal root
ganglion (DRG) neurons and therefore it was hypothesised
to function not as a gating modifier but as a pore blocker
by binding at neurotoxin receptor site 1 (Li et al., 2004).
However, this would be a very unusual pharmacology for
NaSpTxs and it remains to be confirmed by site-directed
mutagenesis and competitive binding studies. The func-
tionally important residues on m-TRTX-Hhn1b have been
proposed to be K27 (which is conserved in most Family 1
peptides) and R29 (which is poorly conserved) as muta-
tions of these residues to alanine showed reduced activity
(Li et al., 2004).
Very little work has been done to examine the activity of
Family 1 peptides against insect NaV channels, but the
limited data available indicates that the insecticidal activity
of these peptides is likely to be highly variable. m-TRTX-
Hhn1b has no effect when injected into cockroaches (Liu
et al., 2003), whereas m/u-TRTX-Hh1a potently inhibits NaV
currents in cockroach dorsal unpaired median (DUM)
neurons (IC50¼ 4.8 nM) (Wang et al., 2012). Falling between
these two extremes is m-TRTX-Hhn2b (hainantoxin-I), which
only weakly inhibits insect NaV channels heterologously
expressed in Xenopus oocytes (IC50¼ 4.3 mM) (Li et al., 2003).
3.2. NaSpTx family 2
Family 2 is the largest family of NaSpTxs with 34
members, all originating from theraphosid venoms. Of
these, 18 peptides were isolated from the Chinese taran-
tula Chilobrachys jingzhao. Family 2 peptides range in size
from 33 to 41 residues and they each contain three
disulfide bonds that form an ICK motif. Currently, there is
experimental proof of NaV channel activity for only four of
the 34 peptides in this family. However, they are very
interesting from a therapeutic perspective as one member
of this family, b/u-TRTX-Tp1a (protoxin I), is one of the
most potent blockers of human NaV1.7 reported to date,
with an IC50 of 51 nM (Middleton et al., 2002; Priest et al.,
2007).
k-TRTX-Cj1a (Jingzhaotoxin-11) is a weak modulator
of NaV currents in cardiac myocytes (i.e., mainly TTX-R
NaV1.5), causing a significant reduction in peak NaV
current amplitude and a slowing of NaV current inactiva-
tion (IC50 ¼ 1280 nM) (Liao et al., 2006). It also inhibits
KV2.1 with moderate potency (IC50 ¼ 740 nM), with even
weaker block of KV4.1 and KV4.2 and no effect on KV1.1,
KV1.2, KV1.3, KV1.4 and KV3.1 (Liao et al., 2006). A peptide
with identical sequence has been isolated from the venom
of the related theraphosid spider Plesiophrictus guangxien-
sis. It has been proposed that k-TRTX-Cj1a binds to the
extracellular S3–S4 linker region of channel domain IV (i.e.,
neurotoxin receptor site 3; see Fig. 2) (Liao et al., 2006),
which is a common target of gating modifier toxins such as
k-TRTX-Gr1a (Hanatoxin-1) in the same family (Li-Smerin
and Swartz, 1998).
b-TRTX-Cm2a (Ceratotoxin-3) has moderate affinity
towards NaV1.5 (IC50 ¼ 447 nM), and at a concentration of
2 mM it weakly blocks NaV1.8 (45% reduction in current) but
has no activity against NaV1.1–1.4 (Bosmans et al., 2006). In
striking contrast with k-TRTX-Cj1a and b-TRTX-Cm2a,
m-TRTX-Cj1a (Jingzhaotoxin-34) is a potent blocker of TTX-S
NaV channels in rat dorsal root ganglion (DRG) neurons
(IC50 ¼ 85 nM) but it has no effect on TTX-R NaV currents
(Chen et al., 2009). Thus, residues that are conserved in
k-TRTX-Cj1a and b-TRTX-Cm2a, but which are absent from
m-TRTX-Cj1a, should provide some insight into residues
that are important for interaction of this family of peptides
with NaV1.5.
Six toxins from Family 2 have confirmed activity on
voltage-gated calcium (CaV) channels, with 12 toxins
active against KV channels. Nevertheless, the high level
of sequence identity within this family and the potency of
the known Family 2 NaV modulators described above
indicates that a thorough functional analysis of all toxins in
this family could reveal many more toxins acting on NaV
channels. However, from a therapeutic perspective, the
promiscuous activity of several family members on
multiple types of voltage-gated channels indicates that it
will be critical to carefully determine the selectivity of any
Family 2 peptides that are being considered as therapeutic
leads (Chen et al., 2008).
3.3. NaSpTx family 3
This family consists of 14 reported toxins with highly
conserved sequences in the C-terminal region. k-TRTX-
Ps1b (Phrixotoxin-2) and k-TRTX-Gr2a (GsMTx-2) are
identical peptides identified from different genera of
tarantulas (Diochot et al., 1999; Oswald et al., 2002); for
simplicity, only k-TRTX-Ps1b is given in the alignment
(Fig. 3). Family 3 peptides are 29–32 residues long, with
three disulfide bonds forming an ICK motif. These peptides
act as gating modifiers by binding to the voltage sensor
region (S3–S4 linker) of channel domain II (i.e., neurotoxin
receptor site 4; see Fig. 2), thus impeding channel activa-
tion and causing the channels to remain in a resting state
(Sokolov et al., 2007). b/u-TRTX-Tp2a (protoxin II) and b-
TRTX-Gr1b (GsAF I) are both selective against the NaV1.7
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subtype, an important analgesic target, but their potency
differs by >100-fold despite w90% sequence identity
(Priest et al., 2007; Redaelli et al., 2010). b/u-TRTX-Tp2a is
the most potent blocker of human NaV1.7 reported to date,
with an IC50 of 0.3 nM (Schmalhofer et al., 2008). It also
inhibits activation of human CaV3.1 currents but at much
higher doses (IC50 w1 mM) (Edgerton et al., 2010). b/u-
TRTX-Tp2a is lethal to rats when administered intrave-
nously at doses 1.0 mg/kg or intrathecally at doses
0.1 mg/kg (Schmalhofer et al., 2008). This is perhaps not
surprising as even though b/u-TRTX-Tp2a preferentially
blocks NaV1.7, it also potently inhibits key peripheral NaV
channel subtypes (e.g., NaV1.5, IC50 ¼ 79 nM) as well as
central NaV channel subtypes (e.g., NaV1.2, IC50 ¼ 41 nM)
(Schmalhofer et al., 2008).
b-TRTX-Gr1a (GrTx1) is 96% identical to b-TRTX-Gr1b,
with the only difference being a Gln at position 22 instead
of Arg. However, this single amino acid change causes a vast
difference in selectivity. b-TRTX-Gr1a has similar potency
towards NaV1.1, NaV1.2, NaV1.3, NaV1.6, and NaV1.7 (IC50
range of 230–770 nM) whereas b-TRTX-Gr1b is >5-fold
more selective towards NaV1.7 (Redaelli et al., 2010).
Significant variations in NaV channel subtype selectivity
due to small sequence variations has been noted previously
in scorpion-venom peptides (Weinberger et al., 2010).
3.4. NaSpTx family 4
Of the seven peptides in this family, six were isolated
from the venom of Australian funnel-web spiders (family
Hexathelidae), whereas the seventh is found in non-related
Australian mouse spiders (family Actinopodidae). These
peptides comprise 42–44 residues with four disulfide
bonds, three of them arranged in an ICK motif. They are
characterised by an unusual sequence of three consecutive
Cys residues in the centre of the primary structure and
a disulfide bond that connects the N- and C-terminal Cys
residues. All peptides in this family are lethal to vertebrates,
including d-HXTX-Ar1a (robustoxin) from the Sydney
funnel-web spider A. robustus, which was responsible for at
least 14 human fatalities prior to the introduction of an
effective antivenom in 1980 (Fletcher et al., 1997). Family 4
peptides bind to neurotoxin receptor site 3 (see Fig. 2) and
slow inactivation of both vertebrate TTX-sensitive NaV
channels and insect para-type NaV channels (Gunning et al.,
2003; Nicholson et al., 2004). Symptoms in primates
include immediate disturbances in respiration, blood
pressure and heart rate, followed by severe hypotension
and death due to respiratory and circulatory failure within
a few hours (Mylecharane et al., 1989). With the exception
of d-HXTX-Hv1b (Szeto et al., 2000), all Family 4 peptides
exhibit insecticidal activity, causing paralysis and/or
lethality in orthopterans, lepidopterans and dipterans
(Little et al., 1998; Grolleau et al., 2001).
The activity of d-HXTX-Mg1a (Magi-4), the only
member of this family not isolated from an Australian
spider, was recently tested against the full range of rodent
NaV subtypes expressed in oocytes (Yamaji et al., 2009). d-
HXTX-Mg1a was found to be a potent blocker of the
Drosophila para/TipE NaV channel (IC50 w23 nM), and it
potently slowed NaV channel inactivation in cockroach
DUM neurons (EC50 w820 pM) (Yamaji et al., 2009).
Activity on vertebrate NaV subtypes was much more
modest, perhaps explaining why envenomation by Macro-
thele gigas does not appear to be a serious medical problem.
At a concentration of 5 mM, d-HXTX-Mg1a had a significant
effect on inactivation of rat NaV1.1 and mouse NaV1.6,
modest effects on rat NaV1.2, NaV1.3 and NaV1.7, and no
effect on rat NaV1.4, rat NaV1.5 and human NaV1.8. In
contrast with d-HXTX-Mg1a, Family 4 toxins from lethal
Australian funnel-web spiders, such as d-HXTX-Hv1a, are
more potent on vertebrate TTX-sensitive NaV channels than
insect NaV channels (Nicholson et al., 1996).
3.5. NaSpTx family 5
This family of NaSpTxs comprises only two peptides
isolated from closely related hexathelid spiders, both of the
genus Macrothele. These peptides contain 28–29 residues
with three disulfide bonds forming an ICK motif. b-HXTX-
Mg1a (Magi-5) and b-HXTX-Mr1a (raventoxin III), from
different species of Macrothele, have identical sequences
(Zeng et al., 2003) so only b-HXTX-Mg1a is presented in the
alignment. These peptides are lethal to rodents, but their
insecticidal activity is variable. Intra-thoracic injection of
U12-HXTX-Mg1a (Magi-11) in crickets (Gryllus bimaculatus)
induced slow-onset paralysis leading to death, while
intracranial injection in mice resulted in lacrimation,
sweating, and urination followed by paralysis of breathing
and death 15 min post-injection. b-HXTX-Mg1a/b-HXTX-
Mr1a caused reversible paralysis when injected into
caterpillars (Spodoptera litura) and had no effect when
injected into cockroaches (Periplaneta americana), whereas
intraperitoneal injection in mice resulted in excitation,
gasping, spastic paralysis, and exophthalmos (bulging of
the eyes) followed by death (Satake et al., 2004). b-HXTX-
Mg1a binds to site 4 on vertebrate NaV channels (see Fig. 2)
and shifts steady-state activation to more hyperpolarised
voltages, whereas it has been reported to bind to site 3 on
insect channels (Corzo et al., 2003, 2007; Zeng et al., 2003).
3.6. NaSpTx family 6
All peptides in this family were isolated from the venom
of spiders in the family Ctenidae. Four were isolated from
the highly venomous Brazilian armed spider Phoneutria
nigriventer, one was isolated from the venom of the closely
related Phoneutria reidyi, and one was identified from
a venom gland transcriptome of Phoneutria keyserlingi. The
final member of the family was isolated from the venom of
a related ctenid, the South American fishing spider (Ancy-
lometes sp.). These toxins comprise 47–54 residues and
contain five disulfide bonds whose connectivity has not
been experimentally determined. Of those that have been
tested in vertebrates, all display lethality even at doses as
low as 7.5 pmol/g (Cordeiro et al., 1992). d-CNTX-Pn2a (Tx2-
6) has a complex pharmacology that results in inhibition of
NaV channel inactivation and a hyperpolarizing shift in the
potential required for channel activation (Matavel et al.,
2002). Due to the high sequence identity (80–89%)
between members of this family, they are all assumed to
modulate NaV channels in this manner. An interesting
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supplementary pharmacology has been observed for
d-CNTX-Pn2a, which originated from the observation that
males bitten by this spider experience a diverse variety of
symptoms including priapism. Although i.c.v. injection of d-
CNTX-Pn2a into rats is lethal, rats with depressed erectile
function can be normalised by subcutaneous administra-
tion of d-CNTX-Pn2a (Nunes et al., 2008). A minimum dose
of only 0.006 mg/kg was required to cause an erection in
mice when injected directly into the corpus cavernosum
and, at this dose, no local and systemic toxic effects were
observed (Andrade et al., 2008). Thus, d-CNTX-Pn2a has
been touted as a lead molecule for the development of new
therapeutics for treatment of erectile dysfunction that
might have fewer side-effects than current drugs.
Only limited information is available regarding the
insecticidal activity of members of this family. d-CNTX-
Pn2a and -Pn2b (Tx2-5) were reported to be insecticidal to
both the larval and adult forms of the housefly Musca
domestica (Cordeiro et al., 1992), however, no LD50 values
have been reported.
3.7. NaSpTx family 7
All peptides in this family were isolated from the venom
of theraphosid spiders. They each contain 33–36 residues
with three disulfide bonds that form an ICK motif. k-TRTX-
Pg1b (guangxitoxin-1) and k-TRTX-Cj3a (jingzhaotoxin-4),
isolated from different genera, are identical (Herrington
et al., 2006; Chen et al., 2008), so only the sequence of
k-TRTX-Pg1b is presented in the alignment. These peptides
appear to have promiscuous activity on both KV and NaV
channels. Although several family members were isolated
as KV channel blockers, these peptides have not been tested
on NaV channels. The only two family members that have
been directly tested on NaV channels displayed significant
activity. Both b/k-TRTX-Cj1a (jingzhaotoxin-3) and d-TRTX-
Cj1a (jingzhaotoxin-1) inhibit activation of NaV1.5 with an
IC50 of 350 nM and 32 nM, respectively (Xiao et al., 2005;
Rong et al., 2011), It was recently shown via mutational
studies that b/k-TRTX-Cj1a binds to the S3–S4 loop of
domain II (i.e., neurotoxin receptor site 4; see Fig. 2) in
NaV1.5 (Rong et al., 2011).
Little is known about the insecticidal activity of these
toxins. Intra-abdominal injection of m-TRTX-Hh1a (Huwen-
toxin-3) into cockroaches induces reversible paralysis that
lasts for several hours. The effects of other family members
on insects or heterologously expressed insect NaV channels
have not been examined.
3.8. NaSpTx family 8
This is a small family comprising only three peptides
derived from two species of ctenid spiders. These peptides
are easily the longest NaSpTxs, with 76–77 residues and
seven disulfide bonds. They are similar in size to scorpion
a and b toxins that also target NaV channels (Rodriguez de
la Vega and Possani, 2005), but they have no sequence
homology and contain a larger number of disulfide bonds.
These toxins are lethal to rodents. m-CNTX-Pn1a (Tx1;
PhTx1) from P. nigriventer has an LD50 of 5.5 pmol/g in mice
(Diniz et al., 1990, 2006), while U5-CNTX-Pk1b (PKTx1B)
caused excitation and spastic paralysis in mice upon i.c.v.
administration at a dose of 1.5 mg/mouse, followed by death
within 5–8 min (Richardson et al., 2006).
Preliminary studies suggested that m-CNTX-Pn1a might
target vertebrate CaV channels (dos Santos et al., 1999,
2002) but more recent studies have shown that it is
a state-dependent blocker of rat NaV1.2 that binds in the
vicinity of channel site 1 (Martin-Moutot et al., 2006). The
high level of sequence identity suggests that all members of
this family will have the same pharmacology.
3.9. NaSpTx family 9
This family consists of only two paralogous peptides
isolated from the venom of the crab spider Heriaeus mel-
loteei. They comprise 37 and 40 residues, with three
disulfide bonds that are predicted to form an ICK motif.
m-TMTX-Hme1a (Hm-1) has similar potency against NaV1.2,
NaV1.4, NaV1.5, and NaV1.6 (IC50 150–500 nM) but no effect
against NaV1.8 (Billen et al., 2008). m-TMTX-Hme1b (Hm-2)
has similar pharmacology, except that it has very little
activity against NaV1.5 (Billen et al., 2008). The insecticidal
activity of these toxins has not been examined.
3.10. NaSpTx family 10
This family comprises venom peptides from the closely
related spider families Amaurobiidae and Agelenidae. All
members of Family 10 are 36–38 residues long and contain
four disulfide bonds, three of which form an ICK motif.
Almost all members of family 10 are C-terminally amidated.
The m-agatoxins (m-AGTXs) in Family 10 shift the voltage-
activation curve to more negative potentials, increasing
the probability of NaV channel opening at the resting
membrane potential. The resultant membrane depolariza-
tion leads to calcium entry into nerve terminals and
spontaneous release of neurotransmitter into the neuro-
muscular junction, as well as repetitive action potentials in
motor neurons (Skinner et al., 1989; Adams, 2004). The
d-amaurobitoxins, previously known as d-palutoxins
(Corzo et al., 2000), have a quite different mode of action to
the m-agatoxins. They bind to site 4 on insect NaV channels
(Ferrat et al., 2005) and inhibit channel inactivation, but
they have no effect on rat NaV1.2 channels at concentra-
tions up to 10 mM (Ferrat et al., 2005). They are the only
spider toxins that have been definitively shown to bind to
site 4 on insect NaV channels but which modulate NaV
channel inactivation (King et al., 2008a).
The only toxic effect in vertebrates reported for any
member of Family 10 was a temporary paralysis (lasting not
longer than 15 min) of the left legs of a mouse that received
an i.c.v. injection of 486 pmol of d-AMATX-Pl1b (d-palutoxin
IT2) (Corzo et al., 2000). However, a wide range of insecti-
cidal activities have been reported for Family 10 peptides.
The d-amaurobitoxins are weakly insecticidal, with LD50
values of 2347–11029 pmol/g when injected into larvae of
themoth Spodoptera litura (Corzo et al., 2000). The m-AGTXs
from Agelenopsis aperta induced irreversible spastic paral-
ysis when injected into range of insects, with m-AGTX-Aa1d
(m-agatoxin IV) being particularly potent in the houseflyM.
domestica with an LD50 of 30 pmol/g (Skinner et al., 1989).
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The m-AGTXs from Hololena curta caused rapid irreversible
flaccid paralysis when injected into house crickets (Acheta
domestica) (Stapleton et al., 1990).
3.11. NaSpTx family 11
Family 11 comprises a group of three paralogous
insecticidal peptides isolated from the primitive weaving
spider Diguetia canities. These toxins are 56–59 residues
long with four disulfide bonds whose configuration has not
been experimentally determined. The most potent of the
three peptides, m-diguetoxin-Dc1a (DTX9.2), causes rapid
paralysis of lepidopteran larvae with a PD50 of 380 pmol/g,
but it is not toxic to mice at doses up to 657 pmol/g
(Krapcho et al., 1995). Neurophysiological experiments
indicate that these toxins are highly specific insect NaV
channel activators that induce hyperexcitability in sensory
insect nerves and repetitive firing in skeletal muscles
(Bloomquist et al., 1996). The fact that the peptides are not
toxic to mice suggests that they are unlikely to have potent
effects on vertebrate NaV channels.
3.12. NaSpTx family 12
This family consists of three paralogous insecticidal
peptides isolated from the hexathelid spider M. gigas. They
comprise 38–40 residues with three disulfide bonds that
are predicted to form an ICK motif. These peptides bind
specifically to site 3 on insect NaV channels, but they have
no effect on NaV channels from rat brain synaptosomes and
are not toxic to mice when injected i.c.v. at a dose of
20 pmol/g (Corzo et al., 2003).
4. Discussion
4.1. Recruitment of NaV toxins into spider venoms
Spiders appear to have evolved a significantly larger
repertoire of NaV channel toxins than any other venomous
animal. Since insects only express a single NaV channel
subtype that plays a crucial role in action potential gener-
ation (King et al., 2008a), this channel is an excellent target
for insect predators wishing to rapidly incapacitate their
prey. Thus, it is not surprising that spiders seem to have
recruited NaV channel toxins into their venoms at a very
early stage of venom evolution.
With only a few exceptions, the members within each of
the 12 different classes of NaSpTxs outlined in this review
were restricted to certain taxonomic families. For example,
all peptides in Families 1 and 2 were isolated from spiders
of the family Theraphosidae, whereas all peptides in Family
6 originated from spiders in the Ctenidae family. The only
exceptions are Family 10, with toxins from the closely
related spider families Amaurobiidae and Agelenidae, and
Family 4, with toxins from the spider families Hexathelidae
and Actinopodidae, which are not closely related but which
belong both to the suborder Mygalomorphae. This corre-
lation between NaV channel toxin classes and spider
families can be easily visualised (see Figs. 3 and 4) using the
rational nomenclature developed for spider-venom
peptides (King et al., 2008b), which makes it easy to
identify orthologous and paralogous relationships. While
the close relationship between toxin classes and spider
families superficially suggests that spiders recruited
particular NaV toxin scaffolds at specific stages during the
course of spider evolution, it seemsmore likely that most of
these scaffolds are ancient recruitments and that deep
phylogenetic relationships are currently obscured by the
relatively poor taxonomic sampling of spider venoms.
There are currently w42,700 characterised species of
spiders, yet venom peptides have been isolated from less
than 100.
4.2. Comparison with NaV channel toxins from other
venomous animals
Only two related families of scorpion-venom peptides
have been described that target NaV channels; they have
been separated based on their pharmacological properties
and are denoted the a and b families (Gordon et al., 2007).
These so-called long-chain toxins comprise 58–76 residues
and they are typically stabilised by four disulfide bonds
with a 1–8, 2–5, 3–6, 4–7 connectivity (Rodriguez de la
Vega and Possani, 2005). These toxins have a babb
topology that is unrelated to any known spider-toxin
scaffolds. Like Family 4 NaSpTxs, scorpion a toxins
interact with NaV channel site 3 and delay channel inacti-
vation, whereas scorpion b toxins bind to site 4 of the
channel and shift the threshold for channel activation to
more negative potentials.
Three classes of NaV channel toxins (Types I–III) have
been isolated from sea anemones. They all have a similar
pharmacological profile to scorpion a toxins and Family 4
NaSpTxs in that they delay channel inactivation by binding
to site 3 (Bosmans and Tytgat, 2007). However, they have
a distinct structural scaffold compared to both NaScTxs and
NaSpTxs (Norton, 1991). Type 1 and Type II toxins typically
comprise 46–49 residues with six cysteine residues
arranged into three disulfide bridges, whereas Type III
toxins are much shorter, typically comprising 27–32 resi-
dues, but also with three disulfide bonds (Norton, 1991;
Honma and Shiomi, 2006; Bosmans and Tytgat, 2007;
Moran et al., 2009). In none of the three classes of sea
anemone NaV toxins do the three disulfide bonds form an
ICK motif, and none of the 3D scaffolds resemble those of
NaScTxs or NaSpTxs.
Three major classes of NaV channel toxins have been
isolated from the venoms of marine cone snails: the m-, d-,
and mO-conotoxins. The m-conotoxins isolated from fish-
hunting cone snails are small peptides (w20 residues)
with three disulfide bonds that are often selective for the
skeletal muscle NaV1.4 subtype (Ekberg et al., 2008; Wilson
et al., 2011). They do not structurally resemble NaV channel
toxins from spiders, scorpions or sea anemones. Moreover,
in striking contrast with these latter toxins, the m-cono-
toxins are pore blockers rather than gating modifiers that
compete with TTX and saxitoxin for binding to neurotoxin
receptor site 1 (see Fig. 2) (Ekberg et al., 2008).
Despite their vastly different primary structures and
dissimilar modes of action, the d- and mO-conotoxins are
evolutionary related members of the O-superfamily with
similar 3D scaffolds (Heinemann and Leipold, 2007). They
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comprise 29–31 residues with three conserved disulfide
bonds that form an ICK motif. Hence, they are structurally
related to those families of NaSpTxs that also contain an ICK
motif. The d-conotoxins delay channel inactivation, result-
ing in prolongation of action potentials, and hence they
functionally resemble scorpion a toxins and Family 4
NaSpTxs. However, unlike these arachnid toxins that bind
to channel site 3, the d-conotoxins are the defining phar-
macology for neurotoxin receptor site 6 on vertebrate NaV
channels (see Fig. 2). In contrast to the d-conotoxins,
mO-conotoxins compete with b scorpion toxins for binding
to neurotoxin receptor site 4 and they appear to block
sodium flow by hindering activation of the voltage sensor
in channel domain II, thereby preventing channel opening
(Leipold et al., 2007).
In summary, while several classes of NaSpTxs func-
tionally resemble NaV channel toxins from other venomous
animals, their only structural relatives are the d- and
mO-contoxins from the venom of marine cone snails. It is
remarkable that two such taxonomically diverse animals,
one confined to marine environments and the other
a terrestrial predator, have evolved such similar molecular
scaffolds for targeting the NaV channels of their prey.
4.3. NaSpTxs as insecticides and pharmacological tools
The 12 families of NaSpTxs described here present
a range of different pharmacologies with respect to their
binding site on NaV channels and their modulation of
channel function. For example, some toxin classes delay
channel inactivation (e.g., Family 4) while others alter the
voltage-dependence of channel activation (e.g., Family 10).
Consequently many NaSpTxs have become valuable tools
for probing the pharmacology and biophysics of NaV
channels (Bosmans and Swartz, 2010).
Some NaSpTxs are also promising leads for bio-
insecticide development due to their potency against insect
pests and minimal activity, if any, in vertebrates (Maggio
et al., 2010; Windley et al., 2012). Many of the peptides in
Families 10–12, for example, display the type of phyletic
selectivity that is desirable for an insecticide. In contrast,
many of the peptides in Families 3–6 display a high degree
of vertebrate lethality and therefore they would not be
suitable as either pharmacological or insecticidal agents.
Because venom-derived NaV channel modulators are
genetically encoded, transgenes encoding the peptides can
be incorporated into crop plants and entomopathogens in
order to deliver them to targeted insect pests (Tedford et al.,
2004; Windley et al., 2012). For example, the insecticidal
potency of the Autographa californica nuclear polyhedrosis
baculovirus was significantly improved by engineering it to
express a transgene encoding m-AGTX-Aa1d (m-Aga IV)
from NaSpTx Family 10 (Prikhod’ko et al., 1996).
4.4. NaSpTxs as therapeutic leads
The extremely high stability, specificity, and potency of
venom peptides, which in the case of spiders is the result of
hundreds of millions of years of evolutionary fine tuning,
have made them a valuable source of natural products for
drug discovery (Lewis and Garcia, 2003; Escoubas and
Bosmans, 2007; Fox and Serrano, 2007; Escoubas and
King, 2009; Vetter et al., 2011). There are now six FDA-
approved drugs derived from venom peptides or proteins,
with a further ten in clinical trials and many more in
various stages of preclinical development (King, 2011).
Thus, the vast number of NaV channel modulators isolated
from spider venoms begs the questions of whether any of
these peptides might be useful therapeutically.
NaV channels are the target of several classes of thera-
peutics such as local anaesthetics (e.g., lidocaine and
ropivacaine) and antiarrhythmics (e.g., mexiletine and fle-
cainide), as well as anticonvulsants used to treat epilepsy or
bipolar disorder (e.g., lamotrigine, carbamazepine, and
phenytoin) (Clare et al., 2000; England and de Groot, 2009).
Moreover, while most tricyclic antidepressants (e.g.,
amitriptyline and imipramine) are serotonin–norepineph-
rine reuptake inhibitors, they also inhibit NaV channels
(Nicholson et al., 2002; Dick et al., 2007). However, currently,
the major pharmaceutical interest in NaV channels stems
from their involvement in pain. Indeed, many of the NaV
channel drugs described above are now used for treating
various types of pain, particularly post-operative and
neuropathic pain.
Normal pain is a key adaptive response that serves to
limit our exposure to potentially damaging or life-
threatening events. In contrast, aberrant long-lasting pain
transforms this adaptive response into a debilitating and
often poorly managed disease. About 20% of adults suffer
from chronic pain, with the incidence increasing to 50% for
those older than 65 (Brennan et al., 2007). There are few
drugs available for treating chronic pain and most have
limited efficacy, dose-limiting side-effects, and in some
cases the potential for addiction (Carinci and Mao, 2010).
Hence, there is much interest in developing novel pain
medications that have minimal or no side-effects and that
do not have problems of tolerance and addiction.
Each of the nine NaV channel subtypes has a different
anatomical distribution that determines their biological
function. For example, NaV1.5 is restricted to the heart
where it is critical for the rising phase of the cardiac action
potential whereas NaV1.4 is restricted to muscle tissue and
is critical for muscle contraction (England and de Groot,
2009; England and Rawson, 2010). The other seven
subtypes are found in the central or peripheral nervous
system. NaV1.7, NaV1.8 and NaV1.9 are selectively expressed
in peripheral sensory neurons where they appear to play
a key role in relaying pain signals to the spinal cord (Dib-
Hajj et al., 2010). Of these subtypes, NaV1.7 has emerged
as an exciting analgesic target based on several remarkable
genetic studies. Gain of function mutations in the SNC9A
gene encoding the pore-forming a subunit of NaV1.7 have
been shown to cause painful inherited neuropathies
(primary erythromelalgia and paroxysmal extreme pain
disorder) (Yang et al., 2004; Fertleman et al., 2006; Estacion
et al., 2008). In contrast, loss of function mutations in
SCN9A result in a congenital indifference to all forms of pain
(Cox et al., 2006; Nilsen et al., 2009). Remarkably, apart
from their complete inability to sense pain, loss of smell
(anosmia) is the only other sensory impairment in indi-
viduals with this channelopathy (Nilsen et al., 2009; Weiss
et al., 2011; Rupasinghe et al., 2012).
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It is probable that the known analgesic effects of
a number of non-specific NaV channel blockers such as local
anaesthetics, anticonvulsants, and tricyclic antidepressants
are at least in part mediated through their effects on NaV1.7
(Nicholson et al., 2002; Dick et al., 2007; Levinson et al., in
press). However, the non-specific block of NaV channels by
these drugs results in a very narrow therapeutic window,
with CNS-related side-effects such as dizziness, headaches,
and ataxia, as well as potential cardiac side-effects
(Cummins and Rush, 2007; Krafte and Bannon, 2008).
Thus, there is much interest in the development of
subtype-selective blockers of NaV1.7 (England and Rawson,
2010; Zuliani et al., 2010). In this regard, there are several
reasons why NaSpTxs might be useful therapeutic leads for
the development of NaV1.7-selective analgesics (Clare,
2010; England and Rawson, 2010; Saez et al., 2010). First,
most NaSpTxs contain an ICK motif that provides them
with tremendous chemical, thermal, and biological
stability. Spider-venom ICK peptides are typically stable in
human serum for several days and have half-lives in gastric
fluid of >12 h (Saez et al., 2010). Notably, an ICK scaffold
forms the core of the analgesic drug Prialt (Miljanich,
2004). Second, because NaSpTxs are gating modifiers
rather then pore blockers they are more likely to be
subtype-selective than small compounds that bind in the
highly conserved pore of the channel. Nevertheless, our
understanding of the molecular basis of the potency and
selectivity of NaSpTxs, which is critical for their progression
to the clinic, is still rudimentary. Indeed, it is remarkable
that we only know the complete NaV selectivity profile for
a handful of peptides in the 12 families of NaSpTxs.
Table 1 summarises some of the salient features of each
NaSpTx family, including an indication of their subtype
preferences. Notably, peptides that potently block NaV1.5
tend to be lethal in rodents, consistent with the critical role
of this subtype in cardiac function. This highlights the need
to pinpoint the residues on these peptides that mediate
their selectivity and potency in order to be able to rationally
engineer improved versions that preferentially bind NaV1.7.
This will be the major challenge in progressing these
peptides to the clinic. On a positive note, however, peptides
have already been isolated from Families 1–3 that potently
block NaV1.7 (IC50  51 nM) and that have at least some
selectivity over other NaV subtypes. Moreover, it is worth
noting that parenterally administered NaSpTxs are unlikely
to cross the blood–brain barrier and enter the CNS, and
therefore off-target activity at centrally located NaV
subtypes is unlikely to be a therapeutic problem.
In conclusion, it is clear that spiders have evolved
a larger repertoire of NaV channel toxins than any other
venomous animal. These NaSpTxs modulate NaV channels
in a variety of different ways ranging from effects on the
voltage-dependence of activation to the kinetics of channel
inactivation. Many of these peptides have become useful
pharmacological tools for studying the pharmacology and
biophysics of NaV channels, while others are being
Table 1
Subtype selectivity and other selected properties of the 12 families of NaSpTxs.
NaSpTx
family
NaV channel subtype TTX-S TTX-R Lethal Other ion
channel targets
High-resolution
structure?p
1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8
1 407a 0.6b 42b 288b 72b – 26c – 1.1d – Yes CaV/KV Yes
2 – – – – 447e – 51f 27f 85g – No CaV/KV/TRPV1 Yes
3 41h 230i 103h 330j 79h 26h 0.3h 146h 30.2k 27.6k Yes KV, CaV Yes
4 – – – – – – – – – – Yes – Yes
5 – 1200l – – – – – – – – Yes – Yes
6 – – – – – – – – – – Yes – No
7 – – – – 32m 130m 130m – – – – KV Yes
8 – 0.08n – – – – – – – – Yes – No
9 – – – 155o – – – – – – – KV No
10 – – – – – – – – – – No – Yes
11 – – – – – – – – – – No – No
12 – – – – – – – – – – No – No
For each NaSpTx family, the IC50 value (in nM) is given for the peptide that most potently modulates the activity of each NaV subtype. Columns labelled “TTX-
S” and “TTX-R” indicate potency of peptides on TTX-S and TTX-R NaV channels, usually tested in rat dorsal root ganglion neurons. The column labelled
“Lethal” refers to the toxicity of peptides in rodents.
a b-TRTX-Cm1b (Bosmans et al., 2006).
b b-TRTX-Ps1a (Bosmans et al., 2006).
c m-TRTX-Hh2a (Xiao and Liang, 2003b).
d m-TRTX-Hhn2b (Xiao and Liang, 2003a).
e b-TRTX-Cm2a (Bosmans et al., 2006).
f b/u-TRTX-Tp1a (Middleton et al., 2002).
g m-TRTX-Cj1a (Chen et al., 2008).
h b/u-TRTX-Tp2a (Middleton et al., 2002).
i b-TRTX-Gr1a (Redaelli et al., 2010).
j b-TRTX-Gr1b (Redaelli et al., 2010).
k k-TRTX-Cj2a (Zeng et al., 2007).
l b-HXTX-Mg1a (Corzo et al., 2003).
m d-TRTX-Cj1a (Xiao et al., 2005).
n m-CNTX-Pn1a (Diniz et al., 1990).
o m-TMTX-Hme1b (Billen et al., 2008).
p We define “high-resolution structures” as NMR-derived solution structures with a backbone RMSD <0.5 Å.
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developed as bioinsecticides due to their selective action on
invertebrate NaV channels. In addition, many NaSpTxs are
vertebrate-active and those with high potency and selec-
tivity for certain NaV subtypes that are localised in
peripheral pain pathways are being used as leads to
develop novel classes of analgesics. Finally, it is worth
noting that the 12 classes of NaSpTxs described here have
been derived from only eight of the 110 extant families of
spiders (Platnick, 1997). Thus, it is likely that additional
classes of NaSpTxs will be discovered through better
taxonomic sampling of the incredible diversity of spider
venoms available.
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